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THE PREDICTIVE VALUE OF EXERCISE TESTING AND INVASIVE 
ASSESSMENT POST MYOCARDIAL INFARCTION FOLLOWING 
TREATMENT WITH THROMBOLYSIS 
SUMMARY FOR EXAMINERS
Introduction
The introductory chapters describe the use of thrombolytic therapy in the treatment of 
myocardial infarction and discuss the usefulness of exercise testing post-myocardial 
infarction in the pre and post-thrombolytic eras.
Methods
Two hundred and twelve patients were recruited from four separate studies of 
thrombolytic agents carried out at Stobhill General Hospital between 1988 and 1993. 
Patients with symptoms of myocardial infarction lasting >30 mins and < 6 hrs with 
diagnostic ST segment elevation on 12 lead ECG between the ages of 18 and 75 years 
were recruited to our studies if they fulfilled the entry and exclusion criteria.
Coronary angiography was performed at 90 mins and 24 hrs post thrombolysis to define 
the patency of the infarct-related vessel by the TIMI scoring system (Grades 0-3), 
additional vessel disease and residual stenosis of the infarct-related artery (> 50% 
stenosis taken as being significant). Prior to discharge from hospital, the patients 
underwent a symptom-limited treadmill exercise test using a modified Bruce protocol. 
Symptoms of angina, breathlessness, fatigue or other limiting symptoms were recorded. 
ST segment depression of > 1 mm, 80 m.secs after the J point was considered indicative 
of reversible ischaemia. ST segment elevation and T wave normalisation were also 
recorded and the exercise test was discontinued if there was a significant fall of > 20 
mmHg in systolic blood pressure in the previous stage of the exercise test or if the 
patient achieved age predicted maximum heart rate. Total exercise time in seconds and 
metabolic equivalents at peak exercise were noted. Systolic blood pressure and heart 
rate were used to calculate rate pressure product.
When discharged from hospital patients were then followed up for a variable period of 
time at the outpatient clinics of one of the three Consultant Cardiologists. After 
approximately 5 years, the case record forms were analysed retrospectively to determine 
clinical outcome. Cardiac events were noted at three time points: in-hospital cardiac 
events occurring after angiography at 90 mins to discharge from hospital, outpatient 
cardiac events occurring from hospital discharge to the end of outpatient follow up, and 
overall cardiac events which combined both inpatient and outpatient events. Primary 
cardiac events were defined as unstable angina, recurrent myocardial infarction, PTC A, 
CABG and sudden cardiac death. Other secondary endpoints were also recorded: peri- 
infarct acute left ventricular failure, congestive cardiac failure and post-infarct angina.
Statistical Analysis
Minitab software package was used to analyse categorical variables using chi. squared 
and continuous variables using Anova. SPSS software package was used to perform 
Kaplan-Meier event-free survival analysis to determine predictive value of univariates. 
Finally, a multivariate analysis using Cox proportional hazard model was performed 
using SPSS to determine independent predictors of clinical outcome. In all statistical 
tests, a significant level of P < 0.05 was defined as significant.
Results
Demographic Characteristics
Patients > the median age of 56 yrs were shown to have a higher incidence of cardiac 
events as an outpatient (p = 0.0054) also to have a greater mortality over the 5 year 
period (p = 0.023). Males were significantly more likely to complain of symptoms 
during exercise compared to females (40% vs 17%, P < 0.05). The RCA was affected in 
47%, the LAD at 45% and Cx in 7% of patients. ST segment depression during exercise 
was more common in patients who had had RCA thrombosis. ST segment elevation 
occurred more commonly in patients with LAD as the infarct-related artery. Patients 
with LAD as the infarct-related vessel had an increased incidence of acute peri-infarct 
left ventricular failure (p=0.029), chronic heart failure as an outpatient (p=0.0136) and 
the development of heart failure overall (p=0.03). As LAD occlusion commonly 
presents as an anterior infarct, similar results were obtained when comparing site of 
infarct.
Reciprocal depression defined as significant ST segment depression 80 m.secs after the J 
point in the non-infarct territory on the admission ECG was associated with ST segment 
depression during exercise testing, a greater incidence of post-infarct ischaemic pain and 
peri-infarct left ventricular failure.
Exercise variables: exercise capacity, systolic blood pressure, rate pressure product, ST 
segment depression, ST segment elevation, T wave normalisation were not associated 
with results of invasive assessment post-thrombolysis or predictive of clinical outcome.
In this study, failure to undergo an exercise test, for whatever reason, predicted total 
mortality, but not cardiac events specifically. Angina during exercise testing pre­
discharge was predictive of development of angina during outpatient follow up.
Patency of the infarct-related vessel as defined by TIMI scoring did not predict results of 
exercise testing pre-discharge. Failure to achieve coronary patency with thrombolysis 
was predictive of post-infarct ischaemic pain as an inpatient, of acute peri-infarct left 
ventricular failure, chronic heart failure as an outpatient and overall heart failure. Full 
patency (TIMI Grade 3) and early coronary patency were associated with improved 
clinical outcome.
Residual stenosis of the infarct-related artery in patients with single vessel or multivessel 
disease failed to predict results of exercise test or clinical outcome. Patients with three 
vessel coronary disease were shown to have an increased incidence of ST segment 
depression during exercise testing and an increased incidence of sudden cardiac death.
Conclusions and Clinical Relevance
Exercise testing pre-discharge in the pre-thrombolytic era was shown to be predictive of 
clinical outcome and coronary anatomy. Widespread use of thrombolysis in the 
treatment of acute myocardial infarction has resulted in potential differences in coronary 
artery anatomy. If a coronary artery is occluded by a thrombosis, this will result in 
necrosis of myocardial muscle and a variable degree of left ventricular dysfunction. The 
results of exercise testing and clinical outcome was therefore dependent upon the amount
of myocardial damage and the presence of additional vessel disease. Thrombolysis, by 
achieving reperfusion of the infarct-related artery in around 60-80% of cases results in 
myocardial salvage. A residual stenosis of the infarct-related artery exists in around 70% 
of patients. If this subtends an area of viable myocardium, there is additional reason for 
reversible ischaemia during exercise testing. Therefore, it is not surprising that non- 
invasive exercise variables no longer carry the same predictive value as suggested by 
studies in the pre-thrombolytic area. As thrombolysis results in an improved prognosis 
following myocardial infarction, any test designed to predict adverse clinical outcome 
will have a reduced positive predictive accuracy. This present study confirms reduction 
in the predictive value of a positive test but shows retained negative predictive accuracy 
in exercise testing post-myocardial infraction in the thrombolytic era. Therefore patients 
with a normal exercise test following thrombolysis for acute myocardial infarction are at 
very low risk of future cardiac events and can safely be discharged from hospital follow 
up. However, it is likely that patients who have significant symptoms of angina post- 
infarct or a grossly abnormal exercise test will be considered for early invasive 
investigation with a view to intervention. There remains a group of patients with an 
abnormal exercise tests result, whose prognosis cannot be defined. They require clinical 
follow up for a period of time to monitor the course of their symptoms and exercise 
response before embarking upon invasive investigation.
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1. THE USE OF THROMBOLYTIC THERAPY IN THE 
TREATMENT OF MYOCARDIAL INFARCTION
1.1 Thromblytic Agents
In this study three thrombolytic agents were used in four separate studies in the 
treatment of acute myocardial infarction: streptokinase, anistreplase and tissue 
plasminogen activator. Although other thrombolytic agents exist, they were not in 
widespread use and therefore not be reviewed in this thesis.
1.1.1 Streptokinase
Streptokinase is a single chain protein produced by group C beta-haemolytic 
streptococci with a molecular weight of 47000 daltons. It combines with plasmin or 
plasminogen to form a complex which activates the conversion of plasminogen to 
plasmin. Streptokinase is a foreign protein and is therefore antigenic. Antibodies in the 
circulation which have resulted from streptococcus exposure can therefore bind to 
Streptokinase molecules and neutralise the thrombolytic effects. Streptokinase itself 
will induce the formation of anti-streptococcal antibodies and thus can reduce the 
efficacy of subsequent treatment with streptokinase. Lee HS et al. (1993) showed 
significant antibody levels five days after administration of streptokinase which 
persisted for up to three years. This obviously has practical implications in terms of the 
thrombolytic agents used in recurrent myocardial infarction following initial treatment 
with streptokinase. There is a small incidence of anaphylaxis of approximately 0.1% 
following administration of streptokinase. Some centres routinely administer 
chlorpheniramine and hydrocortisone prophylactically to prevent allergic reactions with 
streptokinase. This treatment is empirical as the evidence to support its effectiveness is 
lacking (Murray N et al. 1986). Although the administration of streptokinase exerts a 
hypotensive effect this does not commonly prevent infusion of the standard 1.5 MU 
dose of streptokinase.
Several large clinical trials have now demonstrated that streptokinase is effective and 
safe in the treatment of myocardial infarction. It is relatively inexpensive (around £200 
for 1.5 million units) and remains the most widely used thrombolytic agent in the
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treatment of myocardial infarction in the UK. It is usually dissolved in 500mls of 
normal saline and given as a continuous infusion, over 1 hour.
1.1.2 Anistreplase
Anistreplase is an anisolated plasminogen streptokinase complex. The active serine site 
on the plasminogen molecule is anisolated with P-anisoic acid which inhibits the effects 
of circulating plasmin inhibitors such as alpha-2 anti-plasmin and alpha-2 
macroglobulin. Anistreplase undergoes deacylation by hydrolysis to form a potent 
plasminogen activator, thus exerting a fibrinolytic effect. Anistreplase is a derivative of 
streptokinase and therefore has similar immunological and haemodynamic effects. 
However it has the advantage that the standard dose of 30 units of anistreplase can be 
administered by a single intravenous injection over 5 minutes. Hogg KJ et al. (1990) 
showed no difference in the efficacy of 30 units of anistreplase compared to 1.5 MU 
streptokinase assessed by coronary artery patency rates at 90 min and 24 hrs post 
thrombolysis. The ease of administration of anistrepelase and usefulness in out-of- 
hospital thrombolysis, particularly in rural settings is a potential advantage of the drug. 
It is relatively expensive at around £500 for the standard dose.
1.1.3 Tissue Plasminogen Activators
Tissue Plasminogen Activators were identified as serine proteases by Astrup T and 
Permin PM in 1947. However at that time they could not be obtained in sufficient 
quantity from human tissue for experimental purposes. Tissue plasminogen activators 
were then isolated and purified from a melanoma cell line (Collen D et al. 1982). The 
gene involved in the synthesis of tPA was then cloned and expressed it in E coli 
allowing the production of recombinant tissue type plasminogen activator (r-tPA) in 
quantities which allowed evaluation in humans (Pennica D et al. 1983).
As a human protein tPA is not antigenic and is therefore not associated with allergic 
reactions caused by streptokinase containing compounds. It has been shown to exert 
minor hypotensive effects (Lew AS et al. 1995). It has a short half-life, around five 
minutes (Garabedian DH et al. 1987) and therefore, its systemic effects are relatively 
short-lived. The ability of r-tPA to cause lysis of a coronary thrombosis was first
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demonstrated by Van der Werf F et al. (1984). Six out of seven patients given r-TPA 
achieved coronary reperfusion without depletion of fibrinogen, plasminogen or alpha-2 
antiplasmin However, it has since been shown that doses of tissue plasminogen activator 
required to provide satisfactory coronary reperfusion rates did cause a significant fall in 
fibrinogen and plasminogen, thus exerting a systemic lytic effect (Rao AK et al. 1988). 
This is now thought to be an advantage in preventing early coronary reocclusion, a 
problem encountered with lower doses. R-tPA exists in two forms: the initial form of 
rTPA was a double-stranded preparation DUTEPLASE but subsequently a single­
stranded chain version ALTEPLASE was developed which had higher specific activity 
and was easier to produce in quantity (Garabedian DH et al. 1987).
Although r-tPA is less antigenic and better tolerated than streptokinase-containing 
compounds, it is relatively more expensive (around £600 per lOOmg). However, in 
patients who have previously been treated with streptokinase, tPA is the drug of choice 
for treatment of recurrent myocardial infarction in some clinical centres. Following 
streptokinase it takes approximately 5 days to achieve significant antibody levels. 
Therefore in clinical practise redosing with streptokinase would be recommended within 
this five day period. Several studies have shown that significant antibody levels persist 
up to 3 years after administration of streptokinase. Thus re-dosing with streptokinase at 
any point after five days for recurrent myocardial infarction is becoming less common. 
The standard regime of r-tPA at present is lOOmg of alteplase as a 3 hour decremental 
intravenous infusion. The short-lived systemic effects of TPA and its ease of 
administration as an intravenous bolus have stimulated a variety of studies considing 
different dose regimes in an attempt to define the most effective. Neuhaus KL et al. 
(1989). showed improved efficacy with administration of TPA in an accelerated regime: 
15mg bolus IV followed by infusion of 50mg over 30 min and then 35mg over lhr
1.2 Historical Review of Thrombolysis
Tillet WS and Sherry S in 1949 used Streptokinase to dissolve fibrinous material in 
vitro. The lysis of intravenous blood clots in rabbits by streptokinase was then 
demonstrated by Johnson A J et al. (1952). Administration of intravenous and 
intracoronary thrombin was shown to lyse thrombotic occlusions in dog coronary
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arteries by Ruegsegger et al. (1959). A sustained systemic lytic state in 22 patients with 
acute myocardial infarction was demonstrated following administration of streptokinase 
(Fletcher AP et al. 1959). No serious haemorrhagic complications were encountered.
The first large scale controlled trial in thrombolysis comparing streptokinase with 
heparin was conducted in 558 patients treated within 12 hours of the onset of symptoms 
for acute myocardial infarction (Schmutzler N et al. 1966). Following a loading dose of 
streptokinase, an infusion was given for 18 hours with a variable dose regime designed 
to maintain a thrombolytic state. A significant improvement in mortality was shown in 
the streptokinase treated group, (14.1% v 21.7 % at 40 days, p<0.01). This benefit of 
streptokinase was confirmed in a further 269 patients treated within 6 hrs of onset of 
symptoms of myocardial infarction with a loading dose of 250,000 units followed by
167,000 units per hour for 18 hours against placebo (Schmutzler N et al. 1971). The 40 
day mortality of the streptokinase treated group was 14.5% v 26% for the placebo group, 
(p<0.01). In addition, there was an improvement in the 24 hr mortality rate (2% v 10%,
p<0.001).
In 1969 the first European Working Party trial was published with 167 patients treated 
within 72 hours of the onset of symptoms of myocardial infarction with either heparin or 
streptokinase (1.25 MU loading dose and 104,000 U/hr for 72 hours) (Amery A et al. 
1969). Those patients treated with streptokinase in fact had a significantly higher 
mortality rate possibly explained by a 72-hour inclusion time.
In 1971, the second European Working Party trial recruited 730 patients within 24 hours 
of onset of symptoms for acute myocardial infarction in a randomised double-blind 
study of streptokinase (250,000 U loading dose followed by 100,000 U/hr for 24 hours) 
or heparin(European Working Party, 1971). At 40 days mortality in the streptokinase 
group was 18.5% compared to 26.3% in the heparin group (p<0.01).
However, in a study of 321 patients treated within 12 hours of symptoms it was shown 
that the treatment group who received 250,000 U of streptokinase as a loading dose 
followed by 1,500 U/hr for 12 hours did not have significant improvement in mortality
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compared to the control group treated with heparin (Dioguardi N et al. 1971). Similarly, 
in a study of 747 patients treated with streptokinase (250,000 loading dose and 1,000 
U/hr for 18 hours) did not have improved survival over a control group treated with 
heparin (Bett JHN et al. 1977).
Aber CP et al. (1976) showed no difference in mortality at hospital discharge in a group 
of 595 patients within 24 hours of the onset of symptoms of myocardial infarction 
randomised to receive 2.5 MU of streptokinase v placebo (12.6% v 13.7%). Similarly at 
6 months there was no difference in mortality (15.9% v 17.8 %). Therefore, the results 
of early thrombolysis studies were conflicting in terms of the benefits of streptokinase 
therapy in acute myocardial infarction.
Several animal experiments demonstrated the ability of streptokinase to achieve 
reperfusion and result in myocardial salvage, reduction in creatine kinase production, 
reduction in necrotic histological changes and increased contractility of the myocardium.
Myocardial salvage was shown to be time-dependent in experiments which 
mechanically occluded coronary arteries in dogs and restored flow at various time points 
after occlusion (Reimer KA et al. 1977). Reperfusion up to six hours resulted in 
significant salvage of epicardial myocardium. The study therefore suggested that 
benefits of thrombolysis given with a view to achieving coronary artery reperfusion may 
be limited to a similar time window following the onset of symptoms. Therefore, 
previous studies which administered streptokinase late after the onset of symptoms of 
myocardial infarction may not demonstrate the true beneficial effects of thrombolysis.
1.2.1 Intracoronary Streptokinase in Acute Myocardial Infarction
In a study of 322 patients admitted within 24 hours of the onset of acute myocardial 
infarction, 87% of the patients studied by angiography within 4 hours of the onset of 
symptoms had thrombotic occlusion of the affected coronary artery (DeWood MA et al. 
1980). In 88% of patients with angiographic features of coronary thrombosis it was 
possible to mechanically retrieve thrombus material using a Fogarty catheter. Therefore, 
the role of coronary thrombosis in the aetiology of myocardial infarction was confirmed.
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The rate of spontaneous reperfusion was estimated at 13% at 4 hrs rising to 35% at 12- 
24 hours.
Forty-one patients were treated with 2,000 U/min of intracoronary streptokinase 
combined with mechanical reperfusion with a guidewire (Mathey DG et al. 1981). 95 % 
of the patients had completely occluded coronary arteries. It was possible to obtain 
reperfusion in 73% of these patients. Repeat coronary angiography at 7-21 days in 15 of 
the 41 patients showed that 80% of them continued to have patent infarct related 
arteries.
Other studies confirmed similar reperfusion rates with the use of intracoronary 
streptokinase, and showed improved left ventricular function in patients with coronary 
artery patency (Timmis AD et al. 1982; Rentrop P et al. 1981; Ganz W et al. 1981). It 
was demonstrated by coronary angiography that 78 of 81 patients treated within 3 hours 
of the onset of myocardial infarction with 0.75 or 1.5 MU of streptokinase over 15-30 
mins had patent infarct related vessels at 3-7 days by coronary angiography (Ganz W et 
al. 1984).
However, other studies, showed similar efficacy of intracoronary streptokinase in 
achieving coronary artery reperfusion but failed to show any difference in left 
ventricular ejection fraction measured at 7-10 days (Leiboff RH et al. 1984; Khaja F et 
al. 1983). Metanalysis of previous studies of streptokinase by Stampfer MJ et al. (1982) 
using the results of 8 randomised trials of intravenous streptokinase compared to a 
control group treated with either placebo or heparin. They showed a statistically 
significant improvement in mortality at 40 days in the streptokinase-treated patients with 
an overall hazard ratio of 0.8 (p<0.1).
Similarly, a metanalysis by Yusuf S et al. (1985)of 33 studies using intravenous and 
intracoronary thrombolysis in the treatment of acute myocardial infarction calculated an 
overall hazard ratio of 0.78 and a reduction in mortality of 22% (p<0.001) in favour of 
those patients receiving streptokinase in the 24 trials of intravenous thrombolysis. In 9 
studies of intracoronary streptokinase, an average odds ratio of 0.8 and a mortality
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reduction of 20% was shown. This did not reach statistical significance, but this may 
have represented a type II error as there were only 128 deaths out of 1,000 patients 
considered for analysis.
Although intracoronary administration of thrombolysis allows direct assessment of the 
thrombotic occlusion of the infarct-related vessel and an instant evaluation of the 
efficacy of thrombolysis in achieving patency, it does not appear to have significant 
advantages in improving mortality rate compared to intravenous administration. 
Coronary angiography is a highly skilled, invasive and expensive procedure which is not 
available to all physicians in the United Kingdom. Arterial cannulation in patients 
treated with thrombolysis state is associated with increased bleeding complications 
because of the induced systemic lytic (Merx W et al. 1981). Even in specialist centres, 
there is a significant amount of time required to organise coronary angiography which 
delays the administration of therapy. A study of 28 patients by Alderman EL et al. 
(1984) randomised to receive intracoronary or intravenous streptokinase confirmed that 
there was no significant difference in rates of reperfusion (73% v 62%). In addition, 
there were similar reductions in fibrinogen with intravenous and intracoronary 
administration despite significantly lower dose administered to the intracoronary route.
It was concluded that a systemic lytic state was necessary to achieve successful coronary 
perfusion rather than high local concentrations of streptokinase. The results were 
supported by a similar study performed by Rothbard RL et al. (1985).
1.2.2 Assessment Of Thrombolytic Efficacy
1.2.2.1 Coronary Reperfusion
A pre-treatment angiogram must be performed to identify an thrombotic occlusion of 
the of the infarct related artery. It is then possible to assess whether thrombolytic 
therapy has achieved lysis of the occlusive thrombus by post treatment angiography. 
This can be quantified according to the TIMI score developed by Williams DO et al. 
(1986). The organisation of a pre-treatment angiogram may lead to a significant delay in 
administration of thrombolysis. Therefore recent studies of intravenous thrombolytic 
therapies do not assess efficacy in this way.
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1.2.2.2 Coronary Patency
To avoid delays in administration of thrombolytic therapy incurred by a pre-treatment 
angiogram, patency of the infarct related vessel is assessed similarly at some point after 
administration of therapy. Obviously, the phenomenon of spontaneous reperfusion 
(around 15-20%) will contribute to patency rates, which will therefore be greater than 
reperfusion rates and lead to an overestimate of the effectiveness of thrombolytic 
agents. This can be similarly quantified by the TIMI score
The rate of spontaneous reperfusion and the rate of coronary artery patency following 
thrombolysis increases with time. A study of 30 U of anistreplase v 1.5 MU 
streptokinase given intravenously showed that patency increased from around 55% at 90 
minutes to around 85% at 24 hours after therapy (Hogg KJ et al. 1990). In addition, 
from the onset of symptoms of myocardial infarction to therapy affects the patency rate 
achieved with thrombolysis (Timmis AD et al. 1987).
1.2.2.2.1 Streptokinase
Intracoronary streptokinase reperfusion rates were calculated in the order of 60-87% 
(Timmis AD et al. 1982) and intravenous streptokinase of around 62% (range 44-75%) 
(Alderman EL et al. 1984).
1.2.2.2.2 Anistreplase
Coronary artery patency rates with 30 U of anistreplase as a 5 min bolus intravenous 
injection is in the order of 50-70%. No significant difference in patency rates were 
shown between anistreplase and streptokinase at 90 minutes (55 v 53 %) or at 24 hours 
(81 v 87.5 %)(Hogg KJ et al. 1990).
1.2.2.2.3 Tissue Plasminogen Activators
Tissue plasminogen activator exists as duteplase, a double-chain r-tPA and alteplase a 
single chain version. It is known that the specific activities of these two preparations 
differ, which may influence the interpretation of results of studies using either agent. In 
addition, because of the relative ease of IV bolus administration, a variety of dose
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regimes of r-TPA have been studied. The specific properties of tPA may be enhanced by 
dose manipulation and this may affect the validity of comparing results of different 
studies. A patency rate of around 68% was achieved using 70mg of duteplase over 90 
minutes and 80% using 1.5 pg/kg of alteplase over 4 hours in conjunction with heparin 
(Topol EJ et al. 1987). The TIMI-1 study used 80mg of rTPA over 3 hours with a 
patency rate of around 56%(The TIMI Study Group, 1987). Accelerated administration 
of rTPA with a 15mg bolus followed by 50mg over 30 mins and 35mg over 90 mins ( a 
total dose of 1 OOmg) gave increased coronary artery patency of around 74% at 60 mins 
and 91% at 90 mins(Neuhaus KL et al. 1989). lOOmg of rtPA given as 4 x 25mg boluses 
over 60 minutes achieved patency of the infarct related artery in 11 of 14 patients (Khan 
MI et al. 1990). There is therefore widely differing reported rates of patency following 
different regimes and forms of tPA administration.
1.2.3 Preservation o f Left Ventricular Function
Thrombolytic therapy results in salvage of a variable amount of myocardium, by 
restoring blood flow to the infarct zone, and therefore should theoretically reduce left 
ventricular dysfunction post myocardial infarction. Methods available for assessment of 
left ventricular function include contrast left ventriculography, echocardiography and 
radionucleotide ventriculography. Left ventriculography is obviously an invasive 
procedure performed in addition to a coronary angiogram and therefore has limited 
potential for serial assessments. Echocardiography, is non-invasive and repeatable. 
However, a significant number of individuals will have poor quality images which 
prevent accurate measurements of left ventricular volumes. Radionucelotide 
angiography is non-invasive and reproducible and can be used for serial measurements 
of both global and regional LV function, however, this facility may not be readily 
available in all centres. Left ventricular function has been shown to improve 
spontaneously up to 2 weeks following myocardial infarction independent of treatment 
with thrombolytic therapy (Schwarz F et al. 1982) In this study, improvement in LV 
function correlated with amount of residual flow to the infarct zone, either antegrade or 
via collateral circulation. Ejection fraction over a 2 week period following infarction 
was elevated in patients with residual flow in the infarct zone compared those without 
(Rogers WJ et al. 1984). It was postulated that an initial compensatory hyperkinesis of 
the non-infarct zone was non-sustained post infarct and resulted in a fall in ejection
fraction. Infarct size was reduced and LV function preserved with i.v. streptokinase but 
these benefits were confined to those patients with anterior infarction treated within 3 
hrs of the onset of symptoms(Ritchie JL et al. 1984).
1.3 Patency Studies
TIMI-1 (The TIMI Study Group, 1987)was a randomised, double-blind angiographic 
trial comparing 1.5 MIU with streptokinase with 80 mg r-tPA in 290 patients with 
suspected myocardial infarction. It demonstrated superior earlier patency with r-tPA 
(62%) compared to streptokinase (31%) (p<0.01) at 90 mins. However, a patency rate 
of 31% for streptokinase is unusually low, compared to most other studies which 
indicated a patency rate of around 51-64% with 1.5 MIU of i.v. streptokinase (Hogg KJ 
et al. 1990) and may reflect the design of the study. An uncontrolled angiographic trial 
of accelerated r-tPA in 80 patients with suspected myocardial infarction demonstrated 
that r-tPA given as an accelerated regime gave a patency rate of 91% at 90 mins 
(Neuhaus KL et al. 1989).The RAAMI Study in 1992 was a randomised, open 
angiographic study comparing accelerated tPA with conventional tPA in 281 patients 
with a suspected myocardial infarction (The RAAMI Study Group 1992). This showed 
accelerated tPA had a greater patency rate (76%) than standard r-tPA (63%) at 60 mins 
(p<0.003) but it did not show a significant difference in patency rates at 90 mins (81% 
vs 77%, p=NS).
The TAPS study (Von Essens R et al. 1991) was a randomised, angiographic trial 
comparing accelerated r-tPA with 30 U of anistreplase in 421 patients with suspected 
myocardial infarction. It showed that accelerated tPA had a significantly higher patency 
rate at 90 mins vs anistreplase (84.4% vs 70.3%, p=0.0007) and also a significantly 
lower in-hospital mortality with accelerated tPA at 2.4% vs 8.1% (p=0.0095). However, 
there was a higher early reocclusion rate (24-48 hrs) with accelerated tPA 10.3% vs 
2.5% anistreplase.
The GUSTO study (1993) (The Gusto angiographic invesigators, 1993) had an 
angiographic sub-study containing 2,431 patients which showed significantly increased 
rate of patency (TIMI grade 2 or 3) with accelerated tPA at 90 mins (p<0.001) and
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increased rate of TIMI grade 3 (54%, p<0.001). This was independent of age, infarct- 
related artery and time to therapy. Patients with full patency (TIMI grade 3) at 90 mins 
were shown to have improved left ventricular function. Mortality rates were also shown 
to depend upon patency at 90 mins, as shown below in table 1.1. 30 day mortality was 
also influenced by the number of coronary vessels diseased : a stenosis of > 75% as 
illustrated in table 1.2. The GUSTO study was the first large scale study to link patency 
at 90 mins with clinical outcome and concluded that thrombolytic regimens which could 
achieve high early patency rates were of additional benefit, particularly if reocclusion 
could be prevented
Patency Group Mortality Rate P Value
TIMI 0,1 
TIMI 2,3
8.9%
5.7% 0.004
Table 1.1 Relationship between patency and mortality in the Gusto Study(The
Gusto angiographic invesigators, 1993)
Vessel
Diseased
Percentage
affected Mortality P values
No of diseased vessels 
multiple comparisons
1 2
1 62% 3.5%
2 24% 6.5% 2 0.03
3 14% 11.2% 3 0.001 0.02
Table 1.2 The no of vessels diseased and mortality in the Gusto Study (The Gusto 
angiographic invesigators, 1993)
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1.4 Mortality Studies
The benefits of thrombolytic agents and the treatment of acute myocardial infarction 
have been established by the results of several large scale mortality studies.
The GISSI-I study in 1986 was a randomised, open trial of 1.5 MIU streptokinase vs 
control in 11,806 patients up to 12 hrs after the onset of symptoms of acute myocardial 
infarction (The GISSI Working Group 1986). There was an 18% reduction in 21 day 
mortality (10.7 v 13%, p<0.0002) with a 10% reduction in mortality at 12 months (17.2 
v 19.0%, p=0.008). Benefit was shown to be time-related with a 23% reduction in 1 
year mortality in patients treated within 3 hrs and a 39% reduction in patients treated 
within 1 hr. No significant benefit was shown in patients treated after 6 hrs. The 
incidence of stroke in this study was 0.2%, major bleeds 0.3% and anaphylactic 
reactions 0.1%, establishing the relative safety of streptokinase administered to a large 
group.
The ISIS-2 study in 1987 was a randomised, double-blind placebo controlled mortality 
study of 17,187 patients receiving 1.5 MIU streptokinase, oral aspirin, both or neither 
for acute myocardial infarction (The ISIS 2 Working Group 1987). The study showed a 
highly significant benefit in 5 week mortality in patients treated with streptokinase, 
aspirin and streptokinase plus aspirin vs placebo. The results are summarised below in 
Table 1.3.
Treatment Mortality P Value
Placebo 
Aspirin 
Streptokinase 
Streptokinase + Aspirin
13.2%
10.7%
10.4%
8%
0.001
0.001
<0.0001
<0.0001
Table 1.3 Mortality rates with Streptokinase, Aspirin and Placebo from ISIS-2
(The ISIS 2 Working Group 1987
Therefore the effects of streptokinase and aspirin appear to be additive, achieving an 
overall reduction in mortality of 25%. Those patients treated within 4 hrs of symptoms 
with streptokinase therefore had a 35% reduction in mortality compared to 16% for
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those treated within 5-12 hrs and 21% treated within 13-24 hrs. Those patients 
receiving streptokinase between 13 and 24 hrs did not have significant improvement in 
mortality when compared to placebo. In ISIS-2 ECG changes of ST elevation were not 
applied as entry criteria to the study. However, the sub-group analysis suggested that 
those patients with normal ECGs or ST depression thought to be clinically experiencing 
myocardial infarction did not receive significant benefit from thrombolysis.
The TIMI-1 study in 1987 was a randomised double-blind, angiographic study of 290 
patients with suspected myocardial infarction comparing 1.5 MIU streptokinase vs 80 
mg r-tPA. Patency at 90 min with r-tPA was 62% vs 31% with streptokinase (p<0.001) 
(The TIMI Study Group, 1987). This trial demonstrated the benefits of tPA in achieving 
early patency, but the numbers were too small to examine mortality.
The ASSET study (Wilcox RG et al. 1990) was a randomised, double-blind, placebo 
controlled study of 100 mg of r-tPA in 5,011 patients within 5 hrs of onset of the 
symptoms with suspected myocardial infarction. r-tPA (alteplase) was given in a 
decremental infusion over 3 hrs and compared against placebo. Mortality in the tPA 
group at 1 month was 7.2% vs 9.8% in the placebo group. This shows a relative 
reduction in mortality of 26% (p=0.011). The benefits of mortality were maintained at 6 
months (relative reduction 21%) and at 1 year (relative reduction 12.6%).
The AIMS study was a randomised, double-blind, placebo controlled trial of 30 U 
anistreplase in 1,004 patients with suspected myocardial infarction up to 6 hrs after the 
onset of symptoms (AIMS Trial Study Group. 1988). Diagnostic criteria of ST segment 
elevation were required for entry into the study. All patients were heparinised followed 
by warfarin for at least 3 months and received a betablocker (timolol) in the absence of 
contraindications. There was a relative reduction in mortality of 47% at 30 days and 
43% at 1 year in the treated group. This study did not demonstrate improved benefit in 
those patients treated after 4 hrs.
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The benefits of thrombolysis vs placebo was therefore established by the studies 
described above. Therefore, further placebo controlled trials could not be justified on 
ethical grounds and the next series of large scale studies looked at the relative benefits 
of different thrombolytic agents.
The GISSI-2 study was an open, randomised trial of 1.5 MIU streptokinase vs 100 mg 
tPA (in a standard decremental infusion) in 20,891 patients with suspected acute 
myocardial infarction. In-hospital mortality was 8.7% and similar within 3 treatment 
arms (The GISSI Working Group 1988) as shown in table 1.4.
Treatment Mortality
r-tPA + Heparin 9.2%
Streptokinase 9.2%
Streptokinase + Heparin 7.9%
Table 1.4 Mortality data from GISSI-2 (The GISSI Working Group 1988)
There was no significant difference between the groups. In addition, there was a 
significant increase in the incidence of strokes in the tPA group compared to 
streptokinase (1.3% v s 0.9%).
The ISIS-3 study was a randomised, double-blind trial comparing 1.5 MIU 
streptokinase, anistreplase 30U and r-tPA (duteplase 0.6 MU/kg) in 41,299 patients with 
suspected myocardial infarction. In addition, each thrombolytic agent was considered 
with/without the addition of subcutaneous heparin 4 hrs after treatment (The ISIS 
Working Group 1992). The results showed that there was no significant difference 
between streptokinase, anistreplase and r-tPA in 5 week mortality rates (10.5, 10.6, 
10.3% respectively). There was a significantly lower incidence of stroke in the 
streptokinase group at 1.1% (p<0.001).
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The GUSTO study was a randomised, controlled trial, comparing 1.5 MIU streptokinase 
and accelerated r-tPA in 41,021 patients with suspected myocardial infarction. 30 day 
mortality in the four treatment groups are shown below(The Gusto invesigators, 1993) 
in table 1.5.
Treatment 30 Day Mortality
SK + s.c. Heparin 7.2%
SK + i.v. Heparin 7.4%
Accelerated tPA 6.3%
r-tPA + SK + i.v. Heparin 7%
Table 1.5 Mortality data from the Gusto Study (The Gusto Invesigators, 1993)
This showed that r-tPA administered in an accelerated regimen had a significant 
mortality benefit over streptokinase (p<0.01), and also that there was no significant 
benefit from streptokinase plus r-tPA (1 mg/kg) plus i.v. heparin. However, there was 
an increased incidence of stroke in the accelerated tPA group but in terms of net clinical 
benefit which is a composite analysis of 30 day mortality or non disabling stroke, 
accelerated rtPA still shows significant benefit, table 1.6.
Treatment Net Clinical Benefit
SK + s.c. Heparin 7.7%
SK + i.v. Heparin 7.9%
SK (pooled results) 7.8%
Accelerated r-tPA 7.9%
Table 1.6 Mortality data from the Gusto study (The Gusto Invesigators, 1993)
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2. EXERCISE TESTING AFTER MYOCARDIAL INFARCTION
2.1 Exercise Testing
2.1.1 Historical Perspective
Before 1960 it was common for patients recovering from an acute myocardial infarction to 
have extended bed rest in hospital and a very gradual resumption of daily activities 
following discharge. Cain HD et al (1962) used a graded activity programme with ECG 
monitoring to assess 335 patients recovering from an uncomplicated myocardial infarction 
Poor exercise capacity was correlated with the development of ST segment depression, ST 
segment elevation, and multifocal premature ventricular contractions. Torkelson LO, (1964) 
was first to use a low level exercise test to assess the functional capacity of 10 patients 
seven weeks post M.I Total exercise time and electrocardiographic changes during exercise 
were used as the basis for exercise prescription in an individualised comprehensive cardiac 
rehabilitation programme. In 1971 bicycle ergometry was used to assess ST segment 
changes occurring during exercise in 12 patients, three weeks after an anterior myocardial 
infarction (Atterhog JH et al. 1971). In 10 of the 12 patients, ST segment elevation with 
normalisation of inverted T waves was noted in the leads relating to the site of infarction. In 
addition, 3 subjects developed pronounced ST segment depression which was attributed to 
coronary insufficiency. Ibsen H et al. (1975) in a study of 209 patients at a mean of 18 days 
post M.I. using symptom-limited bicycle ergometry showed that angina or breathlessness 
occurred as the limiting symptoms in 23% of patients and significant ST segment 
depression indicative of myocardial ischemia in occurred in 70% of patients.
No complications with early exercise testing post myocardial infarction were reported and it 
was therefore concluded that the test was safe. As an objective assessment of functional 
capacity it was also used to prescribe baseline exercise levels in the resumption of daily 
activity. In 1973 a heart rate limited treadmill test was performed on 100 patients 3 weeks 
post myocardial infarction (Ericcson M et al. 1973). The occurrence of ventricular ectopic 
beats during exercise testing was greater, but not statistically significant in those patients 
who sustained an arrhythmia during the acute phase of myocardial infarction. In addition,
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20% of the patients developed angina pectoris during exercise testing and it was concluded 
that this procedure allowed objective evaluation of the exercise response in each patient. It 
was therefore essential prior to rehabilitation.
Abnormal symptomatic, electrocardiographic and haemodynamic responses to exercise 
were described in this patient group and formed the basis for further studies to determine 
the prognostic significance of these variables.
2.1.2 Type o f Exercise Test
An exercise test in the clinical setting should be designed to yield the maximum amount of 
information regarding the patient’s functional capacity and prognosis, with minimal risk. In 
1978 the effects of isometric and dynamic exercise were compared in 40 patients, 7 weeks 
post myocardial infarction (DeBusk RF et al. 1978). Dynamic whole body exercise was 
superior to isometric exercise in eliciting abnormal electrocardiographic exercise responses. 
In addition, it was shown that dynamic leg exercise was superior to dynamic arm exercise in 
assessing patients maximum exercise capacity. This result was supported in a further study 
by Galbraith et al. (1975) which compared the usefulness of isometric hand grip testing to 
low level treadmill testing in 55 patients, 3 weeks post myocardial infarction. The 
isometric hand grip test did not produce an abnormal exercise response in patients post 
myocardial infarction. The use of treadmill testing was recommended to provide an 
adequate stimulus to the cardiovascular system to enable the assessment of maximum 
exercise capacity and elicit responses to physical activity which reflected underlying clinical 
pathology.
Isometric exercise requires sustained muscle contraction, without change in muscle length. 
This prevents adequate muscle perfusion by mechanical compression of the vascular supply 
and may increase total peripheral resistance. Although this results in an increased pressure 
load on the heart, there is a minimal increase in myocardial oxygen demand with isometric 
exercise compared to whole body dynamic exercise.
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Isometric exercise is achieved by anaerobic metabolism and does not result in the 
significant increase in muscle blood flow and total body oxygen consumption caused by 
dynamic exercise.
2.1.3 Intensity o f Exercise
Patients recovering from myocardial infarction were previously perceived to be at risk of 
acute ischemic or arrhythmic events during maximum, symptom-limited exercise testing. It 
was therefore recommended that they should undergo a low level sub-maximal exercise test 
in preference. A low level exercise test has defined end-points such as the achievement of a 
pre-determined heart rate or workload. Heart rate limited tests have been arbitrarily defined 
as absolute values in the range of 110-130 beats/min or at a given percentage of age- 
predicted maximum heart rate (200-Age beats/min). Similarly, workload limited low level 
tests have been defined by the achievement of an exercise level in the range of 3-5 
metabolic equivalents. Symptom-limited and heart rate limited exercise testing were 
compared 3 weeks post myocardial infarction (De Busk RF et al. 1982). The low level 
exercise test was terminated at a heart rate of 130 beats/min in the absence of limiting 
symptoms. There was a higher peak heart rate and workload in patients who completed the 
symptom-limited protocol. However, the incidence of exercise induced ST segment 
depression and premature ventricular ectopics was not significantly different in the two 
groups. In both groups of patients, ST segment depression but not premature ventricular 
ectopic activity was predictive of early cardiac events. The study does not state whether the 
patients were randomised, and therefore the results may reflect selection bias. However, 
Starling MR et al. (1981) compared predischarge low level heart rate limit and symptom- 
limited exercise testing in a crossover study of 29 patients following an uncomplicated 
myocardial infarction The sequence of the exercise tests was randomised. The symptom- 
limited exercise test resulted in a significant increase in total exercise time, peak heart rate, 
peak rate pressure product and maximum workload when compared to the heart rate limited 
exercise test. The incidence of ST segment depression and angina was significantly greater, 
in the symptom-limited exercise test.
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In 1992 low level and symptom-limited exercise tests were compared by Juneau M et al. 
before hospital discharge after uncomplicated myocardial infarction. 200 patients were 
exercised using both protocols in a randomised sequence on consecutive days at a mean of
7.4 + 2.3 days after infarction. The symptom-limited protocol achieved a greater exercise 
duration, peak workload, peak heart rate and rate pressure product. There was a significant 
increase in the number of patients who exhibited ST segment depression of > 1 mm with a 
symptom-limited exercise test. Differences between the exercise protocol was independent 
of type of infarction (Q wave versus non-Q wave) or administration of thrombolytic 
therapy. They concluded the increased cardiovascular stress of a symptom-limited protocol 
is associated with a greater diagnostic accuracy in terms of exercise-induced ischemia.
2.1.4 Timing o f Exercise Testing
The timing of an exercise test following a myocardial infarction may have implications on 
the safety of the test and its predictive value. In 1979 low level exercise testing prior to 
discharge was evaluated by Smith JW et al. in 109 patients with uncomplicated myocardial 
infarction Patients were exercised using a modified Bruce protocol to 60% of the patients 
age predicted maximum heart rate at a mean of 18 days post myocardial infarction. Patients 
who developed ST segment depression during exercise had a significantly increased 
incidence of recurrent ischemic events during a mean follow up period of 21 months. 
However, the overall number of events in both groups was small and the results of exercise 
testing led to therapeutic interventions which may have potentially influenced outcome. 
However, it was demonstrated that early exercise testing post-myocardial infarction was 
safe and of potential predictive value. Starling MR et al. (1981) used a modified Naughton 
protocol to compare a symptom-limited exercise test performed pre-discharge and at 6 
weeks post-myocardial infarction in 89 patients recovering from uncomplicated myocardial 
infarction. 9 patients who failed to perform the exercise test at 6 weeks post discharge, 
because of an early recurrent ischemic event, had abnormal electrocardiographic responses 
in the pre-discharge exercise test. ST segment depression was highly reproducible in the 
patients who completed both pre-discharge and 6 weeks post discharge exercise tests. Other 
abnormal exercise responses such as angina, inadequate rise in systolic blood pressure and
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ventricular ectopic activity had limited reproducibility. This study therefore demonstrated 
that if a symptom-limited exercise test was performed prior to discharge, there was no 
additional information to be gained from repeating the test at 6 weeks post myocardial 
infraction.
Senaratne MPJ et al. (1988) compared low level pre-discharge and 6 weeks post discharge 
symptom-limited exercise testing in a further study of 518 patients and showed that ST 
segment changes and also symptoms of angina were similar during the low level pre­
discharge test and the symptom-limited post discharge test.
In a review by Stang and Lewis (1981) of the early studies in pre-discharge exercise testing 
it was concluded that exercise testing pre-discharge in low risk patients was safe, but the 
predictive value of an ischemic response and the indications for intervention remained 
unclear. The addition of thallium scintigraphy was recommended to enhance the predictive 
value of exercise testing post- myocardial infarction.
In 1988 it was shown by Topol EJ et al that following an uncomplicated myocardial 
infarction an exercise test performed at 3 days was safe, feasible and cost-effective. In a 
group of 179 patients who were exercised and subsequently discharged three days after 
uncomplicated myocardial infraction it was shown that there was no increased incidence of 
fatality or recurrent events, compared to control patients who were exercised between 7 and 
10 days and then discharged.
2.1,5 Safety o f Exercise Testing Post Myocardial Infarction
The studies cited above, confirm the safety of exercise testing post myocardial infarction. 
None of the studies reported a significant incidence of adverse events. In addition, exercise 
testing as early as 3 days and the use of a symptom- limited protocol have been shown to be 
feasible and safe post uncomplicated myocardial infarction.
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However, it is difficult to evaluate the overall safety of exercise testing from these studies, 
as the patients are being carefully selected to fulfil entry criteria and have usually sustained 
an uncomplicated myocardial infarction and therefore may not represent the true clinical 
spectrum.
Potential complications of post myocardial infarction exercise testing include myocardial 
rupture, aneurysm formation, extension of the myocardial infarction or precipitation of 
lethal arrhythmias (Hamm LF et al. 1986). Two cases of ventricular fibrillation were 
reported during exercise testing at 4 weeks post myocardial infarction in a total group of 
325 patients (Norris RM et al. 1984). In a series of over 1500 patients exercised post 
myocardial infarction reported a 4% incidence of ventricular arrhythmias requiring 
termination of the exercise test and 1 fatality from ventricular fibrillation (Pedersen A et al. 
1980).
In 1979 concern was raised by Lindsay J, about the safety and usefulness of early exercise 
testing. They highlighted 1 fatality during exercise testing at 13 days post myocardial 
infarction which was shown at post mortem to be due to myocardial rupture.
Contraindications to early exercise test post-myocardial infarction were identified 
(Goldschlager N Sox HC, 1988):
1. Advanced age
2. Chest pain at rest, 2-5 days prior to exercise test
3. Systolic hypertension >150 mmHg
4. Clinical evidence of heart failure
5. Poorly controlled atrial or ventricular arrhythmias
6. Resting ECG changes consistent with myocardial ischemia
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The ESC Working Group (1993) guidelines for cardiac exercise testing recommended that 
early post-infarct angina, severe heart failure and AV conduction abnormalities were 
contraindications to exercise testing in the post infarct period. These contraindications were 
used to define a complicated myocardial infarction in its broadest sense. Once medical 
therapy has been optimised, it may then be desirable to exercise patients with the above 
conditions to complete the clinical assessment or determine whether invasive investigation 
is indicated. The clinical significance of abnormal exercise test variables in complicated 
versus uncomplicated myocardial infarction was studied in 455 patients, 3 weeks post 
myocardial infarction (Saunamaki KI and Anderson JD, 1987). No deaths were reported 
during exercise testing in either group. During a 4.5 year follow up period, mortality was 
49% in complicated infarcts versus 23% in uncomplicated infarcts. ST segment depression 
did not predict mortality in either of these clinical groups.
However, the definition of complicated myocardial infraction was relatively non-specific, 
which included patients with left bundle branch block and patients receiving medications 
such as Digoxin, betablockers, calcium antagonists and antiarrhythmics.
2.2 Risk Stratification Post Myocardial Infarction
The clinical rationale for risk stratification post myocardial infarction after myocardial 
infarction is to identify patients at high risk of further ischemic events, life-threatening 
arrhythmias or sudden death. These patients may benefit from invasive investigation with a 
view to intervention which may improve prognosis. The clinical course following 
myocardial infarction and the results of exercise testing have been extensively studied to 
determine the predictive value of clinical variables and abnormal responses during exercise.
2.2.1 Clinical Variables
In 1984 a study of 205 patients post infarct it was found that a history of previous MI, high 
CK value and resting ST segment depression were predictive of outcome. The only exercise 
variable which independently predicted future events in a multivariate analysis was exercise 
duration (Williams WL et al. 1984). Cripps T et al. (1988) in a study of 176 patients post
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infarct found that exercise variables predicted further ischemic events, clinical variables and 
late potentials on signal averaged ECG predicted future arrhythmia. In the same year, a 
study of 559 survivors of less than 66 yrs of age used clinical variables and an abnormal 
exercise test to define a complicated myocardial (Campbell S et al. 1988):
1. Angina 1 month prior to infarction
2. Ventricular arrhythmias
3. Recurrent pain
4. Cardiac Failure or cardiomegaly
5. Abnormal ETT:
Angina
ST Segment Depression 
Inadequate BP response
Increased mortality at a median time of 2.4 yrs in patients with complicated compared to 
those with uncomplicated myocardial infarction (24.6% v 10.2%).. Therefore clinical 
characteristics such as recurrent myocardial ischemia, common persistent left ventricular 
dysfunction and significant cardiac arrhythmias identified patients at high risk of sudden 
death following myocardial infarction. These clinical characteristics were defined as 
(O'Rourke RA, 1991):
A. Recurrent Myocardial Ischemia
1. Recurrent chest pain after first 24 hours
2. New ST changes on electrocardiogram with/without angina
3. Further elevation of cardiac enzymes
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B. Severe left ventricular dysfunction
1. Persistent sinus tachycardia
2. Systolic blood pressure < 90 mmHg
3. Third heart sound
4. Radiographic evidence of pulmonary venous congestion
5. Cardiomegaly
C. Recurrent Arrhythmias
1. Ventricular tachycardia
2. Ventricular fibrillation
3. Asystole
4. New bundle branch block
5. AV conduction abnormalities
6. Atrial tachycardia
Such clinical events define a complicated myocardial infarction with a 15-30% risk of a 
further myocardial infarction or cardiac death within the first year. Therefore patients in this 
category, if suitable, should be considered for invasive investigation with a view to early 
intervention to reduce mortality. Although exercise testing is of value to complete the 
clinical assessment of patients with complicated myocardial infarction, it is perhaps more 
useful in assessing patients with uncomplicated myocardial infarction to identify patients 
with exercise-induced reversible ischemia and other abnormal exercise responses who also 
require early investigation. Fioretti P et al (1986) showed that clinical variables associated 
with the development of left ventricular function, dysfunction and significant arrhythmias 
also identified those patients with an adverse clinical outcome. The mean ejection fraction 
and radionucleotide ventriculography was strongly associated with survival. Patients who 
died had a mean ejection fraction of < 30% compared with 43% in those patients who 
survived.
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2.2.2 Predictive Value o f Exercise Test Variables
The electrocardiographic and haemodynamic responses to exercise have been extensively 
investigated in patients post myocardial infarction in an attempt to identify which variables 
are most sensitive and specific for the identification of patients at high risk of recurrent 
ischemic events or sudden death. Such patients might benefit from invasive investigation by 
means of coronary angiography to define their specific coronary artery anatomy, and if 
indicated, undergo revascularisation by PTCA or CABG.
2.2.2.1 ST segment depression
ST segment depression which occurs during exercise and resolves during the recovery 
period is termed reversible ischemia. Significant ST segment depression is defined as 
horizontal or downsloping > 1 mm 80 m.sec after the J point (the junction of the ST 
segment of the QRS complex) in three consecutive complexes in two contiguous leads. In 
normal individuals, ST segment depression occurs at high levels of exercise with an 
appropriate heart rate response. However, the direction of the ST segment is commonly 
upsloping and does not indicate underlying coronary artery disease. Kentala E, (1976) in a 6 
yr follow up study of 158 men post infarct under 65 yrs of age showed an association 
between early onset ST segment depression and sudden death In an influential study, 
Theroux et al (1979) investigated 210 patients with uncomplicated myocardial infarction 
with a low level exercise test at a mean of 11 days post infarct. They found patients who 
had ST segment depression during exercise testing post myocardial infarction had a 27% 
mortality at 1 year compared to a 2.1% 1 year mortality rate in those without ST segment 
depression. ST segment depression predicted mortality but not other ischemic events such 
as unstable angina, myocardial infarction or post-infarct angina during the follow up year. 
The study was the first to show an association between abnormal exercise test variables and 
mortality in post-infarct patients. However, the authors included patients with sub­
endocardial myocardial infarction (n=37) which is now known to represent a different 
clinical entity with an altered short term prognosis. The authors did not perform subgroup 
analysis of Q wave versus non-Q wave infarction. The result of the exercise test did not 
influence therapeutic decisions or the indications for invasive investigation. Five percent of
27
patients who underwent coronary artery bypass surgery were referred for invasive 
investigation on clinical grounds. In this study medical treatment was prescribed on clinical 
grounds and not on the basis of the presence of ST segment depression or other exercise test 
variables. In addition, a further analysis removing patients receiving Propranolol and 
Digitalis still showed an increased mortality in patients with ST segment depression (22% 
versus 2.6%). Fifteen patients developed ST segment elevation during exercise and were 
excluded on this basis from the analysis. This electrocardiographic response is not thought 
to represent reversible ischemia and therefore could still have been included in the analysis 
of the group who did not develop ST segment depression. Table 2.1 below shows the 
cardiac event rate in patients with either angina, ST segment depression or both during the 
exercise test.
Coronary Events
No Angina 
or ST l
Angina
Alone
S T l
Alone
Angina + 
S T l
None 70 2 10 1
Angina 45 10 15 18
(CABG) (5) (1) (1) (5)
Unstable Angina 4 0 1 1
Myocardial infarction 8 4 1 0
Death 3 0 10 7
Total 130 16 37 27
Table 2.1 Cardiac event rate in patients with either angina, ST segment depression or 
both during the exercise test (modified from Theroux 1979)
Coronary artery bypass surgery but not stable angina would be considered as hard ischemic 
end point in follow up of patients post myocardial infarction. A reanalysis of the data from 
Theroux et al 1979 is presented in Table 2.2
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Coronary Events No ST I ST -I
None 12 11
Unstable Angina 4 2
Myocardial Infarction 12 1
Death 3 17
Total Events (X2 = 50.361, P < 0.001) 25 26
Table 2.2 The incidence of cardiac events excluding angina in patients with ST 
segment depression (modified from Theroux 1979)
Further calculations were performed to derive 2 x 2  contingency tables to consider total 
events and death in relation to ST segment depression during exercise. This is shown in 
Tables 2.3 and table 2.4.
Coronary Events No S T l ST I
No Event 12 11
Events (X2 = 22.495, p < 0.001) 25 26
Table 2.3 Total events in relation to ST segment depression during exercise.
This shows that patients who experienced ST segment depression during exercise had a 
significantly greater increased cardiac event rate in the follow up period of 1 year.
Coronary Deaths No ST I ST i
No Death 143 47
Death (X2 = 31.015, p < 0.001) 3 17
Table 2.4 Coronary death in relation to ST segment depression during exercise
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As shown above, ST segment depression during exercise identifies patients at risk of death 
in the first year. From this analysis of data from Theroux et al, sensitivity, specificity, 
predictive accuracy of the positive test and the predictive accuracy of the negative test were 
calculated for all cardiac events combined and death. This is summarised in Table 2.5.
All Cardiac event ST>U Death S T i
Sensitivity 41% 50%
Specificity 76% 80%
Predictive Accuracy of +ve Test 50% 50%
Predictive Accuracy of -ve Test 80% 90%
Table 2.5 The predictive value of exercise testing
As shown, ST segment depression and angina have low sensitivity and poor positive 
predictive accuracy. However, the test is relatively specific and there is very good predictive 
accuracy of a negative result. Therefore patients with no ST segment depression during 
exercise have an excellent prognosis. In addition angina during the follow up period in the 
absence of other cardiac events was considered an ischemic end point. If angina preceding 
unstable angina, recurrent myocardial infarction or cardiac death had be considered as a 
secondary independent end point then the prediction of post infarct angina from the exercise 
test may have been improved. Chi squared tests were used in the analysis of the data which 
does not take the timing of an event or the loss of follow up into account. Kaplan Meier 
Survival analysis would have perhaps been a more appropriate statistical method and there 
was no attempt at multivariate analysis. However, this paper was the first to clearly 
establish a relationship between ST segment depression during exercise testing post 
myocardial infarction and mortality at 1 year. The design of the study, which allowed 
therapeutic or surgical interventions only on clinical grounds and not on the results of the 
exercise test, increased the impact of their observations within the existing literature.
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Further studies Beider M et al. (1988) supported these results. In a group of 262 survivors 
of acute myocardial infarction, those with an abnormal exercise test response pre-discharge 
were 13 times more likely to die in the first year. They defined an abnormal exercise test 
response as :
1. angina pectoris
2. ST segment depression horizontal or downsloping > 1 mm,
3. an inadequate systolic blood pressure response
4. dyspnoea or fatigue
5. frequent ventricular extrasystoles.
In addition, those with an abnormal response to exercise were three times more likely to 
have an ischemic event and twice as likely to develop left ventricular failure than those with 
a normal exercise response post infarct. A study of 195 men undergoing post infarct 
exercise testing showed that in a multivariate analysis ST segment depression of > 2 mm 
was predictor of further cardiac events (Davidson MD and DeBusk RF, 1980). However, 
clinical and exercise variables in 259 male patients following a myocardial infarction were 
studied to determine which variables predicted a poor prognosis (Sanz G et al. 1982). In a 
univariate analysis they found that the only predictors of survival were ejection fractions 
50% and the number of diseased vessels at coronary angiography performed at 4 weeks post 
myocardial infarction. They did not find that abnormal exercise test variables predicted 
mortality in this group of patients during a mean follow up period of 34 months. However, 
the exercise test post myocardial infarction was not performed until 6 months. Deaths and 
other cardiac events occurring within this period of time could not be included in the 
analysis which may have altered the predictive value of the test.
The relative value of clinical variables, bicycle ergometry, resting nucleotide 
ventriculography and 24 hour ambulatory electrocardiographic monitoring, were to predict
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one year mortality in a group of 351 survivors of myocardial infarction (Fioretti P et al.
1986). It was concluded that the development of ST segment depression or angina during 
the exercise test did not have a significant predictive value. The results were unchanged 
when the patients who underwent revascularisation were excluded from the analysis. 
Similarly it was shown that ST segment depression in lead 5 during exercise testing was not 
significantly associated with increased risk of death in the first year (Jennings K et al. 1984) 
or long-term prognosis, in 54 patients followed for 9 years post infarction (Nielsen JR et al. 
1990).In a meta-analysis by Jespersen C M et al. (1993) of 12 studies from 1979-1989 in 
which the predictive value of exercise testing in patients recovering from myocardial 
infarction was assessed, ST segment depression of > 1mm was shown to significantly 
increase the risk of sudden death or reinfarction with an overall odds ratio of 1.90 (Cl 
1.43,2.51). ST segment depression in inferior and non q wave infarcts compared to q wave 
anterior infarcts was shown to improve risk assessment. Anterior infarcts were more 
commonly associated with heart failure which was strongly associated with adverse 
outcome, and there was reduced sensitivity of ST depression in combination with anterior 
infarcts.
2.2.2.2 ST Segment Elevation
The significance of ST segment elevation during exercise remains unclear. It usually occurs 
in the exercise ECG in the leads showing sequential changes following a Q wave 
myocardial infarction. It is thought to represent an exercise induced wall motion 
abnormality rather than reversible ischemia. A study of 74 patients in 1984 undergoing low 
level exercise testing at a mean of 9.7 days following acute myocardial infarction showed 
that ST elevation, ST depression or both were predictors of subsequent cardiac events 
including cardiac death, left ventricular failure, recurrent myocardial infarction and angina 
during 11.3 months of follow up when compared with patients with normal exercise test 
responses (Sullivan ID et al. 1979). Further multivariate analysis showed that ST segment 
elevation was the only independent variable which predicted cardiac death. A significant 
association was shown between the development of ventricular arrhythmias and exercise 
induced ST segment elevation (Beider M et al. 1988). However other studies showed that
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ST segment elevation during exercise testing at a mean of 14 days in 407 survivors of 
myocardial infarction, did not predict clinical outcome (Fioretti P et al. 1986) and no 
significant differences were found between survivors and non survivors of myocardial 
infarction who developed ST elevation during exercise (Nielsen JR et al. 1990). It is likely 
that ST segment elevation during exercise represents a wall motion abnormality of the 
infarct site and has a complex relationship with exercise ejection fraction (Sanz G et al.
1982).
2.2.2.3 Angina Pectoris
The development of angina pectoris during the pre-discharge exercise testing post 
myocardial infarction has been shown by some authors to be predictive of future fatal and 
non fatal cardiac events. The original study by Theroux et al (1979) found that 65% of 
patients who developed angina pectoris during exercise testing developed stable angina in 
the follow' up year. Re-analysis of this data presented above, excluding post infarct angina 
as a ischemic event shows that angina during the exercise test predicted cardiac events but 
not death as shown in tables 2.6-2.9.
Coronary Events No angina Angina
None 134 25
CABG 6 6
Unstable Angina 5 1
Myocardial Infarction 9 4
Death 13 7
Total Events 33 18
Table 2.6 Angina during exercise testing in the prediction of coronary events other 
than post infarct angina (modified from Theroux 1979).
33
Coronary Events No Angina Angina
No Events 134 25
Events(X^ = 9.08, p < 0.05) 33 18
Table 2.7 Angina during exercise testing in the prediction of all coronary events 
combined other than post infarct angina (modified from Theroux 1979).
Coronary Deaths No Angina Angina
No Deaths 154 36
Death(X2 = 2.84, p = NS) 13 7
Table 2.8 Angina during exercise testing in the prediction of coronary deaths
(modified from Theroux 1979).
All Cardiac Events Death
Sensitivity 31% 35%
Specificity 79% 81%
Predictive Accuracy of +ve Test 31% 16%
Predictive Accuracy of -ve Test 80% 90%
Table 2.9 Angina During exercise in the prediction of all cardiac events and sudden 
death (modified from Theroux 1979).
Angina during exercise testing post infarct does predict future cardiac events. The absence 
of angina identifies patients at low risk post infarct. It was reported that angina pectoris 
reported during exercise testing was predictive of future coronary artery bypass surgery 
within 2 years of follow up, in 195 men following uncomplicated myocardial infarction 
(Davidson MD and DeBusk RF, 1980). However, it failed to show any relationship between 
the development of angina during exercise testing and further cardiac events such as 
recurrent myocardial infarction and sudden death.
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A study by Starling MR et al. (1981). reported that angina associated with ST segment 
depression or an inadequate systolic blood pressure response was predictive of all cardiac 
events during a mean follow up period of 11 months A further study in 1982 in a group of 
188 patients recovering from an uncomplicated myocardial infarction, showed that those 
who experienced angina during the pre-discharge exercise test at a mean of 10 days had a 
significantly increased incidence of recurrent myocardial infarction during a 27 month 
period of follow up (Jelinek VM et al. 1982). In a study of 184 males of less than 55 yrs, 
angina during the exercise test, but not ST segment depression was shown to predict angina 
and the need for CABG in the follow up period for 1 yr (Peart I et al. 1989). In a study of 
867 patients post myocardial infarction the 33% of patients with early angina (including 
predischarge exercise test) had a greater incidence of cardiac admissions and CABG but no 
increase in overall mortality at 1 or 4 yrs (Benhorin J et al. 1988). A further study showed 
no difference in mortality, left ventricular function, lipid profile or type of infarct (q wave v 
non q wave) in those patients with or without angina during exercise testing. Angina was 
significantly more common in patients defined as having a positive exercise test result (> 
lmm STl) (30% v 8%,p,0.0001)(Kamegis JN et al. 1982).
2.2.2.4 Ventricular Ectopic Beats
In a symptom-limited exercise test 3 weeks post myocardial infarction in 317 patients 
multifocal ventricular ectopic activity was a predictor of cardiac death during a mean follow 
up period of 5.7 years (Saunamaki KI and Anderson JD, 1982).However in Debacker G, 
(1982). in a review of the prognostic significance of ventricular ectopic activity during 
exercise testing post M.I. It was concluded that ventricular ectopic activity was common, 
occurring in over 50% of patients, but that the predictive value was not fully established 
with the majority of existing studies failing to show ventricular ectopic activity as an 
independent predictor of morbidity and mortality However, the study reported that 
ventricular ectopic activity correlates with impaired left ventricular function which had 
been shown in some studies to have prognostic importance. A study of risk stratification 
post myocardial infarction reported ejection fraction < 40% by RNVG, ventricular ectopics 
>10/min and clinical evidence of left ventricular dysfunction as the only independent
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predictors of mortality in a multivariate analysis(Multicenter post infarct research group,
1983). Therefore patients with ventricular ectopic activity should be investigated for 
evidence of left ventricular dysfunction as they may benefit from therapeutic intervention. 
Vermeulen A (1988) showed ventricular ectopy had no affect on factors influencing return 
to work post infarct. However there was an association between ventricular ectopic activity 
and angina.
2.2.2.5 Systolic blood pressure response
An abnormal systolic blood pressure response during exercise testing post myocardial 
infarction has been shown by several authors to be a predictor of cardiac events and 
increased mortality (Nielsen JR et al. 1990; Jennings K et al. 1984). Starling MR et al. 
(1980). reported that a systolic blood pressure rise of < 10 mmHg, a peak systolic blood 
pressure of < 140 mmHg during exercise testing post myocardial infarction was predictive 
of future cardiac events Patients with an inadequate rise in systolic blood pressure of < 30 
mmHg during exercise testing had a 13% mortality rate in the year following myocardial 
infarction compared to 2% who had normal blood pressure response (Fioretti P et al.
1984).Inadequate systolic Blood pressure response during exercise implies there is impaired 
LV systolic function due to myocardial damage at the time of infarct or myocardial 
ischemia during exercise.
2.2.2.6 Rate Pressure Product
This is defined as the product of heart rate and systolic blood pressure. The absolute rate 
pressure product and change in rate pressure product can be calculated following exercise 
testing. Rate pressure product was shown to predicted cardiac death in patients post MI 
during a mean follow up period of 5.7 years (Saunamaki KI and Anderson JD, 1982).
2.2.2.7 Functional Capacity
The amount of work performed during exercise testing has been found by several authors to 
be an independent predictor of future cardiac events. Valesco JA (1981) showed that 
mortality was predicted by exercise duration of < 5 mins in a symptom-limited ergometer
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test 3 months post myocardial infarction in 200 patients Weld FM et al. (1997)That showed 
38% of patients who exercised for < 6 mins in a low level pre-discharge exercise test died 
within 1 year compared to 1% of patients exercising for > 6 mins. Jennings K et al. (1984). 
studied a group of 103 patients who were exercised prior to discharge post myocardial 
infarction, the mortality rate was 16% at 1 year for patients failing to achieve 5 mets or a 
heart rate on exercise testing of > 130 beats/min on the Naughton protocol, compared to 2% 
for patients completing the test. Davidson MD and DeBusk RF (1980) showed that patients 
failing to achieve a peak workload of < 4 mets during exercise testing 3 weeks post 
myocardial infarction had a significantly increased rate of subsequent reinfarction, cardiac 
death and coronary artery bypass surgery during a 2 year follow up period.
Madsen EB et al. (1987). in a study of 466 patients to assess which clinical, demographic 
and electrocardiographic variables associated with myocardial infarction, predicted 
functional capacity in predischarge treadmill exercise test, showed that age and resting ST 
segment shift were the only independent predictors of functional capacity during exercise. 
Functional capacity analysed as a continuous variable was the most important single 
predictor of death and reinfarction in this patient group. Patients were categorised on the 
basis of functional capacity: > 4 mets as low risk, had a 2% mortality rate or reinfarction 
within 1 year. Patients who failed to achieve this workload were categorised as high risk 
and had an 18% cardiac event rate at 1 year. A maximum exercise capacity of < 72 watts 
was shown to predict prognosis (Nielsen JR et al. 1990). Poor exercise tolerance may be 
related to either ongoing myocardial ischemia or significant left ventricular dysfunction or 
both. The studies outlined above do not attempt to differentiate between these subgroups as 
they may have different predictive value in subsequent cardiac event rate. In addition, 
prognosis of patients with ongoing ischemia could be significantly affected by 
revascularisation.
2.2.3 Correlation with the extent o f coronary artery disease
The relationship between clinical and exercise test variables and the extent of coronary 
artery disease has been extensively investigated. If a non-invasive assessment can be shown
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to correlate with coronary anatomy, then patients who might benefit from revascularisation 
on symptomatic and prognostic grounds could be identified and referred for confirmatory 
coronary angiography. In a study of 221 patients exercised 3 weeks post myocardial 
infarction, coronary angiography was performed on 72 of the 89 patients who had 
significant ST segment depression during exercise testing(Mannering D et al. 1987). 
Downsloping or horizontal ST segment depression associated with early onset and late 
recovery after exercise identified 90% of patients with triple vessel disease. An inadequate 
systolic blood pressure response of < 10% rise from resting values with exercise was also 
predictive of triple vessel disease.
The relationship between reciprocal changes on the electrocardiogram at the time of acute 
myocardial infarction, exercise-induced ST segment depression and coronary artery 
anatomy was studied in 125 patients following myocardial infarction (Murray DP et al. 
1997). It was shown that patients with reciprocal changes on the admission ECG had a 
higher peak cardiac enzyme release and a lower ejection fraction compared to patients with 
no reciprocal changes. Multivessel disease was significantly more common among patients 
with reciprocal changes and patients with exercise-induced ST segment depression. ST 
segment depression during exercise testing compared to reciprocal change had superior 
sensitivity of 90%, specificity of 61% and a positive predictor of accuracy of 80% in the 
detection of triple vessel disease.
The extent and distribution of coronary artery disease and left ventricular dysfunction in 
123 patients in relation to the presence or absence of ST segment depression during the pre­
discharge low level exercise test post myocardial infarction was assessed by coronary 
angiography at a mean of 50 + 20 days post myocardial infarction (Griffith LSC et al.
1997). The authors found that patients with ST segment depression of > 1 mm had a 
significantly greater incidence of triple vessel disease, > 75% stenosis of the LAD or 
circumflex artery. Patients with ST segment depression during exercise were shown to have 
a greater incidence of normal or hypokinetic segmental wall motion abnormalities in areas 
of the myocardium supplied by significantly stenosed coronary arteries. They concluded
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that critical or significant stenosis subtending an area of viable myocardium is required for 
reversible ischemia during the exercise test, particularly if left anterior descending (LAD) 
disease is present. Conversely, 88% of patients with no ST segment depression during 
exercise had akinetic or dyskinetic wall segments. However Peart I et al. (1997) showed 
that in 100 patients post myocardial infarction under the age of 55 years, only 32% of 
patients with multivessel disease could be identified by ST segment depression occurring 
during low level exercise testing at 3 weeks post myocardial infarction. However, at 6 
weeks post M.I. a symptom-limited exercise test identified 60% of patients with multivessel 
disease. Eighty-seven percent of patients with angina pectoris during the symptom-limited 
exercise test were found to have multivessel disease. This study was restricted to patients of 
<55 years of age and it is likely that there is a reduced incidence of multivessel disease in 
this population. Significant stenosis was considered to > 50% narrowing of the luminal 
diameter of a major coronary artery in two orthogonal views. However, no attempt was 
made to correlate the exercise findings with the severity of stenosis of individual arteries.
A normal exercise test response post myocardial infarction identified approximately 75% of 
patients with either no coronary artery disease or single vessel disease in 40 survivors of 
uncomplicated myocardial infarction (Fuller CM et al. 1981). This emphasises the value of 
a negative test result which can be used to identify patients with a good prognosis who 
could potentially be discharged early from clinical follow up. The prognostic value of 
coronary angiography was compared to exercise testing and left ventriculography in a study 
by De Feyter PJ et al. (1982).of 179 patients. Increased morality was associated with 
ejection fraction < 30% 3 vessel disease and reduced exercise capacity (<10 ins Bruce 
Protocol). Exercise to this level would not normally be considered as reduced functional 
capacity. Failure to achieve the mean or median exercise time would perhaps been a better 
definition of reduced workload.
2.2.4 The effect o f vessel patency on outcome
The prognostic importance of infarct vessel patency following coronary angiography at a 
mean of 12 days post infarct, on clinical outcome in 97 patients with single vessel disease
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was studied by Wilson WW et al. (1988). A patent vessel was associated with non q wave 
infarct, increased ejection fraction and lack of collateral circulation There was no difference 
in cardiac event rate (cardiac death, further myocardial infarction, unstable angina, CABG 
or PTCA) in patients with or without patent vessels. Thrombolysis was not given in this 
study which was reflected in the patency rate of 41% at angiography. Patency was assessed 
a 12 days post infarct an therefore did not necessarily reflect salvage of myocardium
• • on iassociated with early patency. Reversible defects on thallium scintigraphy were however 
associated with vessel patency. ST segment depression during predischarge exercise testing 
did not predict vessel patency or clinical outcome.
A decision scheme for coronary angiography in post infarct patients was developed in 
patients under 75 yrs (Ross et al. 1989). Patients with resting reversible ischemia beyond 
day 5 post myocardial infarction, history of previous MI, evidence of peri infarct LVF 
exercise induced ischemia and reduced exercise capacity should undergo coronary 
angiography as intervention may reduce the average mortality rate in this group estimated to 
be around 16%.
2.2.5 Type o f Myocardial Infarction (Q wave v Non Q wave)
In a prospective study of 241 patients < 65 years of age with uncomplicated acute 
myocardial infarction, showed that in patients with non-Q wave infarction there was a 
reduction in infarct size, improvement in left ventricular function but no difference in 
overall mortality compared to Q wave infarcts (Gibson RS et al. 1987). In patients with 
non-Q wave infarcts, 54% had patent coronary arteries in the infarct territory with coronary 
angiography at a mean of 11 days post infarct. In addition in patients with non-Q wave 
infarct, there was an earlier peak in creatine kinase release and an increased incidence of 
reversible thallium defects in the infarct zone. Patients with non-Q wave infarcts had a 
significant increase in re-infarction rate compared to Q wave infarcts (18% v 6%) during 30 
months of follow up. There was a higher incidence of revascularisation by means of CABG 
and PTCA performed in the non-Q wave infarct group (33% versus 19%). Risk statification 
of 141 patients with first non q wave infarct was performed using clinical and exercise
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variables. Failure to perform the exercise test was associated with adverse outcome.
Patients with ST segment depression had an increased incidence of cardiac events in the 
first year post infarct with an odds ratio of 3. However the discriminatory value of 
reversible ischemia was limited to a sub group of patients with pulmonary congestion 
(Krone DJ et al. 1989). Miranda CP et al. (1991).showed that in both Q wave and non Q 
wave infarctions ST segment depression > 1 mm was a marker of the severity of coronary 
artery disease They found in a 4.4 year follow up period patients with Q wave and non Q 
wave infarcts had a similar survival rate (81% after non-Q wave, 85% after Q wave). 
However, they found a significant difference between the infarct-free survival rates of 
patients with (72%) and without (86%) severe coronary artery disease. However, the 
authors did not consider time scale of cardiac events to determine whether the events 
occurring in non-Q wave infarction occurred early following infarction. The mean ejection 
fraction in the group with Q wave myocardial infarction was 51+13% versus 68+11% in the 
group with non-Q wave infarction. Therefore, the preservation of left ventricular function 
with non-Q wave infarct did not appear to confer improved survival. However, the mean 
ejection fraction for both groups would still be considered within normal limits and a sub 
group analysis of patients with abnormal left ventricular function < 40% ejection fraction 
(Q wave versus non-infarct) may have altered long-term survival. 29% of patients 
underwent revascularisation by means of PTCA or CABG. These patients were assessed for 
recurrent infarcts to the point of intervention and were thereafter censored from further 
survival analysis. The positive predictive accuracy of the exercise test in both non-Q wave 
and Q wave myocardial infarction to identify severe coronary artery disease was improved 
by using the criteria of > 2 mm ST segment depression to define reversible ischemia. These 
studies suggest that non-Q wave infarction and Q wave infarction do not represent the same 
anatomical or clinical entity and should not be combined in studies of myocardial 
infarction.
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2.2.6 Exercise Testing with Nuclear Medicine
Multiple thallium defects were shown to identify 94% of patients at high risk of recurrent 
cardiac event during the first year of follow up, compared with 56% with other abnormal 
exercise test results (Gibson RS and Taylor GJ, 1981). The same author showed that low 
level exercise testing with thallium scintigraphy could identify 71% of post M.I. patients 
with multiple coronary artery disease (Gibson RS et al. 1983).
Thallium imaging defects in the non-infarct territory, inadequate blood pressure response to 
exercise, inadequate heart rate response or ST segment depression at a low workload were 
highly predictive of left main or three vessel disease in a group of 40 patients who had 
previously sustained myocardial infarction and who had been referred for cardiac 
catheterisation (Patterson RE et al. 1997). Thallium 201 scintigraphy performed by 
experienced staff in conjunction with early exercise testing post myocardial infarction has 
increased sensitivity and specificity for the detection of myocardial ischemia (Detrano et al. 
1997). Thallium 201 scintigraphy accurately detected previous myocardial infarction and 
was more accurate than clinical or electrocardiographic responses to exercise for detection 
of coronary artery disease in non-infarct territory in a group of 66 men with previous 
myocardial infarction (Chouraqui P et al. 1990). Gibson RS and Watson DD in 1991 
concluded that the advantages of thallium 201 scintigraphy were:
1. Increased sensitivity detecting myocardial ischemia.
2. The ability to localise ischemia to a area supplied by a specific coronary artery.
3. The ability to identify exercise-induced left ventricular dysfunction.
4. Improved risk stratification of individual patients
Ninety-seven patients with uncomplicated q wave or non q wave myocardial infarction due 
to single vessel disease not receiving thrombolysis or PTCA were studied (Wilson WW et 
al. 1988). The relationship between myocardial ischemia assessed by the pre-discharge 
exercise thallium 201 scintigraphy, and vessel patency defined by coronary angiography at a 
mean of 12 days post infarct, was studied. A significant stenosis was considered as >50%
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luminal narrowing. Patients were followed for a mean period of 39 months. However, there 
were no deaths indicating excellent prognosis in this group. 6% had a further myocardial 
infarction and 26% were hospitalised with unstable angina. Exercise-induced angina and 
ST segment depression during exercise were not predictive of recurrent cardiac events. 
However, in a quantitative assessment thallium 201 redistribution was greater in patients 
who experienced a late ischemic event. The infarct-related artery was angiographically 
patent in 41% of patients. Patency did not influence event-free survival, although in the 
absence of thrombolytic therapy, this represents spontaneous reperfusion which could occur 
at any point post-infarct, and does not equate with accelerated patency and resultant 
myocardial salvage thrombolysis. Vessel patency, reversible infarct zone thallium defects 
and a higher ejection fraction were associated with the non-Q wave infarction.
A study of viability of myocardium post infarct showed 40% of fixed defects with thallium 
201 scintigraphy had evidence of metabolic activity with positron emission tomography, 
using nitrogen-13 ammonia and fluorene-182 fluoro-deoxyglucose (FGD) (Tamaki N et al. 
1988). The authors suggests that such patients may benefit from revascularisation.
Persistent defects without metabolic activity had impaired wall motion.. However, the study 
did not perform coronary angiography to define the status of the infarct related vessel at the 
time of PET scanning. Following thrombolysis for acute myocardial infarction Thallium 
201 scintigraphy identified more patients with reversible ischemia than symptom limited 
treadmill exercise testing (Jain A et al. 1997)
Early submaximal thallium 201 SPECT exercise testing following thrombolysis for acute 
myocardial infarction was evaluated by Stewart RE et al (1991) .The extent of Thallium 
201 defect correlated with LV function. Detection of coronary disease in the non infarct 
territories by thallium 201 SPECT was poor. The size of perfusion defect was associated 
with occlusion of the infarct related artery on repeat angiography .
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2.2.7 Stress Testing with Echocardiography
Risk stratification was reviewed by Crawford MH (1997) after myocardial infarction with 
exercise and doppler echocardiography. It is possible to image 80-95% of patients before 
and after treadmill testing. New or worsening wall motion abnormalities identify 63-80% of 
patients at risk of recurrent cardiac events. In addition, exercise echocardiography detected 
multivessel disease with a sensitivity of 80% and a specificity of 90%. However, this 
technique must be very operator-dependent as echocardiographic images must be obtained 
very rapidly after the termination of exercise.
2.2.8 Pharmacological Stress Testing
Severi S and Michelassi C (1997) reviewed preliminary data on intravenous dipyridamole 
echocardiography, suggesting its usefulness for diagnosis and risk stratification in patients 
with coronary artery disease and provides additional information to that provided by 
exercise electrocardiography Dipyridamole echocardiography with stress testing performed 
early after acute myocardial infarction in a group of 131 patients prior to hospital discharge 
was safe, feasible and could accurately predict the extent of coronary artery disease and the 
clinical outcome up to 18 months (Bolognese L et al. 1991). Coma-Canella I, (1991). 
reported that if ST segment depression occurred during dobutamine stress testing in a study 
of 104 patients post myocardial infarction their prognosis was significantly worse the test. 
The safety and usefulness of dipyridamole 201 thallium scintigraphy in the prediction of 
further cardiac events after acute myocardial infarction was evaluated in 51 patients (Leppo 
JA et al. 1984). It was concluded that dipyridamole thallium scan was superior to routine 
submaximal exercise test in the prediction of subsequent cardiac events.
The usefulness of dipyridamole thallium 201 imaging compared to submaximal exercise 
thallium testing for risk stratification following thrombolysis was studied by Lette J et al. 
(1990). A case study described a patient who was shown to have severe perfusion defect on 
dipyridamole thallium imaging, but only a small ischemic area on the submaximal exercise 
test and this correlated with severe disease of the left anterior descending and suggested that
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dipyridamole thallium imaging was of additional benefit in non-invasive assessment of 
certain patients.
2.2.9 The Effect o f Therapy
There is controversy over the usefulness of exercise testing post myocardial infarction in 
patients taking betablocking agents. In 207 patients post myocardial infarction it was found 
that betablocking agents did not influence the ability of a low level exercise test to identify 
patients at high and low risk of further cardiac events (Krone RJ et al. 1987). Patients on 
betablocker obviously had a lower resting heart rate, peak exercise heart rate and rate 
pressure product. Murray DP et al. (1988) confirmed these results in a group of 125 patients 
who underwent cardiac catheterisation Betablockade did not influence the ability of the test 
to identify patients at high risk of subsequent cardiac event. However, it did reduce the 
sensitivity of the test in identifying patients with multivessel disease. Mannering D et al. 
(1987). showed that there was no significant difference in the prevalence of ST segment 
depression and abnormal systolic blood pressure response in patients on betablockers, and 
demonstrated that betablockers did not affect the accurate detection of triple vessel disease 
post infarct However, Curtis JL et al. (1991). Showed that betablockers administered 
following myocardial infarction significantly reduced the prevalence of ST segment 
depression during a submaximal exercise test and can therefore alter risk stratification.
If patients have reversible ischemia, it would be expected from clinical trials of anti-anginal 
agents that there would be a delay to time of onset of ST segment depression when patients 
were taking these drugs. However, it is likely that patients would still display reversible 
ischemia if exercised maximally. Therefore, during low level exercise testing a reduced 
incidence of ST segment depression would be expected.
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3. EXERCISE TESTING FOLLOWING THROMBOLYSIS FOR 
ACUTE MYOCARDIAL INFARCTION
3.1 Predictive value of exercise testing post thrombolysis
GISSII was the first large scale trial to demonstrate the benefits of thrombolysis. In a study 
of 11,806 patients there was a significant reduction in 21 day mortality following 
streptokinase (10.7%) versus placebo (13%)(The GISSI Working Group 1986). There was a 
10% reduction in mortality at 12 months. This led to the widespread use of intravenous 
thrombolytic therapy in myocardial infarction. Thrombolysis results in salvage of 
myocardium by reperfusion of the infarct-related artery but in 70% of cases there is a 
residual stenosis. This may result in an increased incidence of recurrence ischemic events, 
including reversible ischemia during the exercise test. Given that thrombolysis has resulted 
in a different coronary anatomy post infarct compared to previous treatment strategies, the 
predictive value of exercise testing post-infarct requires re-evaluation in the thrombolytic 
area.
3.1.1 Recurrent Early Isch emia
Schaer DH et al. (1987) compared the incidence of recurrent early ischemic events after 
intracoronary administration of streptokinase for acute myocardial infarction Patients of < 
70 yrs of age admitted within 4 hrs of the onset of symptoms of acute myocardial infarction 
who had diagnostic electrocardiographic changes were studied. A pre-treatment angiogram 
was performed in 81 patients. Those patients (n=64) with a total occlusion of the infarct- 
related artery were randomised to receive intracoronary streptokinase or intracoronary 
nitrates. 17 patients with a subtotal occlusion did not receive thrombolysis or control 
therapy. Recurrent ischemic events were defined as:
1. Spontaneous angina at rest or during ward ambulation
2. Angina provoked during pre-discharge exercise test
3. Reinfarction
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Of the 35 patients who received streptokinase, 21 (60%) reperfused within 90 mins. Of the 
29 patients who were randomised to receive intravenous nitrates only 3 reperfused at 90 
mins. 65% of those patients who had a subtotal occlusion and 48% of those patients who 
reperfused had an ischemic event. However, only 11% of patients who failed to reperfuse 
had a further ischemic event compared to the patients in the subtotal occlusion or 
reperfusion group (p < 0.01). Patients with single vessel disease were also analysed 
separately to eliminate the effect of multivessel disease as a cause of ischemic events. 
Although the numbers in this subgroup were small, those patients with a subtotal occlusion 
or those patients who reperfused at 90 mins following thrombolysis had an increased 
incidence of ischemic events. The results of the exercise testing were not analysed 
separately from the other ischemic events. The study did not include non q wave infarction. 
It is therefore interesting that 17 patients had subtotal occlusions at the time of pretreatment 
angiography. The authors therefore concluded that patent infarct-related arteries had a 
higher prevalence of in-hospital ischemic events relative to patients without reperfusion.
Topol EJ et al. (1987) evaluated exercise testing 3 days after uncomplicated acute 
myocardial infarction in 53 consecutive patients who had received reperfusion therapy by 
means of thrombolysis + coronary angioplasty. A heart-rate limited (140 beats/min) 
treadmill exercise test accompanied by thallium 201 scintigraphy was used. 26% of patients 
were shown to have a reversible perfusion defect. Of the 14 patients with a perfusion defect, 
4 had an adverse clinical outcome in the first 10 days post myocardial infarction. 69% of 
patients had no evidence of reversible ischemia and none of these patients experienced 
recurrent ischemic events during hospital admission. The study however does not state 
whether the patients were randomised to receive thrombolysis alone, angioplasty alone or 
thrombolysis plus angioplasty. It also fails to state the criteria for acute angioplasty. The 
authors could not find a clear relationship between residual stenosis of the infarct-related 
artery and reversible ischemia during the exercise test. They did not study the influence of 
multivessel disease. Non q wave infarcts were included in this study but no subgroup 
analysis was performed.
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3.1.2 Thallium Scintigraphy
A study of 236 patients with thallium 201 exercise scintigraphy 9 to 14 weeks after acute 
myocardial infarction was performed by Van Der Wall EE et al. (1997). 128 patients had 
received intracoronary streptokinase and 108 patients control therapy. 13 patients who 
received thrombolysis reinfarcted prior to thallium scintigraphy. Revascularisation was 
performed on the basis of clinical symptoms of angina and were evenly distributed between 
thrombolytic and control groups between patients allocated to the thrombolytic group.
There were no significant differences in symptoms, electrocardiographic changes, 
haemodynamic performance or peak workload during exercise testing. There was a 
significant increase in the number of segments with normal thallium activity in the 
thrombolytic group, indicating myocardial salvage and improved perfusion. No attempt was 
made to relate patency, thallium redistribution and ST segment changes during exercise 
within the thrombolytic group, and no assessment was made of residual stenosis of the 
infarct-related artery or additional vessel disease. The authors however concluded that in 
patients with first anterior myocardial infarction, early thrombolysis followed by additional 
revascularisation procedures leads to an improved myocardial perfusion, without an 
increased occurrence of exercise-induced ischemia.
The functional significance of predischarge exercise thallium 201 testing following 
intravenous streptokinase for acute myocardial infarction in 21 patients was studied by 
Touchstone DA et al. (1988). They concluded that both delayed and reverse redistribution 
during predischarge exercise thallium 201 imaging are associated with myocardial salvage, 
as defined by serial improvement in regional systolic function. However, despite the high 
patency rate of the infarct-related vessel (76%) only 30% demonstrated an improvement in 
regional function associated with delayed or reverse redistribution on the predischarge 
exercise test.
171 patients recovering from acute myocardial infarction were followed for a mean of 374 
days by Tilkemeier PL et al. (1990) to determine whether the use of thrombolytic therapy in 
acute myocardial infarction affected predictive value of low level exercise thallium 201
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testing. Sixty-four of the 171 patients (37%) received thrombolysis. There was no 
significant difference in the incidence of death, reinfarction, coronary artery bypass surgery 
or PTCA in patients treated with thrombolytic therapy versus those without interventional 
therapy. Only in the non-intervention group was the presence of ST segment depression of 
> 1 mm a predictor of cardiac events with a sensitivity of 81%. This implies that ST 
segment depression during exercise testing post myocardial infarction in patients who have 
received thrombolysis no longer has the same predictive value. In those patients who 
received thrombolysis, left ventricular dilatation was the only predictor of future cardiac 
events with a modest sensitivity of 55%. Exercise test performed was submaximal and may 
not reflect the true incidence of reversible ischemia. Routine cardiac catheterisation was not 
part of this study and no conclusions regarding patency in those patients with thrombolysis 
can be made or relationship with recurrent ischemic events defined. Therapeutic decisions 
were made on the basis of the exercise test thallium study.
Hamouratidis N et al. (1991) in a placebo-controlled study, assessed the value of exercise 
testing in patients with acute myocardial infarction treated with intravenous streptokinase 
The authors attempted to relate the results of exercise testing to recanalisation of the infarct- 
related artery by performing angiography at a mean of 22.9f7 days. 31 patients who 
received intravenous streptokinase and 39 patients who received placebo were exercised to 
a workload of 6 mets by the modified Bruce protocol, 3 weeks following myocardial 
infarction. There was no significant difference in the number of positive exercise tests as 
defined by typical angina, or ST segment depression of > 1 mm, or both in the streptokinase 
or placebo group. However, the patients treated with streptokinase had a significant 
increase in the rate of recanalisation (65% versus 38%). Patients with multivessel disease 
had an increased incidence of abnormal exercise responses. In patients with recanalised 
arteries there was an increased incidence of negative exercise tests. However, in these 
patients there was no attempt to assess the viability of the myocardium supplied by the 
infarct-related artery. In patients with an occluded artery there was an increased incidence 
of collateralisation. The authors also used the combined criteria outlined above to define a 
positive exercise test and did not consider the development of angina or ST segment
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depression as separate entities. They also did not investigate other abnormal exercise 
responses such as inadequate rise in systolic blood pressure or development of ventricular 
ectopic activity. Coronary angiography was performed late at 22.9 days and it is likely that 
time-dependent reperfusion has occurred without salvage of the myocardium in a number of 
patients.
3.1.3 Clinical and Exercise Variables
The effect of thrombolytic therapy on the chronotropic response to exercise in patients 
recovering from AMI was studied by Svendsen JH et al. (1992). 41 patients received 
intravenous streptokinase and 44 patients placebo within 12 hrs of the onset of symptoms of 
myocardial infarction, symptom-limited bicycle ergometry was used 12 days post 
myocardial infarction to assess a variety of exercise test responses in both groups. Patients 
treated with streptokinase had a significantly greater maximum heart rate and rate pressure 
product at peak exercise (p < 0.01). The total exercise time, occurrence of angina, time to 
onset of angina, maximum ST-T changes, and left ventricular ejection fraction were not 
different in the two groups. In this study, patients were included up to 12 hrs following the 
onset of symptoms of acute myocardial infarction and therefore the benefits of thrombolysis 
may not be apparent in those treated between 6 and 12 hrs and may reduce the clinical 
distinction between treated and placebo groups. Coronary angiography was not performed 
to determine the outcome of treatment in terms of patency of the infarct-related vessel.
Data from GISSI-2 (GISSI Working group, 1990, 1993, 1993) considered the clinical and 
exercise variables which predicted non fatal reinfarction and 6-month mortality post- 
myocardial infarction following thrombolysis in 10,219 patients. Inability to perform 
exercise test, early or late left ventricular failure, echocardiographic left ventricular 
dysfunction, advanced age, complex ventricular arrhythmias and previous myocardial 
infarction were all independently predictive of mortality. Early post-infarct angina, a 
positive exercise test (angina or ST segment depression 80 m.secs after the J point) or 
anterior myocardial infarction did not predict clinical outcome in terms of mortality at 6 
months. Definition of a positive exercise test did not include low workload or abnormal
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haemodynamic response. No angiographic assessment was made. Overall mortality was 
3.5% at 6 months. Rates of CABG and PTCA were low (7%)but mortality analysis 
included these patients and this intervention may have influenced the clinical outcome of 
these patients. In patients with late left ventricular dysfunction, 60% did not exhibit 
echocardiographic evidence of LV dysfunction in the peri-infarct period. In the prediction 
of outcome, the study did not analyse ST segment depression alone but included angina in 
the definition of a positive exercise test. The test was therefore qualitative. The majority of 
patients were on beta-blockers which may reduce the ischemic response during exercise. 
There appears to be a reduced incidence of ventricular dysrhythmias post-thrombolysis and 
this may be related to reduction in scar tissue formation reperfusion therapy. Increasing age 
is associated with multi-vessel disease and changes in cardiovascular function, and although 
the elderly cohort in this study is limited to < 75 yrs, increasing age is still an independent 
predictor of outcome.
The ability of the treadmill test post-infarct in 256 patients treated with thrombolysis was 
reassessed in 1993; two hundred patients underwent late coronary angiography as part of 
the study by Stevenson R et al. (1993). Intervention was offered on the basis of the 
angiogram result (ie prognostic grounds) and symptoms of limiting angina.
Cardiac events: Cardiac death, myocardial infarction, unstable angina, coronary artery 
bypass surgery and coronary angioplasty were noted over a follow-up period of 12 months 
post-infarct. A symptom limited modified Bruce exercise test was performed. Event free 
survival showed ST segment depression at a low workload and failure to achieve a median 
workload was predictive of future cardiac events. The ST depression alone, ST elevation, 
inadequate haemodynamic response, ventricular extrasystoles did not predict future events. 
Sudden death only occurred in 5 patients and no attempt was made, due to the small 
numbers, to analyse mortality data separately. The predictive value of the exercise test of 
cardiac events is shown below in table 3.1
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Sensitivity Specificity
Positive
Predictive
Accuracy
Negative
Predictive
Accuracy
s t 4- 68 53 20 88
ST* low workload 50 73 26 89
Workload < 7 mets 70 49 21 89
Abnormal Test 83 25 17 89
Table 3.1 The predictive value of the exercise test (modified from Stevenson et al)
Thus, the test has modest sensitivity and specificity but low positive predictive accuracy. 
However, the high negative predictive accuracy indicates that a negative test result defines a 
low risk population who may not require intensive cardiac follow-up. The entry criteria for 
this study included non q wave infarcts and did not sub classify types of myocardial 
infarction in the analysis. Hence, non q wave infarction associated with early recurrent 
ischemic events may have affected the results. No attempt was made to correlate infarct 
related vessel patency or additional vessel disease with outcome. Revascularisation was 
performed on patients for prognostic reasons as well as symptomatic. Although it may not 
be valid to include these patients in the analysis, removing them from the data did not affect 
the overall result.
The value of coronary angiography following thrombolysis for acute myocardial infarction 
was assessed in 1,043 patients in prediction of mortality in the European Cooperative Study 
Group where patients were randomised to alteplase/placebo or alteplase/or PTCA (Arnold 
AER et al. 1993). The age limit was <71 years and patients had > 30 minutes of chest pain 
with ST segment elevation. A symptom limited sub-maximal exercise test was performed. 
Additional exercise end points were significant arrhythmia, systolic blood pressure fall of > 
15 mmHg, and achievement of maximum heart rate (200 - age).Radionucleotide 
ventriculogram was performed prior to the exercise test and full ECGs were scored by 
Silvester scoring system and cardiac infarction injury score. Clinical variables considered 
were age, sex, sum of ST elevation, time to treatment, medical therapy, angiography and
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infarct size by cardiac enzyme. Exercise test variables included ST segment depression, ST 
elevation, maximum workload and inability to perform exercise. Global left ventricular 
ejection fraction from RNVG and contrast left ventriculography and severity of coronary 
artery disease from angiography performed at 10-22 days were also considered. Predictors 
of mortality included age, infarct size on enzymes, clinical signs of heart failure ,RNVG 
ejection fraction, inadequate systolic blood pressure rise and extent of coronary artery 
disease independent of treatment in a multivariate analysis. Symptoms of angina at rest or 
during exercise did not predict mortality. Inadequate systolic blood pressure rise led to a 
2.2-fold increase in mortality. ST segment elevation or depression did not contribute to risk 
assessment. Multi-vessel disease, residual stenosis and patency of infarct related artery 
were related to mortality. Left main disease with a residual stenosis of > 50% had a low 
incidence (0.9%)and did not predict mortality but this may be subject to a Type II error. In 
this study, revascularisation was performed if clinically indicated, and these patients were 
not censored from mortality analysis and therefore this may affect the overall result, 
assuming revascularisation influences mortality. Coronary angiography was performed late 
at 10-22 days and no early assessment of patency or residual stenosis was made. It is 
conceivable that early patency may have more influence on clinical outcome.
The thallium 201 exercise test after thrombolysis for acute myocardial infarction was shown 
to have limited prognostic value in 210 patients followed for a mean of 21 months (Miller 
TD et al. 1995). No single exercise variable predicted outcome and the only variable 
predictive of outcome was left ventricular dilatation. The study did not state whether non q 
wave infarcts were included. Coronary angiography was performed within 3 months of the 
thallium study and therefore there was no early assessment of the effects of thrombolysis. 
The exercise test was sub-maximal. There is a relationship between the severity of 
coronary artery disease and overall mortality (p = 0.03), but not with cardiac death or non- 
fatal re-infarction. They applied very strict criteria for cardiac death. However, it is likely 
that overall mortality does on the whole reflect cardiac death and that a percentage of the 
deaths defined as non cardiac would be misclassified due to lack of information regarding 
the terminal event.. The trial was not randomised and the number of events were very low
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and this may have produced a Type II error. Referral for early revascularisation may 
improve survival and therefore may bias the mortality results.
The prognostic value of a normal submaximal predischarge exercise test following 
thrombolysis was assessed in 80 patients treated conservatively following myocardial 
infarction (Marx et al. 1997). 4 patients required revascularisation on clinical grounds and 
23 had ischemic events over a mean follow up period of 12 months. This study contains 
relatively small numbers and does not define the criteria for a submaximal test, but it 
suggests limited value of exercise testing post infarct following thrombolysis. 
Administration of thrombolysis late between 12 and 49 hours was shown to reduce the 
incidence of exercise induced Ischemia compared to a control
3.1.4 Reciprocal Depression during Exercise testing following thrombolysis.
ST depression occurring during exercise in conjunction with ST segment elevation 
(Reciprocal Depression) in the site of infarct, as defined by sequential changes in the ECG 
may simply be an electrical phenomenon and not indicative of a residual stenosis of the 
infarct related artery or additional vessel disease (Stevenson RN et al. 1994)
Isolated but not Reciprocal ST depression predicted multivessel disease (predictive positive 
accuracy of 72%)Absence of ST depression was predictive of patency of the infarct related 
artery at angiography at a mean of 30 days post infarct. Reciprocal or isolated ST 
depression did not identify site of infarct. Isolated ST segment depression occurred more 
frequently in non Q wave infarcts and in association with angina during exercise. There was 
a trend for reciprocal ST segment depression to be related to occlusion of the infarct related 
vessel, reflecting unsuccessful thrombolysis and more extensive myocardial necrosis. 
Angiography was performed late in this study and no attempt was made to assess viability 
of the myocardium subtended by the infarct related vessel, therefore the relevance of 
patency in this context is questionable. However this study suggests that reciprocal 
depression should be considered as a negative result in risk stratification post infarct.
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3.2 Coronary Anatomy Post Thrombolysis and Recurrent Ischemia
Sutton JM and Topol EJ (1991) assessed the significance of negative exercise thallium 201 
exercise tests in the presence of a critical residual stenosis after thrombolytic therapy for 
acute myocardial infarction. The authors state that despite the overall benefits of 
thrombolysis, there is a limited 50-75% reperfusion rate at 90 mins , 5-15% reocclusion rate 
and a 70% incidence of a significant residual stenosis (>  70%) in the infarct-related vessel. 
101 patients who had a significant residual stenosis following thrombolysis + PTCA at 
angiography at 90 mins post treatment were exercised by a submaximal exercise treadmill 
test accompanied by 201 scintigraphy on the third or fourth hospital day post infarct. 
Exercise tests were terminated at a target heart rate of 140 beats/min in the absence of 
clinical or electrocardiographic evidence of reversible ischemia. The electrocardiographic 
diagnosis of reversible ischemia required > 2 mm of downsloping or horizontal ST segment 
depression. Thallium studies revealing fixed perfusion defects only, were considered as 
negative, as were tests which had a fixed perfusion defect with only small areas of peri- 
infarct redistribution in the absence of clinical or electrocardiographic myocardial ischemia. 
A positive test was considered as:
1. Significant completely or partially redistributing thallium 201 defect in any 
myocardial region
2. A predominantly fixed thallium 201 defect with peri-infarct redistribution associated 
with abnormal exercise electrocardiographic changes
Table 3.2 shows the clinical data relating to exercise test outcome in all patients with a 
>70% residual stenosis. As shown, the only significant difference was in the clinical data 
for patients with and without reversible ischemia is an increased peak CK level in those 
with no reversible ischemia during exercise testing. Table 3.3 shows demographic, clinical 
and exercise thallium variables for patients with and without reversible ischemia during 
exercise testing treated with thrombolysis alone. Reversible ischemia was more common in 
patients with anterior myocardial infarction (p < 0.03) and again, size of infarct defined by 
peak CK level was higher in those with no reversible ischemia during exercise. Therefore
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the effects of PTCA did not significantly influence stress test outcome. The effects of 
multivessel disease stress outcome were eliminated by considering patients with single 
vessel disease as an isolated subgroup. Results are shown in Table 3.4.
Peak CK levels again were higher in patients with no reversible ischemia, but there was no 
other difference between the groups in terms of clinical or exercise test variables. The 
authors concluded a negative early stress thallium 201 tomogram after successful 
reperfusion therapy was associated with more extensive myocardial necrosis and not delay 
in therapy or inadequate exercise performance. Angina during exercise was associated with 
a three-fold increase in the detection of significant reversible ischemia by thallium 201 
scintigraphy.
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Positive ETT Negative ETT
Patients (n) 52 49
Age (yr) 58 ± 10.4 54 ± 10.0
Male sex (n) 48(92) 39(80)
Time to t-PA therapy (min) 199±89 186±132
Prior myocardial infarction (n) 8(15) 5(10)
Infarct location
Anterior/lateral(n) 29(56) 23(47)
Inferior/posterior 23(44) 26(53)
Infarct artery (n)
LAD 29(56) 23(47)
RCA 18(35) 21(43)
LCx 5(10) 3(6)
Bypass Graft 0 2(4)
Peak CK level (IU/ml) 2605±1805 3820±3123*
Multivessel disease (n) 21(40) 19(39)
LVEF by ventriculography (%) 54±15 53=1=14
Residual stenosis of infarct vessel(%) 90±9 88±9
Heart failure (Killip’s class II or III) (n) 33(63) 28(57)
PTC A performed (n) 29(56) 30(62)
Post-PTCA residual stenosis (%) 61±33 55=1=29
Exercise Test
Peak heart rate (beats/min) 123±18 129±19
Peak systolic pressure (mmHg) 154±33 150=1=34
Time stressed (min) 6±3 8±12
Table 3.2 Clinical Data For All Patients With > 70% Residual Stenosis (modified from 
Sutton JM and Topol EJ 1991)
Values are mean±SD where appropriate; Values in parentheses are percentage, *p=0.04
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Positive ETT Negative ETT P value
Age (yr) 57±10 51±10 0.06
Male sex (n) 21(91) 17(89) 0.40
Infarct location (n)
Anterior/lateral 16(70) 7(37) 0.03*
Inferior/posterior 7(30) 12(63) 0.03*
Multivessel disease (n) 6(26) 5(26) 0.98
Time to t-PA therapy (min) 175±85 202±173 0.50
Peak CK level (IU/ml) 2399±1443 3290±2504 0.04*
LVEF by ventriculography 56±14 (%)55±13 0.64
Heart failure (Killip’s class II or III) (n) 12(52) 9(47) 0.76
Post thromboltyic stenosis (%) 85±15 82±17 0.20
Exercise thallium study
Exercise-induced angina (n) 6(26) 1(5) 0.07
Peak heart rate (beats/min) 123±21 172±17 0.40
Peak systolic pressure (mmHg) 156±37 157±30 0.92
Time stressed (min) 6±2 6±2 0.60
Table 3.3 Stress Test Outcome For Patients Treated With Thrombolysis Alone
(modified from Sutton JM and Topol EJ 1991)
Values are mean±SD where appropriate; Values in parentheses are percentage;
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Positive
ETT(N=31)
Negative
ETT(n=30) P value
Age (yr) 57±10 54±11 0.31
Male sex (n) 27(87) 23(77) 0.30
Prior MI (n) 3(10) 1(3) 0.32
Infarct artery (n)
LAD 20(65) 16(53) 0.66
RCA 10(32) 13(43) 0.66
LCx 1(3) 1(3) 0.66
Time to t-PA therapy (min) 183±94 180±142 0.93
Peak CK level (IU/ml) 2396±1891 3936±3282 0.03
LVEF by ventriculography(%) 57±14 52±13 0.18
Heart failure (Killip’s class II or III) (n) 15(48) 16(13) 0.89
Post-thrombolytic stenosis(%) 87±15 (%)88±11 0.75
PTC A performed (n) 13(42) 16(53) 0.37
Exercise thallium study
Exercise-induced angina (n) 2(7) 0.07
Peak heart rate (beats/min) 121±19 131±17 0.05*
Peak systolic pressure(mmHg) 153±35 152±31 0.95
Time stressed (min) 6±3 6±2 0.48
Table 3.4 Stress Test Outcome For Patients With Single-Vessel Disease Only
(modified from Sutton JM and Topol EJ 1991)
Values are mean±SD where appropriate, Values in parentheses are percentage;
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The lack of provokable residual ischemia after thrombolysis in patients with a significant 
stenosis of the infarct-related vessel was also seen in phase IIB of the TIMI study (The 
TIMI Study Group, 1989,1993). The results of exercise testing in the TIMI II trial did not 
predict reinfarction. It is possible that infarct-vessel remodelling following acute 
angiography occurs in the first few days following thrombolysis, therefore early 
angiography does not reflect the situation prior to exercise testing. The authors noted a 10- 
15% rate of conversion in a positive test and full symptom-limited thallium 201 stress 
testing at 6 weeks post infarct. The use of delayed (24 hour rest scanning) may have 
improved detection of viable myocardial ischemia.
In the thrombolysis in myocardial infarction (TIMI) II Trial, 2,502 patients were exercised 
by supine ergometry within 2 weeks of myocardial infarction. Patients with ECG changes 
of ST elevation or a typical history were randomised to a conservative or invasive 
management. Patients in the invasive group all underwent coronary angiography at 18 to 
48 hours post infarct. If the infarct-related vessel had a significant residual stenosis, 
patients received PTC A. In the conservative group, patients were investigated invasively if 
they experienced post-infarct unstable angina or exercise-induced reversible ischemia (ST 
segment depression > 2mm), a reduction in systolic blood pressure (> 20 mmHg), reduced 
exercise ejection fraction or complex ventricular arrhythmias. The test results was 
considered inconclusive if patients could not achieve a heart rate of 120 beats/minute or a 
workload of 400 Kpm.
Cardiac Events: Reinfarction, congestive cardiac failure, angina pectoris, CABG or further 
PTCA and death were recorded for a period of one year post-infarct. There was no 
significant difference in early cardiac event rate, incidence of ST depression during 
exercise, or the numbers able to perform exercise between the conservative and invasive 
groups. Elderly subjects, women, presence of multi-vessel disease, patients with previous 
myocardial infarction, were significantly less likely to manage the exercise test. Patients 
unable to exercise had a significant increased incidence of all cardiac events and 
specifically mortality at one year. There was no difference in rest or ejection fractions
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between invasive and conservative groups. There was also no difference in the incidence of 
ST segment depression between the groups. Exercise test variables; ST depression, ST 
elevation, angina, peak heart rates and systolic blood pressure response did not predict the 
clinical outcome in either group or both groups combined. ST segment elevation during 
exercise was associated with reduced ejection fraction (p < 0.001) and was associated with 
an increase in one year mortality. Therefore, ST elevation may be associated with reduced 
left ventricular function which is known to be associated with poor outcome. Those patients 
who had undergone PTCA and had ST segment depression during exercise had an increased 
incidence of multi-vessel disease and a higher mean per cent residual stenosis of the infarct 
related artery (p > 0.001). There was an overall trend of increased per cent residual stenosis 
in patients with ST segment depression when both groups were combined. The presence of 
collateral circulation and TIMI grade of reperfusion with the infarct related artery did not 
relate to ST segment depression during exercise. Table 3.6 below, modified from TIMI II 
data shows the relationship between exercise induced ST segment depression in both 
groups and the findings of cardiac catheterisation. Although the ST segment depression > 1 
mm was considered as an abnormal exercise response, indication for angiography was set at 
> 2 mm ST segment depression. Therefore less patients in the conservative group 
underwent angiography and thus may have influenced the results. TIMI patency grade was 
assessed before PTCA in the invasive group at 18-24 hours post-infarct. This implies the 
patients were assessed at a variable time point post-infarct and includes no early assessment 
of patency at 90 minutes post-thrombolysis. Early patency is likely to be the main 
determinant of myocardial salvage and may be more closely related to exercise induced 
myocardial ischemia. Low workload without additional reversible ischemia was treated as 
an inconclusive exercise test result and not an indication for angiography. Other studies 
have shown low workload to be related to poor left ventricular function and, therefore, 
should have been considered along with inadequate systolic blood pressure response and 
ejection fraction during exercise as an indication for angiography. Few patients had exercise 
induced ventricular arrhythmias or isolated premature ventricular beats and this is not 
associated with increased risk. Patients with the LAD artery as the infarct related vessel 
were less likely to develop ST segment depression. Before the widespread use of
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thrombolytic therapy, 30% of patients post-infarct had ST segment depression and 20% 
angina during the exercise test. Post-thrombolysis ± PTCA the incidence of ST segment 
depression during exercise testing has fallen to around 12% and angina to 5%. This refutes 
the concept that there is an increased incidence of ischemic events post-thrombolysis, but 
may reflect the addition of PTCA and early revascularisation in the TIMI 11 study. Patients 
also received thrombolytic therapy very early at< 4 hours post-onset of symptoms. If the 
patients had residual stenosis of < 60% with one vessel disease following PTCA they were 
classified as 0 vessel disease during follow-up. An insignificant coronary stenosis may not 
result in reversible ischaemia during Exercise Testing, but can still be a precursor of other 
coronary events which are caused by rupture of an atherosclerotic plaque. One year 
mortality of 1.4% in the invasive group and 2.3% in the conservative group (p = ns) 
indicate low overall mortality in those patients who survived the 14 days to perform 
exercise. There was an increase in mortality in those patients who did not perform exercise, 
but this would presumably include the early deaths. The TIMI II study (Zaret BL et al.
1995) also found that both rest and exercise radionucleotide ejection fraction in 2,567 
patients were important prognostic indicators of one year survival.
One hundred and ninety patients from TAMI 1 and 111 studies who did not undergo 
immediate PTCA following thrombolysis were studied to determine the relationship 
between morphology of the infarct related artery post thrombolysis and in hospital ischemic 
events: Cardiac death, Recurrent ischemic pain requiring emergency CABG or PTCA or 
reocclusion of infarct related artery at repeat angiography (Ellis SG et al. 1989). 21% of 
patients had recurrent ischemic events but they could not be predicted by any anatomical 
variables from the initial angiogram. A further study of the effect of infarct artery status on 
clinical outcome in 50 patients showed that residual stenosis of >50% of the infarct related 
vessel, TIMI 2 reperfusion grade(ie sub optimal flow), intermittent patency in combination 
predicted reocclusion. Residual stenosis of the infarct related artery was associated with a 
significant increase in number of in hospital ischemic events (Grines CL et al. 1988).
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Total
N=l,168
ST 4, N=127 
(%)
No ST -I 
N=l,041 (%) P Value
No of vessels > 60% 0 115 5(4.4) 110(11.7) 0.001
1 642 60(52.6) 582(61.7)
2 243 32(28.1) 211(22.4)
3 57 17(14.9) 40(4.2) 0.001
Infarct related artery RCA 490 66(55.9) 424(43.6)
IRA
LAD 463 26(22) 437(44.9)
Cx 136 26(22) 110(11.3) 0.001
Mean % stenosis 75.0 77.9 74.6 0.09
TIMI grade 0 117 17(15) 100(10.9)
1 24 2(1.8) 22(2.4)
2 99 16(14.2) 83(9)
3 794 78(69) 718(77) 0.14
Collaterals to IRA yes 121 15(13.2) 106(11.2)
no 936 99(86.8) 837(88.8) 0.54
PTCA performed yes 719 66(52) 653(62.7)
no 449 61(48) 388(37.3) 0.02
Table 3.5 The relationship between exercise induced ST segment depression and the 
findings of cardiac catheterisation (modified from TIMI II)
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4. METHODS
4.1 Admission to Coronary Care Unit
Between 1988 and 1992 two hundred and twelve patients were recruited to this study. All 
patients were admitted to the Coronary Care Unit, Stobhill General Hospital by three 
possible routes. Firstly, by direct admission to the Coronary Care Unit referred by local 
General Practitioners using a separate phone line. This facilitated early admission via the 
"back door" for patients with suspected acute myocardial infarction and significantly 
reduced the "door-to-needle" time in the administration of thrombolytic therapy. Secondly, 
patients were referred by middle grade medical staff in the usual way from the Accident & 
Emergency Department. Thirdly, patients were transferred from other wards within the 
hospital if they sustained an acute myocardial infarction during an in patient stay for other 
medical conditions.
On admission to Coronary Care, all patients had a clinical history, examination and ECG 
performed prior any therapeutic intervention. Once the diagnosis of acute myocardial 
infarction was made, standard therapies of aspirin, oxygen and opiate analgesia were 
administered unless there were specific contraindications. IV nitrates were given if 
clinically indicated at the discretion of the medical Registrar in attendance. With reference 
to the absolute and relative contraindications for thrombolysis, a decision was made as to 
whether the patient was a candidate for this treatment. If the patients were suitable for 
thrombolysis they were then considered for inclusion in one of the four studies outlined 
below. The Cardiology Registrar and Consultant on-call for thrombolysis research were 
contacted. The patient's suitability for current research study was then assessed 
immediately. The risks and benefits of the study were carefully explained to the patient and 
any attending relatives. An information sheet was issued, written informed consent was 
obtained. An example of the Patient Sheet and accompanying Consent Form are shown 
Appendix III.The patient was then entered into one of the four studies outlined below, once 
the inclusion and exclusion criteria specific for each study had been met.
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4.2 Thrombolytic Studies
The 4 separate studies are outlined briefly below. Full description of the individual studies 
are outlined in appendix I and II
4.2.1 Study l:Anisterpilase 30 U v Streptokinase 1.5 MU
128 patients were included in a randomised, controlled, double-blind, double-dummy study 
of 30 U of anistreplase vs 1.5 MU of Streptokinase. The primary endpoint of the study was 
to compare angiographic patency rates at 90 mins and 24 hrs by TIMI scoring following 
therapy. 1.5MU of Streptokinase was given intravenously over 1 hour and 30 U anistreplase 
given as an i.v. bolus over 5 miris.
4.2.2 Study 2:Bolus administration o f rTPA 2 x  35mg
33 patients were recruited to an open study to determine the efficacy of 2 x 35 mg boluses 
of Tissue Plasminogen Activator (TPA) given at 30 min intervals. The primary endpoint 
was similar to that of study 1, ie angiographic patency at 90 mins and 24 hrs following 
therapy.
4.2.3 Study 3:Bolus administration o f rTPA 3 x 20 mg
21 patients recruited in open evaluation of the efficacy of three 20mg bolus doses of TP A 
given at an interval of 10 mins between doses. The endpoint of this study was angiographic 
patency at 45, 60 and 90 mins and 24 hrs post therapy. For the purpose of this study to 
allow direct comparison with the other studies. Only angiographic patency at 90 mins and 
24 hrs were considered in the final analysis.
4.2.4 Study 4:Comparison o f 3 bolus regimes o f rTPA
31 patients in a randomised open study comparing three regimes of double bolus TPA given 
at an interval of 30 mins between boluses (a) 50 mg, followed by 50 mg, (b) 20 mg, 
followed by 50 mg, (c) 20 mg followed by 50 mg. The primary endpoints of this study were 
to assess patency at 90 mins and 24 hrs.
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4.3 Acute Angiography
Time from onset of symptoms of acute myocardial infarction to administration of 
thrombolysis was noted. Following treatment, angiography was performed in an area 
adjacent to the main Coronary Care Unit, to define patency at the time points outlined 
above. In all cases the right femoral artery was used for arterial access. Coronary 
angiography was performed using the standard Judkins's technique. A mobile x-ray Image 
Intensifier with a television display (SIREMOBIL 2N-2H) and a circular arm allowing 
rotation about the horizontal axis, was used to obtain standard angiographic views. The 
right coronary artery, visualised in a 60° LAO and a 30° RAO projection. The left anterior 
descending and circumflex arteries were visualised in a 10° RAO, a 30° RAO and a 60° 
LAO projection. A left ventriculogram was performed following the 24 hr angiogram 
however the results of this investigation was not considered in this present study. This unit 
was linked to a heavy duty video cassette recording system (JVC CR-8200E) which allowed 
permanent recordings of coronary angiograms and left ventriculograms. Each angiogram 
was performed by a Consultant Cardiologist assisted by a Cardiac Registrar. Further 
assistance was provided by the Coronary Care Nursing Staff. The Image Intensifier was 
operated by a Radiographer and an ECG Technician was present to record intra-arterial 
pressures and monitor the electrocardiogram during the procedure. Conventional Seldinger 
technique was used and a number 7 Sheath (Hemaquet, USCI International) inserted in the 
right femoral artery. On the basis of the infarct site on the admission ECG the presumed 
infarct related artery was cannulated first to determine patency. The non infarct related 
arteries were then visualised to define additional vessel disease. Following acute 
angiography, the sheath was flushed with heparin and left in situ for 24 hrs. Four hours after 
thrombolysis intravenous heparin was given as a 5000 U bolus followed by a continuous 
infusion of 1000 U/hr to achieve anticoagulation. The APPT was maintained between 2-3x 
the control value by dose adjustment of the continuous heparin infusion. Heparin was 
discontinued 30-60 mins prior to a second angiogram at 24 hrs. The sheath was removed 
once the coagulation status had reverted to normal following the second angiogram.
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Antibiotics, mainly cephalexin 500 mg tid were given as prophylaxis during the time that 
the sheath was in situ.
4.4 Patient Selection
All patients presenting at the Coronary Care Unit with suspected diagnoses of acute 
myocardial infarction were considered for thrombolytic therapy if they fulfilled the 
following criteria:
1. The onset of symptoms of myocardial infarction lasting >30 mins and < 6 hrs by the 
time of admission to the Coronary Care Unit.
2. Confirmatory electrocardiographic evidence of acute myocardial infarction with ST 
segment elevation > 1 mm in at least two standard limb leads, or > 2 mm ST 
elevation in at least two contiguous precordial leads.
3. Absence of standard contraindications for thrombolysis to limit the potential side- 
effects of this therapy.
Entry into the ongoing research study required additional entry and exclusion criteria 
outlined in appendix I and II..
Severe peripheral vascular disease or physical disability preventing coronary angiography, 
were exclusion criteria for entry into the study, but not a contraindication to thrombolysis. 
Patients with a previous myocardial infarction were eligible for the studies if the ECG 
changes of acute ST segment elevation were present in a new infarct territory.
4.5 Clinical characteristics
The following clinical characteristics were recorded for each patient, and used to predict 
the result of the predischarge exercise test and outcome during the 5 years of clinical follow 
up:
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Age was used as a continuous variable but patients were also divided into 2 group based on 
the median age to facilitate analysis of categorical data and prediction of future cardiac 
events.
Sex was compared in analysis of all data.
Infarct site was defined by the location of diagnostic ST segment elevation on the ECG on 
admission to the coronary care unit and categorised as follows:
1. Anterior:Vl-V6
2. Inferior :II, III, aVF
3. Lateral: Isolated changes in V5 and V6 or lead I and aVL
Reciprocal Depression on the admission ECG was defined as coexistent horizontal or 
downsloping ST segment depression of > 1mm 80msec after the j point in the non infarct 
territory.
Time to Thrombolytic therapy from onset of symptoms was noted. The entry criteria for 
all the research studies stipulated that thrombolysis had to be given within 6 hrs of the onset 
of symptoms. For the purpose of this analysis the patients were divided into 3 subgroups 
according to time to treatment: 0-2hrs, 2-4hrs and 4-6hrs.
4.6 Coronary Patency
The artery presumed to be the infarct-related artery from ECG changes on admission to 
Coronary Care, was visualised first during angiography at 90 min. Patency was defined by 
the TIMI scoring (Appendix IV). A score of 0 or 1 was considered as non-patent and a 
score of 2 or 3 considered as patent. Patency was reassessed angiographically at 24 hrs by 
the same scoring system. All angiograms were analysed blind by two experienced 
Consultants. If their interpretation was different, a consensus of opinion was reached
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following discussion. The effect of TIMI score 0-3 on the results of exercise testing and 
clinical outcome were considered as four distinct groups. TIMI scores were then combined 
by defining patency as TIMI score 2 or 3 and non patency as 0 or 1. The effect of patency 
on the results of exercise testing and clinical outcome could then be assessed. The 
predictive value full patency TIMI score 3 was compared against the combination of TIMI 
scores 0,1 and 2. Coronary artery patency of the infarct-related vessel was further assessed 
by combining the TIMI scores from both angiographic assessments defining time to patency 
as outlined below in Table 4.1.
Time Score 
90 mins
Time Score 
24 hrs Group
(2,3) (2,3) Early Patency (EP)
(0,1) (2,3) Late Patency (LP)
(0,1) (0,1) Non Patent (NP)
(2,3) (0,1) Reocclusion (R)
Table 4.1 Time to Patency Groups 
4.7 Residual Stenosis
Residual stenosis of the infarct related artery was defined following the angiogram at 24 hrs 
by the TIMI scoring system for coronary stenosis (appendix V). A significant stenosis was 
considered as 50-90% (score 2). However a stenosis of 90-99% with complete or 
incomplete filling (score 3 and 4 respectively) were categorised qualitatively as a significant 
stenosis and not considered as separate sub groups for the purpose of this present study. A 
total occlusion (score 5) of the infarct related artery was considered as a distinct subgroup 
and compared against no stenosis (<50%,score 1) and significant stenosis (50-99%,score 2- 
4). Following cannulation of the infarct-related vessel, the other coronary artery was 
visualised to define additional vessel disease. A similar scoring system was used to define 
significant stenosis of additional vessels. Firstly the effect of residual stenosis or occlusion 
of the infarct related artery on the results of exercise testing and clinical outcome was 
considered regardless of additional vessel disease. Patients with no significant stenosis of
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the infarct related artery and no additional vessel disease were considered as single vessel 
disease not 0 vessel disease The effect of stenosis or occlusion in single vessel disease was 
considered as a separate sub group.
4.8 Multivessel Disease
The influence of single , double and triple vessel disease on the results of exercise testing 
and clinical outcome was studied. The influence of triple vessel disease was further 
assessed by comparing it against a combination of single and double vessel disease.
4.9 Pre-discharge Exercise Testing
The arterial sheath was removed when satisfactory haemostasis had been established by 
measurement of the APPT after the 24 hr angiogram. Patients were then mobilised in the 
usual way post-infarct under the supervision of the nursing and physiotherapy staff involved 
with cardiac rehabilitation. Prior to discharge from hospital (7-33 days, mean 12 days) 
patients underwent a symptom-limited exercise test on a motorised treadmill using the 
modified Bruce protocol. It was general policy to treat patients prior to exercise testing 
conservatively, but the prescription of medication was at the discretion of the Consultant 
Cardiologist responsible for the patient's care. The exercise test was terminated for one of 
the following reasons:
1. Symptoms of angina, breathlessness, fatigue or other symptoms such as leg pain 
which prevented continuation of exercise.
2. ST depression > 3 mm Downsloping or horizontal, 80 m.secs after the J point.
3. ST segment elevation in the non-infarct territory.
4. Fall in blood pressure of > 20 mmHg in the previous stage of exercise.
5. Achievement of an age-predicted maximum heart rate (200 -age).
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Prior to the exercise test a resting 12 lead ECG was performed and blood pressure measured 
manually. The exercise test was performed using a Quinton motorised treadmill with 
continuous ECG monitoring in 3 leads (AVF, V \ and V5). A modified Bruce protocol
(Appendix VI) was used. Hard copy 12 lead ECG was produced at rest, at the end of each 3 
min stage and at 3 min intervals into the recovery phase for a period of time depending 
upon the exercise response. Blood pressure was measured manually immediately at the end 
of the exercise test
4.9.1.1 Exercise Variables
The following exercise variables were obtained from analysis of the hard copy summaries 
of the exercise test:
1. The development of ST segment depression, downsloping or horizontal > 1 mm,
80 secs after the J point in two contiguous leads.
2. The development of ST segment elevation > 1 mm in two contiguous limb leads or 
> 2 mm after the J point in the precordial chest leads, 80 m.secs after the J point.
3. T wave normalisation defined as any negative deflection of the T wave in the 
infarct territory which becomes isoelectric or positive during exercise.
4. Systolic blood pressure was measured at rest and at peak exercise. Patients were 
divided into 2 groups depending on whether they achieved a rise in systolic blood 
pressure of > 30mmHg.
5. Rate pressure product at rest and at peak exercise. Median rise in rate pressure 
product was calculated and patients were divided into 2 groups depending on 
whether they achieved the median rise in rate pressure product.
6. Any symptoms occurring during exercise. All reported symptoms were combined to 
compare symptomatic versus asymptomatic patients. Patients who were 
asymptomatic either reached target heart rate for their age or were stopped by the 
operator because of ECG or Blood pressure abnormalities on the exercise ECG. 
Angina reported during the exercise test was also considered separately in the 
analysis.
7. Total Exercise time in secs was recorded.
8. Metabolic equivalents at peak exercise.
4.10 Clinical follow up
Patients were followed up for a variable period of time at the outpatient clinic of one of the 
three Consultant Cardiologists. Intervention was on clinical grounds and not on the results 
of the angiogram at the time of acute myocardial infarction. Medication again was 
introduced on symptomatic grounds on clinical judgement of the Physician in attendance at 
the Outpatient Clinic. Five years after the administration of thrombolytic therapy, case- 
notes were reviewed to determine retrospectively which patients experienced cardiac 
events. Clinical data,the results of the angiogram performed at 90 mins and 24 hrs and the 
pre-discharge exercise test variables were related to clinical outcome.
4.11 Cardiac Events
For the purpose of this study, three time points were identified:
1. In-hospital cardiac events occurring after angiography at 90 mins to discharge from 
hospital.
2. Outpatient cardiac events occurring from hospital discharge to 5 years.
3. Overall cardiac events which combined in-hospital and outpatient events.
Events were considered as primary or secondary. Primary events were considered as likely 
to result in alteration of underlying coronary anatomy and potentially influence prognosis. 
Secondary events were thought to occur as a result of coronary anatomy defined following 
the initial invasive assessment. A patient could have a secondary event recorded and then 
experience a primary event. However once a primary event was recorded the patient was 
censored from further survival analysis and further primary or secondary events were not 
entered.
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The exception to this rule was overall mortality from sudden cardiac death, which was 
analysed separately from other end points regardless of a previous primary or secondary 
events such as recurrent myocardial infarction. It was also included in the analysis of all 
combined cardiac events as a single primary endpoint resulting in censorship of further 
events as described above.
Primary Events
1. Unstable Angina
2. Recurrent Myocardial infarction
3. Revascularisation with PTCA or CABG
4. Sudden Cardiac Death
Secondary Events
1. Peri infarct acute left ventricular failure
2. Congestive cardiac failure as an outpatient
3. Post Infarct Angina
4.11.1 Inhospital Events
4.11.1.1 Cardiac pain occurring post-infarct (unstable angina).
complaining of cardiac sounding chest pain at rest or on ward ambulation for > 10 min with 
or without accompanying ECG changes occurring in the peri infarct period following 
thrombolysis or during the period of in hospital admission. This was a primary endpoint.
4.11.1.2 Peri-infarct acute left ventricular failure.
Acute left ventricular failure (ALVF) was defined as symptoms of breathlessness at rest 
accompanied by one of the following signs:
Sinus tachycardia
Third Heart Sound
Basal Crepitations to Mid zone
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An entry in the case record by the cardiology consultant or registar confirming this clinical 
diagnosis was required. Radiological documentation was sporadic and dependent on the 
attending physician and was not used to define ALVF. This was a secondary end point 
allowing the patient to continue in the survival analysis until the first primary end point was 
recorded. It was not incorporated as a cardiac ischemic event and analysed separately
4.11.1.3 All cardiac ischemic events
1. Cardiac pain occurring post infarct
2. In hospital Mortality
3. Recurrent myocardial infarction
4. Emergency PTCA
5. Emergency CABG
The numbers of individual events in categories 2-5 were very small and could not be 
analysed seperately. They were therefore combined to define a cardiac ischemic event. 
However only primary cardiac events were recorded and thus angina and heart failure post 
infarct were not included in this group.
4.11.2 Outpatient Cardiac Events
4.11.2.1 Post-infarct angina
Angina reported to the attending physician during outpatient follow up was recorded from 
the retrospective review of the outpatient letters from the case sheet. A diagnostic exercise 
test was not required. Post infarct angina was considered a secondary end point and 
considered in isolation from the other primary ischemic endpoints.
4.11.2.2 Post Infarct Congestive Heart Failure
A diagnosis of congestive cardiac failure recorded in the case sheet by the attending 
consultant physician was required to register an event in this category. Documentation of 
clinical signs was variable as was non invasive investigations such as chest x ray or
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echocardiography and therefore not required to record congestive cardiac failure as an 
event. No analysis of medication for congestive heart failure was made. This study predated 
the widespread use of ACE I .An analysis of diuretic treatment would have been useful but 
extraction of accurate data from the outpatient letters proved very difficult. Outpatient 
Congestive Cardiac Failure was considered a secondary end point and considered in 
isolation from the other primary ischaemic endpoints.
4.11.2.3 All Cardiac Ischemic Events
The frequency of individual primary cardiac ischaemic events outlined in bold below was 
low and therefore all events were combined in this analysis.
1. A diagnosis by the consultant of Post infarct Unstable Angina requiring 
hospitalisation with or without ECG changes in the case sheet.
2. Recurrent myocardial infarction requiring 2 of the following 3 criteria 1) 
Diagnostic ECG changes of ST Elevation > 1mm or pathological T Wave Inversion 
2)chest Pain or symptoms consistent with Myocardial Infarction 3)a serial rise in 
Cardiac enzymes (CK AST LDH)
3. Revascularisation by PTCA or CABG on symptomatic or prognostic grounds. 
Patients were not referred on prognostic grounds on the basis of the results of the 
peri infarct angiograms and therefore usually required on going symptoms of angina 
and repeat diagnostic angiography.
4. Documentation of Sudden Cardiac Death occurring following a further admission 
to hospital or the A/E department from arrhythmia or end stage congestive heart 
failure was required to record this event. Death from non cardiac causes was 
recorded but not used in the analysis unless specifically indicated. Deaths at home 
not documented in the case record were defined as non cardiac. No attempt was 
made to analyse death certificate data and therefore some of these deaths may have 
been cardiac in nature an the total no of cardiac deaths underestimated over the 5 yr 
period.
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4.11.3 Overall Cardiac Events
Inhospital cardiac events were combined with out of hospital events to define overall events 
using the criteria described above for primary and secondary endpoints
4.11.3.1 All cardiac ischemic events
1. Ischemic pain post infarct
2. Unstable angina
3. Recurrent myocardial infarction
4. PTCA or CABG
5. Sudden Cardiac Death
4.11.3.2 Heart failure overall
1. Peri infarct Acute Left Ventricular Failure
2. Out patient congestive cardiac failure
both of these events were secondary end points
4.11.3.3 Mortality.
Mortality during both inpatient and out patient follow up were combined as described above 
primary events such as recurrent myocardial infarction were allowed to occur an mortality 
still recorded as a primary end point.
4.12 Statistical Analysis
Categorical variables were analysed using Chi squared analysis with MINITAB computer 
Software converting to a P value using chi squared tables. Continuous variables were 
analyse using ANOVA with MINITAB computer Software. Where appropriate continuous 
variables were converted to categorical variables to facilitate group analysis for example the 
median total exercise time was calculated and used to define 2 groups of patients those 
who failed to achieve median exercise time and those who achieved median exercise time 
or more. A macro program operating within MINITAB was written to facilitate this 
analysis. To determine the predictive value of the results of angiography and exercise
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testing on cardiac events. Kaplan Meir event-free survival analysis was used with an SPSS 
software package, comparing the groups with a log rank test. Finally to determine the 
independent predictors of clinical outcome a multivariate analysis was performed using 
Cox Regression with SPSS software package. In all statistical test significant levels were 
defined P < 0.05 however p values not quite achieving statistical significance are described 
as a trend.
4.13 Aims and Objectives
The results of Exercise testing, post myocardial infarction has been shown in the pre- 
thrombolytic era to be predictive of future cardiac events. Recent studies have reassessed 
the usefulness of the exercise test following thrombolysis and have shown reduced 
sensitivity, specificity and predictive accuracy for the exercise test in the prediction of 
future ischaemic events or cardiac death. However, no study has attempted to correlate the 
early angiographic assessment ( 90 min and 24 hrs) of coronary artery patency of the infarct 
related artery following thrombolysis and additional coronary artery disease, with the 
results of symptom limited pre-discharge exercise testing and long term clinical follow up.
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5. EXERCISE TESTING
5.1 Patient Characteristics
The demographic characteristics of the 212 patients, listed below, in this study who 
received thrombolysis within 6 hrs of the onset of symptoms of myocardial infarction, were 
analysed to determine whether they predict the results of predischarge Exercise Testing and 
clinical outcome.
1. Age
2. Sex
3. Infarct Related Artery
4. Site of Infarct
5. Reciprocal Depression
6. Time to Treatment
5.1.1 Age
The mean age was 55.9+9.1 yrs ,the age range 31-74 yrs and the median age 56 years. 
Patients were divided into 2 groups based on the median age of 56 yrs to facilitate analysis 
of categorical data. The influence of age on the results of exercise testing by ANOVA is 
shown below in Table 5.1. As shown, patients achieving less than median workload of 5.8 
mets were significantly older (57.8 ± 8.1 yrs versus 52.3 + 9.5 yrs, p < 0.001). This is 
illustrated in fig 5.1. There was no relationship between age and other exercise variables. 
The influence of age on clinical outcome in terms of in-hospital events ,out-patient events 
and overall events is summarised below in Tables 5.2, 5.3 and 5.4 respectively. As shown 
by event free survival analysis, patients older than the median age of 56 yrs had a increased 
mortality (16% v 6%,p = 0.023). There was a trend towards a greater incidence of 
outpatient cardiac events (41% v 34%,p = 0.054) and total cardiac events (50 % v 
42%,p=0.061) in older patients compared to those < the median age. This is illustrated in 
fig 5.2.
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Age (mean) SD P value
Exercise Time
< 540 sec 55.5 8.2
> 540 sec 53.7 9.9 0.227
Metabolic Equivalents
<5.8 57.8 8.1
>5.8 52.3 9.5 0.001
Change in Double Product
<8500 56.2 7.8
>8500 54.9 11.2 0.662
Change in Systolic B.P.
< 30 mmHg 55.3 8.5
> 30 mmHg 55.9 11.4 0.834
Symptoms
Asymptomatic 54.3 9.8
Symptomatic 54.6 8.5 0.831
No Angina 54.4 9.3
Angina 54.8 9.0 0.848
ST-T Changes
No ST 4- 53.7 9.8
s t 4 55.7 8.0 0.191
No ST t 54.4 9.4
ST t 54.7 8.7 0.835
N o T l 54.6 9.3
T l 54.2 9.2 0.785
Table 5.1 Age and Exercise Variables
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Figure 5.1 Exercise Capacity and Age
Age Total Patients Total Events % P Value
Ischemic Pain <56 yrs 99 9 9
>56 yrs 106 10 9 0.890
Acute LVF <56 yrs 99 10 10
>56 yrs 106 16 15 0.227
All Cardiac <56 yrs 99 14 14
Events >56 yrs 106 20 19 0.351
Table 5.2 Age and in Hospital Cardiac Events
Age Total Patients Total Events % P Value
Angina <56 yrs 99 38 39
>56 yrs 106 38 36 0.894
Heart Failure <56 yrs 99 20 20
>56 yrs 106 22 21 0.918
All Cardiac <56 yrs 99 34 34
Events >56 yrs 106 44 41 0.054
Table 5.3 Age and Outpatient Cardiac Events
Age Total Patients Total Events % P value
Mortality <56 yrs 99 6 6
>56 yrs 106 17 16 0.023
Heart Failure <56 yrs 99 27 30
>56 yrs 106 32 30 0.614
All Cardiac <56 yrs 99 41 42
Events >56 yrs 106 52 50 0.061
Table 5.4 Age and Overall Cardiac Events
Fig 5.3 shows the Kaplan Meier cumulative survival curve for patients < or > the median 
age of 56 yrs. Patients of > 56 yrs had a significant increase in mortality (p=0.023).
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5.1,2 Sex
The distribution of males and females and respective ages in the study is shown in below in 
table 5.5
Number % Age Mean ± SD P Value
Males 161 76 54.4 ± 9
Females 51 34 60.5 ± 8 0.001
Table 5.5 Age and Sex Distribution
The study population contained 34% females who were significantly older. The influence 
of sex type on the results of exercise testing by chi squared analysis, are summarised in 
Table 5.6. This table is constructed to show the true positive data ie. the number of males 
and females with the abnormal exercise variable. The total number of patients exercised 
who had the abnormal exercise response can be calculated from the percentage figures 
quoted. The total number of males or females in whom the exercise variable was recorded 
can be similarly calculated from the percentage figures in parenthesis for each sex type. 
This avoids presentation of the whole chi squared table for each variable. A total of 145 
patients were exercised. Some exercise variables such as Systolic Blood pressure response 
were not well recorded resulting in missing data and reduced numbers of observed counts.
The influence of sex on clinical outcome over 5 yrs is shown in tables 5.7 ,5.8 and 5.9. As 
shown in, 40% of males reported symptoms during the exercise test, compared to 17% of 
females (p < 0.05). This is illustrated in Fig 5.4. More males reported angina during 
exercise testing but this was not statistically significant. Chi squared analysis requires at 
least five expected counts in each cell. Therefore as only 1 female complained of angina 
during exercise this statistical method is invalidated. Sex did not affect the incidence of in­
patient, outpatient or overall cardiac events over the 5 yr. follow up period.
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Exercise Variables n = 
(% Total)
Male
n=(%Total)
Female
n=(%Total) X2 P value
Exercise Time < 540 sec 
n = 69 (44) 57 (46) 12 (38) 0.739 NS
Workload < 5.8 mets 
n = 71 (50) 55 (49) 16 (53) 0.169 NS
A In Double Product<8500 
n = 23 (48) 15(42) 8 (66) 2.254 NS
A In Systolic BP < 30 
mmHg 
n =30 (62) 21 (58) 9(75) 1.067 NS
Symptomatic 
n = 71 (46) 50 (40) 21 (17) 6.567 <0.05
Angina 
n =19 (12) 18(14) 1(3) 3.086 NS
ST Depression 
n =60 (38) 50 (40) 10(31) 0.885 NS
ST Elevation 
n =42 (27) 37 (30) 5(16) 2.682 NS
T Normalisation 
n = 65 (41) 51 (41) 14 (43) 0.072 NS
Table 5.6 Sex and Exercise Variables
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Sex Total Patients Total Events % P Value
Ischemic Pain Male 161 17 10
Female 51 4 7 0.539
Acute LVF Male 161 21 13
Female 51 7 14 0.897
All Cardiac Male 161 28 17
Events Female 51 8 16 0.700
Table 5.7 Sex and in Hospital Events
Sex Total Patients Total Events % P Value
Angina Male 161 54 24
Female 51 24 47 0.126
Heart Failure Male 161 32 19
Female 51 11 21 0.986
All Cardiac Male 161 62 39
Events Female 51 17 33 0.728
Table 5.8 Sex and Outpatient Cardiac Events
Sex Total Patients Total Events % P Value
Mortality Male 161 18 9
Female 51 5 9 0.995
Heart Failure Male 161 46 27
Female 51 16 32 0.950
All Cardiac Male 161 75 47
Events Female 51 21 41 0.441
Table 5.9 Sex and Overall Cardiac Events
83
Symptoms during Exercise test
■  Females 
□  Males
AnginaAll symptoms
Figure 5.4 Sex and Symptoms during Exercise
5.1.3 Infarct Related Artery
The infarct related artery was identified at angiography 90 min following treatment with 
thrombolysis. Table 5.10 shows the distribution of the infarct-related artery of patients in 
the study.
Infarct related artery n %
RCA 94 47
LAD 91 45
Cx 15 7
Table 5.10 Infarct Related Artery
In 12 patients angiography could not be performed and therefore the infarct related artery 
could not be defined. Only 15 patients had circumflex as the infarct-related artery. The 
numbers of events in this case was not sufficient to allow statistical analysis and this group 
was omitted allowing direct comparison between RCA and LAD arteries.
The relationship between the infarct-related artery and the results of the exercise testing is 
shown in Table 5.11. The construction of this table is similar to fig 5.6. Patients with a 
LAD occlusion had a reduced exercise capacity compared to those with RCA with more 
failing to achieve a median workload of 5.8 metabolic equivalents in the exercise test (62% 
v 40%,p<0.05). This is illustrated in Fig 5.5. There was an increased incidence of ST 
segment depression during exercise in patients with RCA compared to LAD as the infarct 
related vessel (48% v 27% p< 0.05). This is illustrated in Fig 5.6. However, ST segment 
elevation during exercise was almost exclusively seen in patients with LAD compared to 
RCA as the infarct related artery (47% v 8%,P<0.001). However T wave normalisation did 
occur in patients with RCA occlusions but was significantly more common with LAD as 
the affected artery (33% v 55%,p<0.05). The relationship between ST-T changes and 
infarct related artery is illustrated in Fig 5.6. The effect of infarct-related artery (LAD 
versus RCA) on in-hospital, outpatient and overall events are summarised in tables 5.12,
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5.13. and 5.14. As shown, patients with LAD compared to RCA as infarct related artery had 
a significantly higher incidence of peri-infarct acute left ventricular failure (20% v 
6%,p<0.003). This is illustrated by Kaplan Meier event free survival analysis in Fig 5.7.
The LAD as infarct related artery compared to RCA was more likely to result in heart 
failure as an outpatient(28% v.13%, p=0.014) and overall heart failure (44% v 16%, 
p=0.001). The Kaplan Meier event free curves are illustrated in Fig 5.8 and Fig 5.9 
respectively.
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Exercise Variables n = 
(% Total)
LAD 
n =(%Total)
RCA 
n= (%Total) X2 P value
Exercise Time < 540 sec 
n = 64 (45)
36 (51) 28 (39) 2.045 NS
Workload < 5.8 mets 
n = 66 (52)
40 (62) 26 (40) 6.131 <0.05
A Double Product < 8500 
n = 22 (51)
11(61) 11 (44) 1.226 NS
A Systolic BP < 30 
mmHg 
n = 30 (70)
15 (83) 15 (60) 2.701 NS
Symptomatic 
n = 63 (44)
34 (49) 29 (40) 0.851 NS
Angina
n = 16 (11)
7(10) 9(13) 0.251 NS
ST Depression 
n = 53 (37)
19(27) 34 (48) 6.466 <0.05
ST Elevation 
n = 39 (28)
33 (47) 6 (8) 25.91 < 0.001
T Normalisation 
n = 63 (45)
39 (55) 24 (33) 6.847 <0.05
Table 5.11 Infarct Related Artery and Exercise Variables
5.1.4 Site O f Infarct
It was possible to identify the site of infarct from the original ECG in 193 of the 212 
patients(91%). Table 5.15 shows the distribution of anterior, inferior and lateral infarcts in 
the study. Only 5 patients (2.5%) had isolated ST segment elevation in V5 and V6 or I and 
aVL defining a lateral infarct. The small number of observations in this group invalidated 
the statistical analysis and lateral infarcts were omitted allowing direct comparison between 
anterior and inferior sites of infarct. Table 5.16 shows the relationship between infarct site
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and infarct related artery. 87% of inferior and 96% of anterior infarcts could be attributed 
the RCA and LAD arteries respectively. This definition of infarct site allows inclusion of 
CX artery in the analysis as 12 inferior infarcts had CX occlusions as infarct related artery.
IRA Total Patients Total Events % P Value
Ischemic pain LAD 91 10 11
RCA 94 9 9 0.752
Acute LVF LAD 91 19 20
RCA 94 6 6 0.003
All Cardiac LAD 91 16 17
Events RCA 94 14 15 0.641
Table 5.12 Infarct Related Artery and In Hospital Cardiac Events
IRA Total Patients Total Events % P Value
Angina LAD 91 33 37
RCA 94 77 82 0.505
Heart Failure LAD 91 26 28
RCA 94 12 13 0.014
All Cardiac LAD 91 36 39
Events RCA 94 33 35 0.956
Table 5.13 Infarct Related Artery and Outpatient Cardiac Events
IRA Total Patients Total Events % P Value
Mortality LAD 91 9 10
RCA 94 5 5 0.136
Heart Failure LAD 91 40 44
RCA 94 15 16 0.001
All cardiac LAD 91 46 52
Events RCA 94 37 40 0.456
Table 5.14 Infarct Related Artery an overall Cardiac Events
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Site of Infarct n = %
Anterior 85 44
Inferior 103 53.5
lateral 5 2.5
Table 5.15 Site of Infarct
Site of Infarct LAD RCA CX
Anterior 78 1 1
Inferior 1 87 12
lateral 2 0 2
Table 5.16 Infarct site and infarct related artery
Table 5.17 shows the relationship between infarct site and exercise variables using Chi 
squared analysis. Patients with anterior compared to inferior infarcts had a reduced 
exercise capacity failing to achieve the median work load of 5.8 mets (63% v 39%,p<0.05) 
and greater incidence of inadequate systolic BP response during the exercise test (77% v 
50%,p<0.05). This is illustrated in fig 5.10. 50% of patients with anterior myocardial 
infarction had ST segment elevation in the infarct site compared to 10% with inferior 
infarcts (p< 0.001). Similarly 54% of patients with anterior compared to 31% of patients 
with inferior infarcts had T wave normalisation in the infarct site during exercise testing 
(p<0.05). However ST segment depression occurred more often in patients with inferior 
compared to anterior infarcts (47% v 27%,p< 0.05). ST -T changes during exercise testing 
and infarct related artery are illustrated in fig 5.11.
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Exercise Variables 
n=(%Total)
Anterior
n=(%Total)
Inferior
n=(%Total)
X2 P
Value
Exercise Time < 540 sec 
n = 65 (44)
35 (53) 30 (37) 3.771 NS
Workload < 5.8 mets 
n = 66 (49)
38 (63) 28 (39) 7.237 <0.05
A Double Product < 8500 
n = 21 (45)
11 (39) 10(55) 1.169 NS
A Systolic BP < 30 mmHg 
n = 28 (60)
14 (77) 14 (50) 3.549 <0.05
Symptomatic 
n = 69 (47)
34 (53) 35 (43) 1.007 NS
Angina 
n = 18 (12)
8(12) 10(12) 0.002 NS
ST Depression 
n = 56 (38)
18(27) 38 (47) 5.949 <0.05
ST Elevation 33 (50) 8(10) 28.65
1
< 0.001
n = 41 (28)
T Normalisation 
n = 61 (41)
36 (54) 25 (31) 8.401 <0.05
Table 5.17 Infarct Site and Exercise Variables
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Infarct Site Total Patients Total Events % P Value
Ischemic pain Inferior 103 11 11
Anterior 90 7 8 0.454
Acute LVF Inferior 103 7 7
Anterior 90 14 16 0.051
All Cardiac Inferior 103 17 16
Events Anterior 90 11 12 0.395
Table 5.18 Infarct Site and in Hospital Cardiac Events
Infarct Site Total Patients Total Events % P Value
Angina Inferior 103 43 42
Anterior 90 33 37 0.299
Heart Failure Inferior 103 16 16
Anterior 90 27 30 0.055
All Cardiac Inferior 103 38 37
Events Anterior 90 38 43 0.845
Table 5.19 Infarct Site and Outpatient Cardiac Events
Infarct Site Total Patients Total Events % P Value
Mortality Inferior 103 9 9
Anterior 90 7 7 0.948
Heart Failure Inferior 103 19 18
Anterior 90 36 40 0.002
All cardiac Inferior 103 43 42
Events Anterior 90 44 51 0.980
Table 5.20 Infarct Site and Overall Cardiac Events
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As shown in tables 5.18, 5.19 and 5.20 patients with anterior infarcts compared to inferior 
infarcts have a significantly increased incidence of peri infarct Acute LVF (16% v 7% 
p=0.051),heart failure as an outpatient, (27% v 16% p=0.055) and heart failure overall(36% 
v 19% p=0.002). The corresponding Kaplan Meier curves are shown in fig 5.12, 5.13 and 
5.14.
5.1.5 Reciprocal Depression
Patients with reciprocal depression (RD) on the admission ECG were identified. The effects 
of reciprocal depression on the results of exercise testing by Chi squared analysis are shown 
in table 5.21. The effect of reciprocal depression on clinical outcome is shown in tables 
5.22 5.23 and 5.24. Patients with reciprocal depression have a significantly greater 
incidence of ST segment depression during exercise testing (51% v 21%, p<0.01) but a 
reduced incidence of ST segment elevation (22% v 35%,p<0.05)during exercise testing 
compared to those without reciprocal depression on the original admission ECG. This is 
illustrated in fig 5.15. 22 % of Patients with cardiac pain post infarct had reciprocal 
depression on the admission ECG compared to 9% of patients without, p=0.021. The 
incidence of Peri infarct acute left ventricular failure was significantly greater in patients 
with reciprocal depression (17% v 6%,p=0.027). This is illustrated in Fig 5.16. There was 
no difference in frequency of events as an outpatient or overall with reciprocal depression 
on the admission ECG.
5.1.6 Time to treatment
Time from onset of symptoms of myocardial infarction to administration of thrombolysis 
was divided into 3 time intervals 0-2hrs, 2-4hrs and 4-6 hrs. The distribution of patients 
within each time interval is shown in table 5.25. 68% of patients were treated within 4hrs 
of onset of symptoms. The effect of time to treatment on exercise variables by Chi squared 
analysis is shown in table 5.26. This is illustrated in fig 5.17. The effect of time to 
treatment on clinical outcome is shown in tables 5.27, 5.28 and 5.29.
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Exercise Variables NoRD RD X 2 P Value
Exercise Time < 540 sec 
n = 65 (44)
26 (41) 39 (46) 0.388 NS
Workload < 5.8 mets 
n = 66 (50)
30 (52) 36 (48) 0.181 NS
A Double Product < 8500 
n = 21 (46)
8(44) 13(46) 0.017 NS
A Systolic BP < 30 mmHg 
n = 28 (60)
10(56) 18(64) 0.351 NS
Symptomatic 
n = 69 (47)
33(52) 36(43) 1.311 NS
Angina
n = 18 (12)
7(11) 11(13) 0.132 NS
ST Depression 
n = 56 (38)
13(21) 43(51) 14.252 P< 0.01
ST Elevation 
n = 41 (28)
22(35) 18(22) 3.896 P<0.05
T Normalisation 
n = 61 (41)
29(46) 32(38) 0.934 NS
Table 5.21 Reciprocal Depression and Exercise Variables
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RD Total Patients Total Events % P Value
Ischemic pain NoRD 79 7 9
RD 133 29 22 0.021
Acute LVF NoRD 79 5 6
RD 133 23 17 0.027
All Cardiac NoRD 79 7 16
Events RD 133 29 12 0.395
Table 5.22 Reciprocal Depression and in Hospital Cardiac Events
RD Total Patients Total Events % P Value
Angina NoRD 79 28 36
RD 133 50 38 0.676
Heart Failure NoRD 79 19 24
RD 133 24 18 0.419
All Cardiac NoRD 79 28 35
Events RD 133 51 39 0.972
Table 5.23 Reciprocal Depression and Outpatient Cardiac Events
93
RD Total Patients Total Events % P Value
Mortality NoRD 79 8 10
RD 133 15 11 0.684
Heart Failure NoRD 79 22 28
RD 133 40 30 0.219
All Cardiac NoRD 79 32 40
Events RD 133 64 48 0.166
Table 5.24 Reciprocal Depression and Overall Cardiac Events
No of Patients %
0-2 hrs 27 1
3
2-4 hrs 117 5
5
4-6 hrs 68 3
2
Table 5.25 Time to Treatment Groups
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Figure 5.15 Reciprocal Changes and ST Segment changes during Exercise
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Figure 5.17 Time to treatment and Angina during Exercise Testing
Time to Therapy
Exercise Variables 
n=(%Total)
0-2 hrs
n=(%Total)
2-4 hrs
n=(%Total)
4-6 hrs 
n=(% Total)
X 2 P Value
Exercise Time< 540 sec 
n = 69 (44)
9(45) 34(37) 26(56) 4.341 NS
Workload < 5.8 mets 
n = 71 (50)
9(50) 39(46) 23(58) 1.329 NS
A Double Product < 500 
n = 23 (48)
5(8) 13(46) 7(58) 0.894 NS
A Systolic BP< 30 
mmHg
n = 30 (62)
6(75) 17(60) 7(58) 0.660 NS
Symptomatic 
n = 86 (55)
11(55) 49(54) 26(56) 0.053 NS
Angina 
n = 19 (12)
6(30) 9(10) 4(9) 6.860 P<0.05
ST Depression 
n = 60 (38)
10(50) 29(31) 12(25) 3.386 NS
ST Elevation 
n = 42 (27)
4(20) 25(28) 13(28) 0.562 NS
T Normalisation 
n = 65 (42)
10(50) 41(46) 14(30) 3.519 NS
Table 5.26 Time to Treatment and Exercise Variables
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Time to Therapy Total Patients Total Events % P Value
Ischemic pain 0-2 hrs 27 4 15
2-4 hrs 117 13 11
4-6 hrs 68 4 6 0.324
Acute LVF 0-2 hrs 27 16 15
2-4 hrs 117 8 14
4-6 hrs 68 6 1 0.909
All Cardiac 0-2 hrs 27 6 22
Events 2-4 hrs 117 22 19
4-6 hrs 68 8 1 0.303
Table 5.27 Time to Treatment and in Hospital Cardiac Events
Time To Therapy Total Patients Total Events % P Value
Angina 0-2 hrs 27 12 44
2-4 hrs 117 51 28
4-6 hrs 68 16 24 0.059
Heart Failure 0-2 hrs 27 6 22
2-4 hrs 117 22 19
4-6 hrs 68 15 23 0.727
All Cardiac 0-2 hrs 27 15 56
Events 2-4 hrs 117 38 33
4-6 hrs 68 22 33 0.116
Table 5.28 Time to treatment and Outpatient Cardiac Events
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Time to Therapy Total Patients Total Events % P Value
Mortality 0-2 hrs 27 6 22
2-4 hrs 117 10 9
4-6 hrs 68 7 10 0.530
Heart Failure 0-2 hrs 27 8 29
2-4 hrs 117 34 30
4-6 hrs 68 20 30 0.980
All Cardiac 0-2 hrs 27 16 59
Events 2-4 hrs 117 53 46
4-6 hrs 68 27 40 0.465
Table 5.29 Time to Treatment and Overall Cardiac Events
As shown, the development of angina during exercise testing was related to early 
thrombolysis. 30% of patients who received treatment within 2 hrs experiencing symptoms 
during exercise testing p<0.05. Patients treated with thrombolysis within 2 hrs of the onset 
of symptoms were more likely to develop angina during outpatient follow up, p=0.058.
This is further illustrated by the multiple comparisons of time to therapy groups for angina 
during the follow up period. Table 5.30 shows the p values for inter group comparisons
Time to therapy 0-2 hrs 2-4 hrs
2-4 hrs 
4-6 hrs
0.577
0.051 0.033
Table 5.30 Multiple comparisons (p values) of Time to Therapy groups and Angina as 
an outpatient.
The effect of time to treatment on clinical outcome showed a trend towards increased 
frequency of all cardiac events as an outpatient with early thrombolysis, p=0.116. Multiple 
comparisons ( p Values) of individual time to therapy groups show significant differences 
between thrombolysis at 0-2 hrs compared to 2-4 hrs (p=0.049)) as shown in table 5.31.
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Time to therapy 0-2 hrs 2-4 hrs
2-4 hrs 
4-6 hrs
0.049
0.097 0.745
Table 5.31 Multiple comparisons (p values) of Time to Therapy and All Cardiac 
Events as an Outpatient
5.2 Exercise Variables In The Prediction Of Clinical Outcome
5.2.1 Exercise Capacity
The results of the exercise test were used to predict future cardiac events but not related 
retrospectively to results of in patient peri infarct data e.g. exercise capacity was not used as 
an independent variable to predict patency but patency was used to predict the results of 
exercise testing. 156 patients exercised for a mean of 543 + 205 secs, range 64-1093 sec. 
The median exercise time was 540 secs. Table 5.32 shows the relationship between median 
exercise time and outpatient events. Patients were divided into 2 groups: those who failed to 
achieve the median exercise time (< 540 secs) and compared to those patients who achieved 
the median time or greater (> 540 secs).
The average metabolic equivalents achieved by the patients was 5.9 + 2.4 mets, range 2.3- 
12.9 mets. The median workload achieved was 5.8 mets. Table 5.33 shows the 
relationship between median mets and outpatient events. As shown there was no 
relationship between exercise capacity measured as total exercise time or metabolic 
equivalents time and cardiac events during outpatient follow up.
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Time Total Patients Total Events % P Value
Angina <540 sec 67 24 36
>540 sec 87 39 45 0.287
Heart Failure <540 sec 69 10 14
>540 sec 87 20 23 0.281
All Cardiac <540 sec 69 24 36
Events >540 sec 87 35 40 0.763
Mortality >540 sec 69 4 6
>540 sec 87 3 3 0.721
Table 5.32 Exercise Capacity (in Secs) and Outpatient Cardiac Events
Mets Total Patients Total Events % P Value
Angina <5.8 mets 70 28 40
>5.8 mets 71 30 43 0.836
Heart Failure <5.8 mets 71 13 18
>5.8 mets 71 15 21 0.826
All Cardiac <5.8 mets 71 21 29
Events >5.8 mets 71 28 39 0.741
Mortality >5.8 mets 71 2 3
>5.8 mets 71 3 4 0.978
Table 5.33 Exercise Capacity (in Mets) and Outpatient Cardiac Events
5.2.2 Systolic Blood Pressure
The mean change in systolic BP was 20 + 15.7 mmHg, range -12 to 70 mmHg. The failure 
to increase systolic blood pressure by 30 mmHg, shown by previous studies to be a poor 
prognostic indicator, was chosen to identify those patients who had an adequate systolic 
Blood Pressure response (>30 mmHg) to exercise. This was used to predict future 
outpatient cardiac events. As shown in Table 5.34 Systolic blood pressure response during 
exercise testing was not useful in identifying patients at high risk of future cardiac events.
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BP Total Patients Total Events % P
Value
Angina <30 mmHg 30 11 37
>30 mmHg 18 7 39 0.392
Heart Failure <30 mmHg 30 7 23
>30 mmHg 18 3 17 0.173
All Cardiac <30 mmHg 30 11 37
Events >30 mmHg 18 7 39 0.465
Mortality >30 mmHg 30 3 10
>30 mmHg 18 1 5 0.562
Table 5.34 Systolic Blood Pressure Rise and Outpatient Cardiac Events
5.2.3 Rate Pressure Product
The mean change in rate pressure product (RPP) during exercise was 8983 + 3255, range 
3248-19970. The median change in rate pressure product was 5800. Table 5.35 shows that 
change in rate pressure product fails to predict outpatient events in this study during follow 
up.
RPP Total Patients Total Events % P Value
Angina <5800 23 9 33
>5800 25 9 36 0.603
Heart Failure <5800 23 5 22
>5800 25 5 20 0.927
All Cardiac <5800 23 9 33
Events >5800 25 9 36 0.627
Mortality >5800 23 2 9
>5800 25 2 8 0.818
Table 5.35 Change in Double Product and Outpatient Cardiac Events
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5.2.4 ST-T Changes During Exercise
5.2.4.1 ST Segment Depression
ST segment depression of > 1 mm, 80 m.sec after J point occurred in 60 (38%) of 156 
patients undergoing exercise testing. The relationship between ST segment depression and 
cardiac events during follow up is shown in Table 5.36. ST segment depression did not 
predict future cardiac events as an outpatient. The infarct site was defined by ECG on 
admission, in 150 patients who were subsequently exercised prior to discharge. Of the 60 
patients with ST depression it occurred in the non-infarct site in 52(87%) patients compared 
to 6(13%) patients in the site of the original infarct. 2 patients (3%) had ST depression in 
both infarct and non infarct sites. Therefore ST segment depression occurs predominantly 
in the non infarct site, 0.001, by Chi squared analysis. This is illustrated in figure 5.18.
STD Total Patients Total Events % P Value
Angina No STD 94 37 39
STD 60 26 43 0.108
Heart Failure No STD 96 19 20
STD 60 11 18 0.764
All Cardiac No STD 96 40 42
Events STD 60 19 48 0.721
Mortality No STD 96 5 5
STD 60 2 3 0.655
Table 5.36 ST Segment Depression and Outpatient Cardiac Events
A further analysis was made using ST depression of > 2 mm as significant. There was no 
improvement in the ability to predict clinical events.
101
Pe
rc
en
ta
ge
ST Depression related to site of infarction
st depression
□  infarct site H non infarct site ■  both
Figure 5.18 ST Segment Depression and Site of Infarct
5.2.4.2 ST Segment Elevation
ST elevation occurred in 42 (27%) of 156 patients exercised. As shown in table 5.37 and 
Fig 5.19 ST elevation occurred predominantly in the infarct site, as defined by admission 
ECG, compared to the non infarct site (83% v 17%,p<0.001):
Site of elevation n %
Infarct site 
Non infarct site
35
7
83
17
Table 5.37 Site Of ST Segment Elevation
The relationship between ST elevation (STE) and outpatient cardiac events are shown in 
Table 5.38. ST segment elevation during exercise testing did not predict clinical outcome.
ST ? Total Patients Total Events % P Value
Angina No STE 114 43 38
STE 42 20 48 0.393
Heart Failure No STE 114 19 17
STE 42 11 26 0.637
All Cardiac No STE 114 43 38
Events STE 42 16 38 0.721
Mortality No STE 114 6 5
STE 42 1 2 0.565
Table 5.38 ST Segment Elevation and Outpatient Cardiac Events
5.2.4.3 T wave Normalisation
T wave normalisation (TE), defined as the return of a negative T wave on the pre test ECG 
to the isoelectric line or beyond during exercise testing, occurred in 65 (41%) of 156 
patients exercised. This occurred exclusively in the site of infarction (pO.OOOl). The 
relationship of T wave normalisation and outpatient cardiac events are summarised in Table
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Figure 5.19 ST Segment Elevation and Site of Infarct
5.39. As shown T wave normalisation did not predict cardiac events although there was a 
trend for increased incidence of angina in those patients who had T wave normalisation.
r j i  ^  ^ Total Patients Events % P Value
Angina No TE 89 30 33
TE 65 33 50 0.097
Heart Failure No TE 91 14 15
TE 65 13 20 0.265
All Cardiac No TE 91 35 38
Events TE 65 24 37 0.996
Mortality No TE 91 6 6
TE 65 1 2 0.252
Table 5.39 T Wave Normalisation and Outpatient Cardiac Events
5.2.4.4 ST Segment Depression at low workload
ST segment depression at a low workload was analysed to determine whether this improved 
the ability of ST depression predict future events. 25 patients (15%) with ST depression of 
> 1 mm failed to achieve the median workload of 5.8 mets. The relationship between ST 
depression at low workload is shown in Table 5.40.
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STD Total Patients Total Events % P value
Angina No STD 116 48 41
STD 25 10 40 0.960
Heart Failure No STD 117 20 17
STD 25 8 32 0.764
All Cardiac No STD 117 42 36
Events STD 25 7 28 0.267
Mortality No STD 117 4 3
STD 25 1 4 0.647
Table 5.40 ST Segment Depression at a Low Workload and Outpatient Cardiac 
Events
Patients with ST segment depression at a low workload during the exercise test were no 
more likely to experience cardiac events compared to those without this abnormality.
5.3 Patients not undergoing exercise testing
The decision to perform predischarge exercise testing was at the discretion of the physician 
in charge of the patients care. The reason for not performing an Exercise test was not 
always recorded but this subgroup was compared to those undergoing exercise testing in the 
prediction of future cardiac events, as shown in Table 5.41. The 12 patients who died (10 
from sudden cardiac deaths and 2 non cardiac death from CVA) during the inpatient period 
were not included in this analysis as they were not eligible to perform the exercise test and 
an event (in patient Mortality) cannot be predicted retrospectively. (26%) of patients did 
not undergo exercise testing. Patients failing to undergo exercise testing did not have an 
increased incidence of cardiac events. However when the deaths from non cardiac causes 
that occurred during outpatient follow up were included in the analysis patients who failed 
to undergo a predischarge exercise test had an increased mortality (18% v 5%, p=0.011). 
This is illustrated in Fig 5.22.
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ETT Total Patients Total Events % P value
Angina No ETT 40 14 35-
ETT 156 65 42 0.651
Heart
Failure
No ETT 40 11 28
ETT 156 30 19 0.193
All Cardiac No ETT 40 16 40
Events ETT 156 54 35 0.341
Outpatient No ETT 40 3 7
Mortality ETT 156 6 4 0.366
All Deaths No ETT 40 7 18
ETT 156 8 5 0.011
Table 5.41 No Exercise Testing and Cardiac Events
5.4 Symptoms During Exercise
5.4.1 All Symptoms during Exercise Testing
The exercise test was symptom limited .However if the patients reached an age predicted 
maximum heart rate ,developed significant arrhythmias or ST segment depression of > 3 
mm the test was terminated. Fig 5.20 shows the distribution of symptoms during exercise. 
Patients with any symptoms (S YMP) during the exercise test were compared with those 
who were asymptomatic. Then, patients with angina were compared to those patients with 
no symptoms of angina. 70 (45%) of patients were asymptomatic during exercise testing 
.Table 5.42 shows that combined symptoms during exercise testing did not predict 
outpatient cardiac events during follow up
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Figure 5.20 Symptoms during Exercise Testing
Symptoms Total Patients Total Patients % P Value
Angina No SYMP 68 24 35
SYMP 86 39 45 0.328
Heart
Failure
No SYMP 70 11 16
SYMP 86 19 22 0.703
All Cardiac No SYMP 70 24 34
Events SYMP 86 35 41 0.308
Mortality No SYMP 70 4 6
SYMP 86 3 3 0.966
Table 5.42 All Symptoms Combined and Cardiac Events
5.4.2 Angina
19 patients (12%) developed angina (ANG) during the predischarge exercise test. The 
effects of angina on the cardiac events in the follow up period is shown in Table 5.43. This 
shows that 63% of patients who reported angina during the exercise test complained of 
angina as an outpatient compared to 37% of patients without angina (p=0.007). This is 
shown by event free survival analysis in Fig 5.21. The majority of patients develop angina
within the first year of follow up.
Angina Total Patients Total Events % P Value
Angina No ANG 135 51 37
ANG 19 12 63 0.007
Heart Failure No ANG 137 25 18
ANG 19 5 26 0.208
All Cardiac No ANG 137 51 37
Events ANG 19 8 42 0.308
Outpatient No ANG 137 7 5
Mortality ANG 19 0 0 0.382
Table 5.43 Angina during Exercise Testing and Outpatient Cardiac Events
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6. THE EFFECT OF CORONARY PATENCY ON VARIABLES 
MEASURED DURING EXERCISE TESTING AND CLINICAL 
OUTCOME
Coronary artery patency of the infarct-related vessel was assessed by TIMI scoring of 
coronary angiograms performed at 90 mins and 24 hrs following thrombolysis. The 
TIMI Score was related to the results of Exercise Testing and used to predict clinical 
outcome.
6.1 TIMI Score at 90 mins
194 of 212 patients underwent angiographic assessment of patency at 90 mins post 
thrombolysis. Table 6.1 shows the distribution of the TIMI scores of the infarct related 
artery in these patients undergoing angiography at 90 mins. 31% of patients had 
persistent coronary occlusion TIMI score 0 at 90 min post thrombolysis, 36% had 
established full coronary patency, TIMI grade 3. This is illustrated in fig 6.1.
TIMI score 90 Mins No. of Patients %
0 60 31
1 14 7
2 51 26
3 69 36
Total 194
Table 6.1 Distribution of TIMI Scores following angiography at 90 min
6.1.1 Symptoms reported during Exercise Testing
analysis was performed to determine whether there was any relationship between 
TIMI score at 90 mins and symptoms reported during exercise. As shown in table 6.2 
TIMI score at 90 min did not affect the development of any symptoms, nor the 
development of angina during exercise testing. This is illustrated in and fig 6.2
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Timi Score at 90 min
_____
Timi Score 90 min
Figure 6.1 Distribution of TIMI Scores following angiography at 90 min.
Symptoms during exercise
□  Angina
0  Symptomatic
□  Asymptomatic
Figure 6.2 Symptoms during exercise testing related to the TIMI score folowing
angiography at 90 mins
Symptoms TIMI Score at 90 min
0 1 2 3
Asymptomatic 24 6 22 32
Symptomatic 19 4 15 26
(X2 = 0.228, NS)
No Angina 38 9 33 49
Angina 5 1 4 9
(X2 = 0.636, NS)
Table 6.2 Symptoms during exercise testing related to TIMI scoring of 90 min 
angiogram
6.1.2 ST-T Changes during Exercise testing
analysis was performed to determine whether there was any relationship between 
TIMI score at 90 mins and ST-T changes occurring during exercise testing. As shown 
in table 6.3 TIMI score at 90 min did not affect the development of ST depression, ST 
elevation or T wave normalisation during exercise testing. This is illustrated in fig 6.3.
ST-T Changes TIMI Score at 90 min
0 1 2 3
ST Depression
N o S T l 22 9 25 35
ST 4- 21 1 12 23
(X2 = 5.978, NS)
ST Elevation
N oS T t 31 5 27 44
s t T 12 5 9 14
(X2 = 2.998, NS)
T Wave Normalisation
N o T t 27 4 19 34
T t 16 6 18 24
(X2 = 2.304, NS)
Table 6.3 TIMI score at 90 mins and ST-T Changes during Exercise
108
ST changes during exercise
25
□  ST depression a  ST elevation □  T normalisation
Figure 6.3 ST changes during exercise testing related to TIMI score of 90 min
angiograms.
6.1.3 Functional Capacity
Analysis of variance showed no relationship between TIMI scoring at 90 mins and:
1. Total exercise time
2. Metabolic equivalents achieved during exercise
3. Failure to achieve median exercise capacity of 5.8 mets
4. Failure of Systolic blood pressure to increase by > 30mmhg
5. Failure of rate pressure product to increase by > 8500
6.2 TIMI Score at 24 hrs
Angiography was repeated at 24 hrs on 187 of the original 212 patients following 
thrombolysis and further assessed by TIMI scoring. The distribution of the TIMI score 
within the patients undergoing angiography at 24 hrs is shown below in Table 6.4. 83% 
of patients had patent infarct related vessels at 24 hrs (TIMI grade 2,3) with 58% full 
patency (TIMI Grade 3). However 12% of patients had no established coronary flow 
with TIMI Grade 0. This is illustrated in fig 6.4.
TIMI Score 24 hrs No.of Patients %
0 23 12
1 8 4
2 47 25
3 109 58
Total 187
Table 6.4 Distribution of TIMI Scores following angiography at 24 hrs
6.2.1 Symptoms Reported During Exercise Testing
analysis was performed to determine whether there was any relationship between 
TIMI score at 24 hrs and symptoms reported during exercise or ST changes occurring 
during the pre-discharge exercise test. As shown below in table 6.5 although not 
statistically significant there was trend towards patients with TIMI score 1 and 2 being 
asymptomatic during exercise testing. All 6 patients (100%) with TIMI score 1 and 22 
(66%) of the 36 patients with TIMI score 2 were asymptomatic. This is illustrated in 
Fig 6.5, TIMI score at 24 hrs did not affect the development of angina during exercise
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Figure 6.4 Distribution of TIMI Scores following angiography at 24 hrs.
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Figure 6.5 Percentage of patients with symptoms during exercise related to TIMI
score at 24 hrs.
0 1 2  3
Timi sco re  24hrs
□  Asymptomatic B  Symptomatic □  Angina
Symptoms TIMI Score at 24hrs
0 1 2 3
Asymptomatic 8 6 23 46
Symptomatic
(X2 = 6.110, NS)
7 0 13 42
No Angina 13 6 33 75
Angina
(X2 = 1.864, NS)
2 0 3 13
Table 6.5 Symptoms reported during exercise related to TIMI score at 24 hrs
6.2.2 ST-T Changes during Exercise Testing
As shown in table 6.6 patients with TIMI score of 0 had a greater incidence of ST 
segment depression during the exercise test, with 60% of patients showing evidence of 
reversible ischemia, p< 0.05. This is illustrated in and fig 6.6. There was no 
relationship between the occurrence of ST elevation and T wave normalisation and the 
TIMI score at 24 hrs
Symptoms TIMI SCORE AT 24 HRS
0 1 2 3
ST Depression 
No ST I 6 6 25 52
ST 4- 9 0 11 36
(X2 = 7.800, p<0.05) 
ST Elevation 
N oS T t 13 5 25 65
ST t 2 1 11 22
(X2 = 1.908, NS) 
T Wave 
Normalisation 
No T t 12 2 18 51
T t 3 4 18 37
(X2 = 5.365, NS)
Table 6.6 ST-T changes during exercise and TIMI score at 24 hrs
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□  II. ST Elevation
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Tfmi Score at 24hrs
Figure 6.6 No of patients with ST changes during exercise testing related to TIMI
score at 24hrs
6.2.3 Functional Capacity
Analysis of variance failed to show any relationship between TIMI score at 24 hrs and
1. Total exercise time
2. Metabolic equivalents achieved during exercise
3. Failure to achieve median exercise capacity
4. Failure of Systolic blood pressure to increase by > 30mmhg
5. Failure of rate pressure product to increase by > 8500
6.3 Coronary Patency
TIMI scores 0 and 1 were combined to define those vessels which were non patent, and 
similarly TIMI scores 2 and 3 were combined to define patent arteries at 90 mins and 24 
hrs. Table 6.7 and table 6.8 show the distribution of coronary patency within these 
groups respectively. 62% patients and 83% patients had patent arteries at 90 mins and 
24 hrs respectively. This is illustrated in fig 6.7.
Patency Group at 90 Mins No.of Patients %
Non-Patent ( 0,1) 74 38
Patent (2,3) 120 120
Total No. of patients 194
Table 6.7 The distribution of patients within each patency group undergoing 
angiography at 90 mins.
Patency Group at 24 hrs No.of Patients %
Non-Patent (0,1) 31 17
Patent (2,3) 156 83
Total No. of patients 187
Table 6.8 The distribution of patients within each patency group undergoing 
angiography at and 24 hrs.
I l l
Patency groups
- — ’—
24 Hrs
□  Non-Patent (0,1) a  Patent (2,3)
Figure 6.7 Patency Groups at 90 min and 24 hrs
6.3.1 Symptoms Reported During Exercise Testing
As shown by X2 analysis in table 6.9 and table 6.10 patency group at 90 mins or 24 hrs 
did not affect the development of any symptoms, nor the development of angina during 
exercise teasing. This is illustrated in figs 6.8 and 6.9.
Symptoms
Patency Group 
(2,3) 90 mins
Patency Group 
(2,3) 24 hrs
Asymptomatic 54 69
Symptomatic 41 55
Total Patent 95 124
Total no of Patients 148 145
X2 0.001 0.891
P Value NS NS
Table 6.9 Patency and all Symptoms Combined during Exercise
Angina
Patency Group 
(2,3) 90 mins
Patency Group 
(2,3) 24 hrs
No Angina 82 108
Angina 13 16
Total Patent 95 124
Total No. of Patients 148 145
X2 0.170 0.189
P Value NS NS
Table 6.10 Patency and Angina during Exercise Testing
6.3.2 ST-T Changes During Exercise Testing
As shown in table 6.11 coronary angiography identified patency of the infarct related 
artery in 95 of the 148 patients at 90mins and 124 of 145 patients at 24hrs. Patency of 
the infarct related vessel did not affect the development of ST depression, ST elevation 
or T wave normalisation during exercise.
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Symptoms related to patency at 90 min
Symptomatic Asymptomatic
29% 57%
Angina
Figure 6.8 Patent infarct related artery at 90 mins and symptoms during exercise
testing
Symptoms related to patency at 24hrs
Symptomatic
31%
Angina
Asymptomatic
56%
Figure 6.9 Patent infarct related artery at 24hrs and Symptoms during Exercise
Testing
ST -T Changes Patency Group 
(2,3) 90 mins 
n=95/148
Patency Group 
(2,3) 24 hrs 
n=124/145
ST Depression
N o S T i 60 77
S T l 35 49
X2 0.313, P=NS 0.816, P=NS
ST Elevation
No ST t 71 90
ST t 23 33
X2 0.996, P=NS 1.505, P=NS
T Wave Normalisation
N o T t 53 69
T t 42 55
X2 0.107, P=NS 0.891, P=NS
Table 6.11 Patency and ST -T changes during Exercise Testing
6.3.3 Functional Capacity
Analysis of variance failed to show any relationship between patency at 90 mins and 24 
hrs and exercise capacity, change in systolic blood pressure or rate pressure product.
6.3.4 Clinical Outcome
Patency (TIMI score 2,3) at 90 mins and 24 hrs was used to predict clinical outcome by 
Kaplan Meier event free survival analysis. Tables 6.12, 6.13 and 6.14 below show the 
event-free survival analysis for in-hospital events, outpatient events and overall events. 
As shown, ischemic pain post infarct was significantly more common in patients with 
non patent arteries at 24 hrs (13% v 7%,p=0.0124). This is illustrated in fig 6.10. There 
was a trend towards the development of acute left ventricular failure in the peri infarct 
period if the infarct related artery was non patent at 24hrs (22%v 1 l%,p=0.079). 30% 
of patients with non patent vessels at 90 mins following thrombolysis developed chronic 
heart failure as an outpatient post hospital discharge compared to 15% of patients with 
patent arteries (p=0.021).This is illustrated in fig 6.11
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Figure 6.10 Patency at 24hrs and Ischemic pain Post Infarct
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Figure 6.11 Patency at 90 min and Congestive Cardiac Failure as an Outpatient
The development of heart failure overall, either acute left ventricular failure or chronic 
heart failure was significantly more common in patients with non patent vessels at 90 
mins (40% v 21%,P=0.028). This is illustrated in figure 6.12.
Time
Patency
(TIMI)
n=
Events % P Value
Ischemic pain 90 mins (0, 1) 74 10 13
(2, 3) 120 9 7 0.186
24 hrs (0,1)31 7 22
(2, 3) 156 13 8 0.012
Acute LVF 90 mins (0, 1) 11 15
(2,3) 14 12 0.477
24 hrs (0, 1) 7 22
(2,3) 17 11 0.079
All Cardiac Events 90 mins (0, 1) 16 20
(2, 3) 15 12 0.110
24 hrs (0, 1) 8 25
(2,3) 22 14 0.076
Table 6.12 TIMI Scores and In Hospital Events
Time
Patency 
(TIMI) n= Events % P Value
Angina 90 mins (0, 1) 72 32 42
(2,3) 116 44 38 0.820
24 hrs (0, 1)31 9 29
(2, 3) 151 60 39 0.164
All Cardiac 90 mins (0, 1) 25 34
Events (2,3) 44 38 0.456
24 hrs (0, 1) 10 32
(2, 3) 56 37 0.361
Heart failure 90 mins (0, 1) 22 30
(2,3) 17 15 0.021
24 hrs (0, 1) 6 19
(2, 3) 35 23 0.585
Table 6.13 TIMI Scores and Outpatient Cardiac Events
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Figure 6.12 Patency at 90 min and Heart Failure Overall
Time
Patency 
(TIMI) N= Events % P Value
Mortality 90 mins (0, 1) 74 9 12
(2, 3) 116 7 6 0.164
24 hrs (0,1)31 4 13
(2, 3) 152 9 6 0.241
Heart failure 90 mins (0, 1) 30 40
(2, 3) 26 21 0.028
24 hrs (0,1) 11 35
(2, 3) 45 29 0.211
All cardiac events 90 mins (0, 1) 36 49
(2,3) 51 44 0.422
24 hrs (0, 1) 15 48
(2,3) 69 45 0.585
Table 6.14 TIMI Scores and Overall Cardiac Events
6.4 The Effect Of Patency On Exercise Variables TIMI Score 3 V (0,1,2)
Following angiography at 90 mins and 24 hrs, those patients with a TIMI score of 3 
were identified and compared against those with TIMI score 0,1,2 to determine the 
effect of full patency. Table 6.15 below shows the distribution of patients with TIMI 
score 3 within patients undergoing angiography at 90 mins and 24 hrs. As shown, 36% 
patients and 58% patients had TIMI score 3 at 90 mins and 24 hrs respectively.
TIMI Score 3 at 90 Mins No. of Patients %
TIMI (0,1,2) 125 64
TIMI (3) 69 36
Total 194
Table 6.15 TIMI Score 3 at 90 min
TIMI Score 3 at 24 hrs No. of Patients %
TIMI (0,1,2) 78 42
TIMI 3 109 58
Total 187
Table 6.16 TIMI Score 3 at 24hrs
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6.4.1 All Symptoms Reported During Exercise Testing
148 of 194 patients and 145 of 187 patients assessed invasively for vessel patency at 90
mins and 24hrs post thrombolysis respectively underwent exercise testing. analysis 
was performed to determine whether there was any relationship between TIMI score 3 at 
90 mins and symptoms reported during exercise. As shown in Table 6.17, TIMI 3 score 
at 90 mins or 24 hrs was not related to the development of any symptoms, nor the 
development of angina during exercise.
Symptoms
TIMI Score 3 
90 mins
TIMI Score 3 
24 hrs
Asymptomatic 32 46
Symptomatic 26 42
X2 0.098,NS 2.258,NS
No Angina 49 75
Angina 9 13
X2 0.612,NS 1.146,NS
Table 6.17 TIMI Score 3 and Symptoms Reported During Exercis
6.4.2 ST-T Changes During Exercise Testing
As shown in table 6.18, there was no relationship between TIMI score 3 at 90 mins or 
24 hrs and the development of ST-T changes during exercise.
6.4.3 Functional Capacity
Analysis of variance failed to show any relationship between full patency TIMI score 3 
at 90 mins and 24 hrs and exercise capacity, change in systolic blood pressure or rate 
pressure product.
6.4.4 Clinical Outcome
The predictive value of full patency, TIMI score 3, in clinical events was determined for 
in-hospital events, outpatient events and overall events. The results of Kaplan Meier 
event-free survival analysis are shown in tables 6.19,6.20 and 6.21. The development of 
peri infarct acute left ventricular failure was less common in patients with TIMI score 3 
at 24 hrs compared to patients with TIMI score 0,1,2 (9 % v 28%) although this did not
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reach statistical significance , p=0.072. This is illustrated in fig 6.13. The development 
of chronic heart failure in 5 years of follow up was significantly less common in patients 
with TIMI score 3 at 90 mins (13% v 24%.p=0.019) and 24 hrs (18% v 30%,p=0.054). 
This is illustrated in fig 6.14 and 6.15 respectively. Cardiac death was also reduced in 
those patients with TIMI score 3 at 90 mins compared to TIMI score 0,1,2 combined 
(4% v 10%,p=0.0694). This is illustrated in figure 6.16. Overall heart failure was 
significantly less common in patients with TIMI score 3 at 24 hrs compared to TIMI 
score 0,1,2 (p=0.007). This is illustrated in fig 6.17.
S T - T  Changes
TIMI Score 3 
90 mins
TIMI Score 3 
24 hrs
ST Depression 
No ST 4 
ST 4
X2
35
23
0.052,NS
52 
36 
0.495,NS
ST Elevation 
No ST 4 
ST 4
X2
44
14
0.457,NS
65 
22 
0.010,NS
T Wave Normalisation 
N o T t  
T t
X2
34 
24 
0.135,NS
51 
37 
0.047,NS
Table 6.18 TIMI score 3 at 90 min and 24 hrs and ST-T changes during exercise
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Figure 6.13 TIMI Score 3 and Peri Infarct Acute Left Ventricular Failure
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Figure 6,14 TIMI Score 3 at 90 min and Outpatient heart failure
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Figure 6.16 Patency Groups and Mortality
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Figure 6.17 TIMI Score 3 and overall Heart failure
Time
Patency 
(TIMI) N= Events % P Value
Ischemic pain 90 min (0,1,2) 125 12 9
(3) 69 7 10 0.687
24 hrs (0,1,2) 78 7 22
(3) 109 13 8 0.206
Acute LVF 90 min (0,1,2) 17 14
(3) 8 11 0.689
24 hrs (0,1,2) 14 28
(3) 10 9 0.072
All Cardiac Events 90 min (0, 1) 21 17
(2,3) 10 14 0.762
24 hrs (0, 1) 14 18
(2,3) 16 15 0.568
Table 6.19 TIMI Score 3 and In Hospital Cardiac Events
Time
Patency
(TIMI) Events % P Value
Angina 90 min 0,1,2 n=120 44 37
3 n= 68 30 44 0.820
24 hrs 0,1,2 n= 75 28 37
3 n=107 41 38 0.953
All cardiac events 90 min 0,1,2 36 30
3 33 48 0.183
24 hrs 0,1,2 26 34
3 40 37 0.775
Heart failure 90 min 0,1,2 30 24
3 9 13 0.019
24 hrs 0,1,2 22 30
3 19 18 0.054
Table 6.20 TIMI score 3 and Out-Patient Cardiac Events
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Time
Patency
(TIMI) Event
s
% P Value
Mortality 90 min 0,1,2 n=122 13 10
3 n=68 3 4 0.056
24 hrs 0,1,2 n=76 7 9
3 n=107 6 6 0.288
Heart failure 90 min 0,1,2 41 33
3 15 22 0.055
24 hrs 0,1,2 31 40
3 25 23 0.007
All cardiac events 90 min 0,1,2 50 41
3 37 54 0.358
24 hrs 0,1,2 37 30
3 47 44 0.351
Table 6.21 TIMI score 3 and Overall Cardiac Events
6.5 Time to Patency
Coronary artery patency of the infarct-related vessel was further assessed by combining 
the TIMI scores from both angiographic assessments, defining time to patency as 
outlined below in table 6.22. The distribution of patients within each patency group is 
shown in table 6.23.
TIMI Score 
90 MINS
TIMI Score 
24 HRS Group
(2,3) (2,3) Early Patency EP)
(0,1) (2,3) Late Patency (LP)
(0,1) (0,1) Non Patent (NP)
(2,3) (0,1) Reocclusion (R)
Table 6.22 Time to Patency Groups
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Patency Group No. of Patients %
Early Patency 108 60
Late Patency 44 24
Non Patent 23 13
Reocclusion 6 3
Total 181
Table 6.23 Distribution of Patients within Patency Groups
Only 6 patients were defined as reocclusions: patency at 90 min becoming non patent at 
24hrs. X2 analysis is invalidated with such small numbers, and therefore this subgroup 
was not analysed separately. However, given that the exercise test occurred after 
angiography, it is reasonable to include those patients who reoccluded in the non patent 
group.
6.5.1 All Symptoms Reported During Testing
X2 analysis was used to determine whether there was any relationship in time to patency 
and symptoms reported during exercise. As shown, patency group did not affect the 
development of any symptoms, nor the development of angina during exercise testing.
Symptoms EP LP NP
Asymptomatic 51 18 14
Symptomatic 37 16 5
(X2 = 2.246, NS)
No Angina 77 29 17
Angina 1 5 2
(X2 = 0.206, NS)
Table 6.24 Patency Groups and Symptoms during Exercise Testing
6.5.2 ST-T Changes During Exercise Testing
2
X analysis showed no relationship between ST-T changes during exercise testing and 
time to patency groupings, as shown in Table 6.25.
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6.5.3 Functional Capacity
Analysis of variance show any relationship between (1) total time of exercise test (2) 
metabolic equivalents achieved during exercise (3) heart rate pre exercise (4) heart rate 
post exercise (5) systolic blood pressure pre exercise (6) systolic blood pressure post 
exercise and patency groups.
S T -T  Changes EP LP NP
ST Depression
No S T i 56 20 12
s t 4- 32 14 7
(X2= 0.247, NS)
ST Elevation
No ST t 66 22 16
ST f 21 12 3
(X2 = 2.726, NS)
T Wave Normalisation
N oT t 48 20 12
T t 40 12 7
(X2 = 0.552, NS)
Table 6.25 Patency Groups and ST-T Changes During Exercise 
6.5.4 Clinical Outcome
Kaplan Meier event-free survival analysis was performed to determine whether there 
was any relationship between time to patency and in-hospital events, outpatient events 
and overall clinical events. The results are shown below in table 6.26, 6.27 and 6.28. 
These tables contain the multiple comparisons of the patency groups; p values are 
shown. Post infarct ischemic pain was more common in patients with non patent 
vessels compared to those with early patency and late patency (22% v 9% v 7%). This 
is illustrated in fig 6.18. There was a trend towards a greater incidence of acute left 
ventricular failure in the peri infarct period with non patency compared to early and late 
patency (26% v 11% v 9%). This is illustrated in fig 6.19. The development of chronic 
heart failure was more common in patients with late patency compared to those with 
early patency (36% v 15%,p=0.073). This is illustrated in fig 6.20. The development of 
heart failure overall (acute left ventricular failure plus chronic heart failure) was again
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Figure 6.18 Patency Groups and Post Infarct Ischemic Pain
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Figure 6.19 Patency Groups and Peri Infarct Acute Left Ventricular Failure
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Figure 6.20 Patency Groups and Outpatient Congestive Cardiac Failure
more common in patients with late patency versus early patency but not statistically 
significant p=0.075.It was significantly more common in patients with non patency 
versus early patency (43% v 22%,p=0.027). This is illustrated in fig. 6.21.
Patency Events %
Ischemic pain EP 8 7
n=108
LP n=44 4 9
NP n=23 5 22
P values EP LP NP
Multiple comparisons EP 0.814 0.032
LP 0.099
Acute LVF EP 12 11
LP 4 9
NP 6 26
P values EP LP NP
Multiple comparisons EP 0.742 0.070
LP 0.073
All Cardiac EP 14 11
Events LP 7 9
NP 6 26
P values EP LP NP
Multiple comparisons EP 0.583 0.210
LP 0.831
Table 6.26 Patency Groups and In Hospital Cardiac Events
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Patency Events %
Angina EP,n=104 38 36
LP,n=43 21 48
NP,n=29 29 6
P values EP LP NP
Multiple comparisons EP 0.308 0.379
LP 0.104
Heart failure EP 16 15
LP 16 36
NP 6 20
EP LP NP
P values EP 0.007 0.611
Multiple comparisons LP 0.155
.All Cardiac Events EP 43 41
LP 12 27
NP 9 31
EP LP NP
P values EP 0.520 0.504
Multiple comparisons LP 0.253
Table 6.27 Patency Groups and Outpatient Cardiac Events
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Patency Events %
Mortality EP n=104 
LP n=44
5
3
5
7
NP n=23 3 13
P values EP LP NP
Multiple comparisons EP
LP
0.767 0.298
0.428
Heart failure EP 24 22
LP 18 40
NP 10 43
P values EP LP NP
Multiple comparisons EP
LP
0.075 0.027
0.413
All Cardiac EP 49 47
Ischemic Events LP 18 23
NP 12 52
P values EP LP NP
Multiple comparisons EP
LP
0.964 0.471
0.409
Table 6.28 Patency Groups and Overall Cardiac Events
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Figure 6.21 Patency Groups and Overall Heart Failure
7. PRE-DISCHARGE EXERCISE TESTING IN THE PREDICTION 
OF RESIDUAL STENOSIS IN THE INFARCT-RELATED ARTERY 
AND ADDITIONAL VESSEL DISEASE
Following thrombolysis angiography was carried out at 90 mins by the Judkins 
technique. On the basis of the electrical changes on the ECG on admission to Coronary 
Care, the presumed infarct-related artery was visualised first by standard radiographic 
views to define patency which was quantified by the TIMI scoring system (appendix 
IV). The non-infarct related artery was then visualised to define additional vessel 
disease. A significant stenosis was defined as stenosis > 50%. The arterial sheath was 
left in situ and a further angiogram was performed at 24 hrs to define:
1. Patency of the infarct-related vessel by TIMI scoring
2. Any significant residual stenosis of the infarct-related vessel (> 50%) by TIMI 
scoring
3. Reocclusion of the infarct-related vessel
The effects of a significant residual stenosis of the infarct-related artery regardless of 
additional vessel disease, was related to the results of pre-discharge exercise testing and 
used to predict clinical outcome. Patients with only the infarct-related artery affected 
and no additional vessel disease were considered as having single vessel disease. 
However these patients were further divided into 3 groups outlined below and related to 
the results of predischarge exercise testing. Residual stenosis was similarly used to 
predict future cardiac events.
1. Significant residual stenosis > 50%
2. No significant residual stenosis
3. Total Occlusion of the infarct related vessel
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7.1 Residual Stenosis in the Infarct-Related Artery ± Additional Vessel Disease
Table 7.1 shows the number of patients with a significant residual stenosis, no 
significant residual stenosis and occlusion of the infarct-related artery with or without 
additional vessel disease following angiography at 24 hrs. As shown 72% of patients 
had a significant residual stenosis of the infarct-related artery at 24 hrs following 
thrombolysis. Only 13% of patients had persistent coronary occlusion at angiography at 
24 hrs post thrombolysis. This is illustrated in and fig 7.1.
Stenosis of Infarct-Related Artery
No. of Patients %
No stenosis 28 15
Stenosis > 50% 134 72 .
Occluded Vessels 24 13
Total 186
Table 7.1 Infarct vessel status following 24 hr angiogram
7.1.1 Symptoms during exercise Testing
147 of the 186 patients who had infarct vessel status determined by angiography at 24
hrs post thrombolysis were exercised prior to discharge. As shown by analysis in 
table 7.2 there was no relationship between residual stenosis and the development of 
symptoms during exercise testing. This is illustrated in Fig 7.2.
Symptoms No Stenosis Stenosis Occlusion
Asymptomatic 15 59 10
Symptomatic 11 46 6
(X2 = 0.230, NS)
No angina 23 92 14
angina 3 13 2
(X2 = 0.015,NS)
Table 7.2 Symptoms during exercise testing related to the presence of a stenosis in 
the infarct related artery
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Infarct vessel status at 24 hrs
Occluded
V e sse ls  No stenosis
Residual
stenosis
72%
Figure 7-1 Percentage of patients with residual stenosis of infarct related 
vesselregardless of additional vessel disease
Symptoms during exercise testing
100%
90%
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0%
Figure 7-2 Residual Stenosis regardless of additional vessel disease and all 
Symptoms during Exercise Testing
Occlusion
□  Asymptomatic 0  Symptomatic □  angina
7.1.2 ST-T Changes During Exercise
As shown in table 7.3 a significant residual stenosis or a completely occluded infarct- 
related did not affect the development of ST-T changes during exercise. This is 
illustrated in and figure 7.3.
ST-T Changes Residual Stenosis
No Stenosis Stenosis Occlusion X2 P Value
n=26 n=105 n=16
ST'I' 9 39 9 2.365 NS
STt 6 29 3 0.744 NS
T t 14 45 4 3.365 NS
Table 7.3 ST changes during exercise related to residual stenosis of the infarct 
related artery.
7.1.3 Functional Capacity
Analysis of variance showed no significant relationship between residual stenosis of the 
infarct-related artery and other exercise variables: total exercise time, metabolic 
equivalents ,systolic blood pressure response or rate pressure product.
7.1.4 Clinical Outcome
Residual stenosis of infarct related artery regardless of additional vessel disease, was 
used to predict clinical outcome by Kaplan Meier event-free survival analysis of in 
hospital, outpatient and overall cardiac events shown in table 7.4, 7.5, and 7.6.
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Figure 7-3 The percentage of patients with stensois,no stenosis or occlusion of the 
infarct related artery with ST changes during exercise.
Residual
Stenosis
Total No. 
Patients
Total No. 
Events %
Ischemic Pain No Stenosis 28 0 0
Stenosis 134 15 11
Occlusion 24 5 20
P Values No Stenosis Stenosis
Stenosis 0.064
Occlusion 0.012 0.1491
Overall 0.043
Left Ventricular Failure No Stenosis 28 3 11
Stenosis 134 14 10
Occlusion 24 6 25
P Values No Stenosis Stenosis
Stenosis 0.993
Occlusion 0.159 0.0423
Occlusion 0.115
All Cardiac Events No Stenosis 28 1 4
Stenosis 134 23 17
Occlusion 24 6 25
P Values No Stenosis Stenosis
Stenosis 0.065
Occlusion 0.022 0.2980
Overall 0.080
Table 7.4 Residual stenosis in the prediction of in hospital events.
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Residual Stenosis Total No. of 
Patients
Total No. of 
Events
%
Angina No Stenosis 28 13 48
Stenosis 134 50 38
Occlusion 24 6 17
P Values No Stenosis Stenosis
Stenosis 0.841
Occlusion 0.211 0.196
Overall 0.405
Heart Failure No Stenosis 28 5 18
Stenosis 134 29 22
Occlusion 24 5 20
P Values No Stenosis Stenosis
Stenosis 0.720
Occlusion 0.962 0.683
Overall 0.881
All Cardiac Events No Stenosis 28 9 33
Stenosis 134 48 36
Occlusion 24 9 37
P Values No Stenosis Stenosis
Stenosis 0.5269
Occlusion 0.8765 0.364
Overall 0.5914
Table 7.5 Residual stenosis in the prediction of outpatient cardiac events.
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Residual
Stenosis
Total No. of 
Patients
Total No. of 
Events %
Mortality No Stenosis 28 0 0
Stenosis 134 10 8
Occlusion 24 3 12
P Values No Stenosis Stenosis
Stenosis 0.1577
Occlusion 0.0671 0.540
Overall 0.2568
Heart Failure No Stenosis 28 6 21
Stenosis 134 38 28
Occlusion 24 10 42
P Values No Stenosis Stenosis
Stenosis 0.6561
Occlusion 0.1311 0.081
Overall 0.1739
All Cardiac Events No Stenosis 28 10 33
Stenosis 134 62 36
Occlusion 24 12 37
P Values No Stenosis Stenosis
Stenosis 0.102
Occlusion 0.178 0.8429
Overall 0.245
Table 7.6 Residual Stenosis and Overall Cardiac Events
Ischemic pain post-infarct was more common in patients with occluded infarct-related 
arteries at 24 hrs compared to arteries with no significant stenosis (20% v 0%,p=0.012). 
This is illustrated in fig 7.4. Similarly, the development of peri-infarct acute left 
ventricular failure was more common in patients with occluded arteries compared to 
those patients who had a residual stenosis post-infarct (25% v 10%,p=0.0423). This is 
illustrated in fig 7.5. The development of in hospital cardiac events (between day 1 and 
hospital discharge) was less common in patients with no residual stenosis in the infarct- 
related artery when compared to patients with a stenosis or an occluded vessel (4% v 
17% v 25%). This is illustrated in figure 7.6. As shown the degree of residual stenosis 
in the infarct-related artery ± additional vessel disease did not affect out-patient events : 
post-infarct angina, all cardiac events or heart failure. In addition, it did not affect 
overall mortality from sudden cardiac death, heart failure or overall cardiac events.
130
C
um
m
ul
at
i\£
 
Su
rv
i\£
l
Event Free Survival 
Post Infarct Pain
1.10
1.00 residual s ten o sis
occlusion
.90'
residual stenosis
.80
no residual stenosis
.70
100 20 30 40
Days post infarct
Figure 7-4 Event free survival for ischemic pain post infarct in relation to residual
stenosis.
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Figure 7-5 Event free survival for peri infarct acute left ventricular failure in
relation to residual stenosis.
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Figure 7-6 Event free survival for all in hospital cardiac events in relation to
residual stenosis.
7.2 Residual Stenosis Of The Infarct-Related Artery In Patients With Single 
Vessel Disease Only
Patients with the infarct related artery as the only affected vessel were analysed as a sub 
group to determine the effect of an isolated significant residual stenosis (> 50%) on the 
results of exercise testing and clinical outcome. 99 (54%) patients of the 184 undergoing 
angiography at 24hrs were identified as having single vessel disease. Table 7.7 shows 
the distribution of patients within each group defined by degree of stenosis. This is 
illustrated in fig 7.7. As shown above, 70% of patients with single vessel disease had a 
significant residual stenosis (>50%).
Infarct-Related Artery No. of Patients %
No stenosis 19 19
Stenosis > 50% 70 71
Occluded Vessels 10 10
Table 7.7 Residual Stenosis in Patients with Single Vessel Disease
7.2.1 Symptoms reported during exercise
analysis was performed to determine whether there was any significant difference 
between symptoms reported during exercise and the presence of a residual stenosis. This 
is shown in table 7.8. This is illustrated in fig 7.8..
Symptoms Stenosis of Infarct Related Artery
No Stenosis Stenosis Occlusion
Asymptomatic 10 27 2
Symptomatic 8 27 3
(X2 = 0.409, NS) n=77
No Stenosis Stenosis Occlusion
Angina 18 48 3
No Angina 0 6 2
(X2 = 6.826, P < 0.05) n = 77
Table 7.8 Residual Stenosis in Patients with Single Vessel Disease and All 
Symptoms during Exercise
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As shown, patients with no residual stenosis in the infarct-related artery following 
thrombolysis did not experience angina during exercise. All 18 patients were 
asymptomatic. 12% of patients with a residual stenosis experienced angina.
7.2.2 ST-T Changes during Exercise testing
The relationship between ST-T changes during exercise testing and stenosis of the 
infarct related artery is shown in Table 7.9 and figure 7.9. A significant residual stenosis 
or a complete occlusion of the infarct-related artery did not affect the development of 
ST-T changes during exercise.
ST-T Changes Residual Stenosis
No Stenosis Stenosis Occlusion X2 P Value
n=8 n=54 n=5
s t J- 8 16 2 0.284 NS
ST 1" 4 16 2 0.705 NS
T t 8 28 2 0.483 NS
Table 7.9 Residual Stenosis in Patients with Single Vessel Disease and ST-T 
Changes during Exercise
7.2.3 Functional Capacity
Analysis of variance showed no significant relationship between residual stenosis of the 
infarct-related artery in patients with single vessel disease other exercise variables: total 
exercise time, metabolic equivalents ,systolic blood pressure response or rate pressure 
product.
7.2.4 Clinical Outcome
The relationships between residual stenosis in patients with single vessel disease and 
subsequent cardiac events was assessed by Kaplan Meier event free survival analysis. 
The results are shown table 7.10 and Table 7.12. The p values for inter group 
comparisons are shown below each clinical outcome measure. Patients with an 
occluded artery had a significant increased incidence of ischemic pain post-infarct 
compared to those patients with no stenosis. (30% v 0%,p=0.059) There was no
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difference in the incidence of peri-infarct acute left ventricular failure or cardiac 
ischemic events as an inpatient in relation to residual stenosis with single vessel disease. 
As shown, the degree of residual stenosis of the infarct-related artery in single vessel 
disease did not affect the incidence of post-infarct angina, heart failure or cardiac events 
in out-patient follow up for 5 years. As shown, degree of stenosis did not affect 
mortality, heart failure or overall cardiac events.
Residual
Stenosis No. of Patients No. of Events %
Ischemic pain No Stenosis 19 0 0
Stenosis 70 9 13
Occlusion 10 3 30
P Values No Stenosis Stenosis
Stenosis 0.101
Occlusion 0.059 0.136
Overall
Acute LVF No Stenosis 19 2 11
Stenosis 70 8 11
Occlusion 10 1 10
P Values No Stenosis Stenosis
Stenosis 0.855
Occlusion 0.159 0.977
Overall
All Cardiac Events No Stenosis 19 1 5
Stenosis 70 11 16
Occlusion 10 3 30
P Values No Stenosis Stenosis
Stenosis 0.218
Occlusion 0.172 0.239
Overall
Table 7.10 Residual Stenosis in Single Vessel Disease and In Hospital Cardiac 
Events
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Residual Stenosis No. of Patients No. of Events %
Angina No Stenosis 18 7 39
Stenosis 70 26 37
Occlusion 10 4 40
P Values No Stenosis Stenosis
Stenosis 0.6332
Occlusion 0.3553 0.633
Overall 0.6278
Heart Failure No Stenosis 18 3 17
Stenosis 70 15 21
Occlusion 10 4 40
P Values No Stenosis Stenosis
Stenosis 0.6836
Occlusion 0.3359 0.454
Overall 0.6410
All Cardiac Events No Stenosis 18 6 33
Stenosis 70 22 31
Occlusion 10 4 40
P Values No Stenosis Stenosis
Stenosis 0.6537
Occlusion 0.4240 0.227
Overall 0.4634
Table 7.11 Residual Stenosis in Single Vessel Disease and Outpatient Cardiac 
Events
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Residual Stenosis No. of Patients No. of Events %
Mortality No Stenosis 18 0 0
Stenosis 70 3 4
Occlusion 10 0 0
P Values No Stenosis Stenosis
Stenosis 0.389
Occlusion 0.562 0.537
Overall 0.567
Heart Failure No Stenosis 19 4 21
Stenosis 70 19 28
Occlusion 10 4 40
P Values No Stenosis Stenosis
Stenosis 0.813
Occlusion 0.567 0.561
Overall 0.809
All cardiac Events No Stenosis 18 7 33
Stenosis 70 29 36
Occlusion 10 4 40
P Values No Stenosis Stenosis
Stenosis 0.303
Occlusion 0.248 0.544
Overall 0.445
Table 7.12 Residual Stenosis in Single Vessel Disease and Overall Cardiac Events
7.3 The Number Of Vessels Affected By Coronary Artery Disease
Following the visualisation of the infarct-related artery, the non-infarct related artery 
was outlined to identify additional vessel disease. A stenosis of > 50% was considered 
significant by the TIMI scoring system of vessel stenosis (appendix V). Table 7.13 
show the distribution of 1, 2 and 3 vessel disease in the patients studied. This is 
illustrated in and fig 7.10. Single vessel disease includes infarct related arteries with no 
significant residual stenosis. All patients suffered a myocardial infarction and therefore 
have an underlying atherosclerotic plaque in the infarct related artery which may act as a 
substrate for further cardiac events.
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No. of Patients
Figure 7-10 Percentage Distribution of Vessel Disease
No. of Affected Vessels No. of Patients %
1 94 47
2 67 34
3 38 19
Total 199
Table 7.13 Percentage of Patients and No of Affected Vessels
As shown approximately 50% of patients had coronary artery disease affecting the 
infarct-related artery only i.e. single vessel disease.
7.3.1 All symptoms during Exercise
X 2 analysis was performed to see if there was any significant relationship between the 
number of vessels affected and symptoms reported during exercise. This is shown in 
table 7.14 and figure 7.11. Patients with single vessel disease had a reduced incidence 
of angina, but this did not reach statistical significance..
Symptoms No. of Affected Vessels
1 2 3
Asymptomatic 39 28 17
Symptomatic 33 25 9
(X2 = 1.304, P=NS)
No Angina 68 43 21
Angina 4 10 5
(X2 = 6.332, P=NS)
Table 7.14 No for Affected Vessels and all Symptoms during Exercise Testing 
7.3.2 ST-T Changes
Similarly analysis was used to determine whether ST-T changes during exercise 
were related to the number of diseased vessels. As shown in Table 7.15 ST segment
depression occurred more frequently in patients with 3 vessel disease (X^ = 11.613, P <
0.05). This is illustrated in and fig 7.12. There was no relationship demonstrated 
between the number of vessels affected and the development of ST elevation (shown in 
figure 7.13) or T wave inversion during exercise (shown in figure 7.14).
136
at
o>re
c
atok .
ata
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
4
29
.
-
39
10
15
.....
28
17
1 2
No of affected v e s s e l s
HAsymptomatic ■Symptomatic □  angina |
Figure 7-11 No of Affected Vessels and Symptoms during Exercise
ST segment depression
□  No ST Depression ■  ST Depression
Figure 7-12 No of affected Vessels and Patients with ST Segment Depression 
during Exercise Testing
ST elevation
60  
50  
40  
30 
20 
10 
0
Figure 7-13 No of affected Vessels and Patients with ST Segment Elevation 
Exercise Testing
52
1 2 3
No of affected v e s se ls
□  No ST Elevation U ST Elevation
T wave normalisation
40  
35  
30  
25  
20 
15 
10 
5 
0
Figure 7-14 No of affected Vessels and Patients with T Wave Normalisation during 
Exercise Testing
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ST-T Changes No. of Affected Vessels
1 2 3
ST Depression 
No ST 4- 54 29 10
s t 4 19 24 16
(X2 = 11.613, P <  0.05)
ST Elevation
No ST t 52 38 21
ST t 21 14 5
(X2 = 0.903, P=NS)
T Wave Normalisation
No T Wave t 37 30 20
T wave T 36 23 6
(X2 = 5.046, P=NS)
Table 7.15 No of Affected Vessels and ST-T Changes during Exercise Testing
7.3.3 Functional Capacity
Analysis of variance showed no significant relationship between the number of vessels 
diseased and other exercise variables: total exercise time, metabolic equivalents ,systolic 
blood pressure response or rate pressure product.
7.3.4 Clinical Outcome
The effect of number of diseased vessels on in-hospital, outpatient and overall cardiac 
events was analysed by Kaplan Meier Event free Survival Analysis. This is shown in 
tables 7.16, 7.17, and 7.18. P values for inter group comparisons are shown below 
cardiac event data. Vessel disease did not affect the development of post-infarct 
ischemic pain, peri-infarct acute left ventricular failure or cardiac ischemic events. As 
shown, patients with 2 vessel disease had a significant increase in the incidence of 
angina. This was statistically significant compared with single vessel disease. Patients 
with 2 vessel disease had a greater incidence of heart failure compared to those with 1 
vessel disease. However, patients with triple vessel disease showed a significant 
increase in the total number of cardiac ischemic events compared with single and double 
vessel disease. The development of heart failure as an outpatient was significantly more 
common in patients with double vessel disease, which was statistically significant
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compared with patients with single vessel disease.(47% v 33% v 30%,p=0.028). As 
shown, the mortality of patients with triple vessel disease is significantly higher 
compared with both 1 vessel and 2 vessel disease. The incidence of overall heart failure 
was higher in patients with 2 vessel disease compared with patients with 1 vessel 
disease. There was no significant difference in the overall number of cardiac events 
from day 1 to 5 years in patients with 1,2 or 3 vessel disease.
No of Affected 
Vessels
No of Patients No of Events %
Ischemic Pain 1 94 11 10
2 67 8 13
3 38 2 30
P Values 2 3
1 0.917
2 0.265 0.251
Overall 0.489
Acute LVF 1 94 10 10
2 67 10 15
3 38 6 16
P Values 2 3
1 0.410
2 0.363 0.806
Overall 0.583
All Cardiac Events 1 94 14 15
2 67 13 19
3 38 6 16
P Values 2 3
1 0.633
2 0.967 0.581
Overall 0.837
Table 7.16 No of Affected Vessels and In Hospital Cardiac Events
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No of Affected 
Vessels
No. of Patients No. of Events %
Angina 1 93 29 31
2 65 34 52
3 38 12 32
P Values 1 2
2 0.001
3 0.225 0.246
Overall 0.627
Heart Failure 1 94 16 17
2 67 20 30
3 38 5 13
P Values 1 2
2 0.024
3 0.813 0.229
Overall 0.065
All Cardiac Events 1 94 31 33
2 67 20 30
3 38 18 47
P Values 1 2
2 0.244
3 0.009 0.039
Overall 0.028
Table 7.17 No of Affected Vessels and Outpatient Cardiac Events
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Residual
Stenosis
No. of Patients No. of 
Events
%
Mortality 1 94 5 5
2 67 3 4
3 38 8 21
P Values 1 2
2 0.533
3 0.001 0.006
Overall 0.567
Heart Failure 1 94 22 23
2 67 25 37
3 38 11 30
P Values 1 2
2 0.040
3 0.252 0.693
Overall 0.117
All Cardiac Events 1 94 42 45
2 67 28 43
3 38 21 57
P Values 1 2
2 0.816
3 0.308 0.539
Overall 0.308
Table 7.18 No of Affected Vessels and Overall Cardiac Events
7.4 3 Vessel Coronary Disease v 1,2 Vessel Disease
The effect of three vessel disease was further assessed by comparing it against a 
combination of 1 and 2 vessel disease. Table 7.19 below shows the distribution of 
patients with 3 vessel disease. As shown, 16% of patients had 3 vessel disease.
No. of Affected Vessels No. of Patients %
1,2 161 81
3 38 16
Total = 199
Table 7.19 No of Affected Vessels (3VD v 1,2VD)
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7.4.1 Symptoms Reported During Exercise
analysis failed to show any significant difference in the development of symptoms or 
angina with 3 vessel disease when compared to 1 or 2 vessel disease. This is shown in 
table 7.20
Symptoms No. of Affected Vessels
1,2 3
Asymptomatic 67 17
Symptomatic 59 9
(x2 = 1.303, P=NS)
No Angina 112 21
Angina 14 5
(X2 = 1.299, P=NS)
Table 7.20 No of Affected Vessels (3VD v 1,2VD) and Symptoms reported during 
Exercise Testing
7.4.2 ST-T Changes During Exercise
The effect of 3 vessel disease compared to 1,2 vessel disease on ST-T changes occurring 
during exercise is shown in table 7.21,.22 and 23. As shown, there was a significantly 
greater incidence of ST segment depression in patients with 3 vessel disease (P<0.05). 
The sensitivity of ST segment depression in the detection of 3 vessel disease was 61.5%, 
with the specificity of 66%. The predictive accuracy of the positive test was 27% and 
the predictive accuracy of the negative test was 89%. Therefore, if a patient had a 
negative exercise test they were very unlikely to have 3 vessel disease. However, if 
patients had evidence of reversible ischemia on a pre-discharge exercise test, this was 
not a good predictor of 3 vessel disease. As shown, no relationship exists between ST 
elevation or T wave normalisation and the incidence of 3 vessel disease.
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ST Segment Depression No. of Affected Vessels
1,2 3
No ST 4- 83 10
ST 4- 43 16
(X2 = 6.819, P<0.05)
Table 7.21 No of Affected Vessels (3VD v 1,2VD) and ST Segment Depression 
during Exercise Testing
ST Elevation No. of Affected Vessels
1,2 3
No ST t 90 21
ST t 35 5
(X2 = 0.850, P=NS)
Table 7.22 No of Affected Vessels (3VD v 1,2VD) and ST Segment Elevation during 
Exercise Testing
T Wave Normalisation No. of Afi'ected Vessels
1,2 3
No T wavet 67 20
T wave t 59 6
X2 = 4.966,P=NS)
Table 7.23 No of Affected Vessels (3VD v 1,2VD) and T Wave Normalisation 
during Exercise Testing
7.4.3 Functional Capacity
Analysis of variance showed no significant relationship between the presence of 3 
Vessel disease and other exercise variables: total exercise time, metabolic equivalents 
,systolic blood pressure response or rate pressure product.
7.4.4 Clinical Outcome
The effect 3 vessel disease on in-hospital, outpatient, and overall cardiac events was 
determined by Kaplan Meier Event free Survival Analysis and shown in table 7.24, 7.25 
and 7.26. 3 vessel disease did not affect the development of post-infarct ischemic pain, 
peri-infarct acute left ventricular failure or cardiac ischemic events. However, patients
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with 3 vessel disease showed a significant increase in the total number of outpatient 
cardiac ischemic events compared with 1,2 vessel disease (50% v 34%,p=0.004). This 
is illustrated in fig 7.15. The mortality of patients with 3 vessel disease was increased 
compared with 1,2 vessel disease (22% v 6%,p=0.0002), illustrated in fig 7.16.
Vessel Disease No of Patients Events % P Value
Ischemic Pain 1,2 161 19 12
3 38 2 5 0.240
Acute LVF 1,2 161 20 12
3 38 6 16 0.552
All Cardiac Events 1,2 161 27 17
3 38 6 16 .830
Table 7.24 No of Affected Vessels (3VD v 1,2VD) and In Hospital Cardiac Events
Vessel Disease Patients Events % P Value
Angina 1,2 158 64 40
3 38 12 32 .883
Heart Failure 1,2 158 36 22
3 38 5 13 .498
All Cardiac Events 1 158 54 34
3 38 19 50 .003
"able 7.25 No of Affected Vessels (3VD i/ 1,2VD) and Outpatient Cardiac Events
Vessel Disease Patients Events % P Value
Mortality 1,2 158 8 6
3 38 8 22 0.001
Heart Failure 1,2 161 47 29
3 38 11 30 .793
All Cardiac Events 1,2 158 70 45
3 38 21 57 .124
Table 7.26 No of Affected Vessels (3VD v 1,2VD) and Overall Cardiac Events
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8. CLINICAL FOLLOW UP
8.1 Follow up of Patients
Table 8.1 below shows the proportion of patients followed up over the 5 year period. 
This data represents the last outpatient or in-patient consultation with the cardiology 
services at the time of retrospective analysis of the case records. The follow up time was 
then calculated in months for each patient by subtracting the admission date (see 
appendix VII).This data is shown using event free survival analysis in Figure 8.1.
Time point No of Patients %
Admission to CCU 212 100
Discharged from hospital 202 95
1 yr post MI 164 77
3 yrs post MI 93 44
5 yrs post MI 48 23
Table 8.1 Proportion of patients followed up over 5 years
8.2 Mortality
Deaths were recorded as sudden cardiac death or non cardiac. The mortality rates and 
time point of death are shown over the 5 year follow up period in Table 8.2 below.
Time point Sudden Cardiac 
Death
Non Cardiac 
Death
Total
In Hospital 10 2 12
Discharge to 1 yr follow up 5 0 5
lyr to 5 yr follow up 8 5 13
Total 30
Table 8.1 Mortality over 5 years
10 patients died of cardiovascular causes and 2 further patients died of a cerebrovascular 
accident during the in hospital phase following myocardial infarction. 77% of patients
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Figure 8.1 Proportion of patients in clinical follow up post myocardial infarction
2
were followed for 1 yr : this includes in the calculation patients who died during the 
acute peri infarct period and those who died during the following year. However from 
the case records 31 patients were either discharged from outpatient clinics or lost to 
follow up during the first year post infarct.
8.3 In hospital Events
In hospital events are shown in Table 8.3. All primary cardiac events include post 
infarct ischemic pain, recurrent Myocardial Infarction, PTC A, CABG, and sudden 
death.
In Hospital Events Total no of No in 1st 48hrs
Patients (%)
Post Infarct Ischemic Pain 21 9(43)
Acute Left Ventricular Failure 28 15 (54)
All Cardiac Events 36 17(47)
Table 8.2 In Hospital Events
8.4 Outpatient Events
All cardiac events from hospital discharge to end of clinical follow up were recorded as 
outpatient events, shown in table 8.4. Once a primary event had occurred patients were 
censored within the survival analysis and further events were not recorded. However 
secondary events such as angina or heart failure and were recorded as cardiac events and 
analysed separately if they occurred before a primary event.
Outpatient Events Total no of No in 1st year
Patients (%)
Outpatient Angina 78 56 (71)
Outpatient Heart Failure 43 29 (67)
All Cardiac Events 75 31 (41)
Table 8.3 Outpatient cardiac events
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8.5 Overall Cardiac Events
All cardiac events occurring from the admission to CCU with acute myocardial 
infarction to end of clinical follow up were recorded as overall events, shown in table
8.5
Overall Events Total no of 
Patients
No in 1st year 
(%)
Overall Cardiac Mortality 23 15 (65)
Inpatient mortality 10(43)
Overall Heart Failure 62 51 (82)
Overall Cardiac Events 96 59 (61)
Table 8.4 Overall Cardiac Events
8.6 Cardiac Events
The total number of recorded cardiac events over the 5 year follow up period are shown 
in table 8.6. As shown 39% of patients were diagnosed as suffering from angina as an 
out patient. A relatively high number of patients had post infarct ischemic pain as an 
inpatient (13%) and overall (24%). This may be explained by the difficulty in 
establishing this diagnosis from retrospective analysis of the case record and that fact 
that ECG changes consistent with ischemia were not required to record this as an event. 
There was a low incidence of revascularisation in this patient group. The low level of a 
PTC A as an inpatient reflects the fact that Stobhill was not a tertiary referral centre with 
facilities for angioplasty. All patients requiring angioplasty as an emergency or 
electively were transferred to Glasgow Royal Infirmary. In addition primary PTC A was 
not common in management of acute myocardial infarction in Glasgow at that time and 
in general the patients were managed conservatively. CABG was performed on 
symptomatic grounds post infarct. Patients with angina or anginal equivalents post 
infarct were usually reinvestigated by further angiography prior to referral for CABG. 
Patients were not referred on prognostic grounds for CABG following acute 
angiography at the time of infarct as the prognosis in this group of patients following 
myocardial infarction treated with thrombolyisis was not established. In hospital 
Cardiac death was well recorded in the case record forms. However cardiac death during
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the post discharge follow up period was only recorded if the incident was well 
documented in writing for example in A/E records. If information was lacking regarding 
the circumstances surrounding the death it was categorised as non cardiac which may 
have underestimated the number of cardiac deaths
Cardiac Event Total % Inpatient %
Angina 78 39
Ischemic pain 51 24 28 13
ALVF 39 18 24 11
CCF 40 18 5 2
Further MI 32 15 7 3
PTCA 10 5 2 <1
CABG 26 13 0 0
Cardiac Death 23 11 10 5
Non Cardiac Death 7 3 2 <1
Table 8.5 Cardiac Events: inpatient and overall
8.7 Mulivariate Analysis
A multivariate analysis was carried out using Cox proportional hazard model to 
determine independent predictors of cardiac events. All clinical, demographic, 
angiographic and exercise variables which were significant univariates with Kaplan 
Meier event free survival analysis were entered in a forward conditional stepwise model 
to determine whether they independently predicted inpatient, outpatient and overall 
cardiac events; shown in bold below in table 8.7.
In Hospital Events Independent predictors Hazard Ratio ( 95% C l )
Ischemic Pain 
Peri infarct ALVF 
All Cardiac Events
none
Reciprocal Depression 
none
2.8(1.1 -5.5)
Table 8.6 Independent predictors of in hospital events
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Outpatient Events s Independent predictors Hazard Ratio ( 95% C l)
Angina
Heart Failure
All Cardiac Events
Angina during ETT 
Anterior Infarct 
none
2.3 (1.2-4.3) 
2.0(1.1 -3.7)
Table 8.7 Independent Predictors of outpatient events
Overall Events s Independent predictors Hazard Ratio ( 95% C l)
Mortality
Heart Failure 
All Cardiac Events
3 Vessel disease 
Age > Median 
Anterior Infarct 
none
5.8 (1.8-18.0)
3.2 (1.2-8.3)
2.2 (1.2-4.1)
Table 8.8 Independent predictors of overall cardiac events
As shown reciprocal depression on the admission ECG was independently predictive of 
peri infarct acute left ventricular failure. Angina during predischarge ETT was a 
independent predictor of post infarct angina as an outpatient. Infarct site was predictive 
of both outpatient heart failure and overall heart failure. Mortality was associated with 
advanced age and 3 vessel disease.
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9. DISCUSSION OF RESULTS
9.1 Introduction
Acute myocardial infarction results from rupture of an atherosclerotic plaque in a coronary 
arteries with subsequent thrombosis. Total occlusion of the coronary artery without 
collateral circulation for a sufficient period of time usually results in a Q wave myocardial 
infarction. The benefits of various thrombolytic agents have now been established in a 
series of large scale mortality studies (The TIMI Study Group, 1987, AIMS Trial Study 
Group. 1988; ISIS-2 Collaborative Group. 1988, Wilcox RG et al. 1988; GISSI Working 
Group 1990; ISIS-3 Collaborative Group. 1992. The Gusto invesigators, 1993). The use of 
thrombolysis has been shown to reduce mortality by approximately 25% from acute 
myocardial infarction and improve left ventricular function Thrombolytic agents cause 
lysis of an occlusive thrombus, with potential salvage of jeopardised myocardium. Animal 
studies (Reimer KA et al. 1977) showed that reperfusion of a coronary artery within 6 hrs 
of ligation resulted in significant myocardial salvage. Infarct size and consequent 
preservation of left ventricular function is dependent on time to reperfusion. This explains 
why some of the earlier studies of thrombolytic agents which enrolled patients in their 
study beyond 6 hrs after the onset of symptoms of acute myocardial infarction failed to 
show true benefits of thrombolysis (Dioguardi N et al 1971, Aber CP et al 1976; Bett JHN 
et al 1977). Residual left ventricular systolic function following myocardial infarction has 
been shown to be a potent independent predictor of late survival in the pre-thrombolytic era 
(Multicenter post infarct research group, 1983; Sanz G et al. 1982). The benefits of 
thrombolysis in terms of mortality may therefore be due to preservation of left ventricular 
function following myocardial infarction.
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Left ventricular function following thrombolysis will depend upon:
1. Previous myocardial infarction
2. Anatomical location of occlusive thrombus, therefore area of myocardium at jeopardy
3. Time to reperfusion
4. Degree of reperfusion by TIMI score
5. Collateral circulation
6. Ongoing myocardial ischemia.
In the pre-thrombolytic era left ventricular function following a q wave myocardial 
infarction was dependent upon size of myocardial infarction which in turn was related to 
site of occlusive thrombus . The area of myocardium at jeopardy became necrotic and 
healed with scar tissue formation. Inducible reversible ischemia during exercise testing was 
therefore likely to be related to the extent and nature of coronary artery disease in additional 
vessels. As described above, thrombolysis potentially alters the coronary anatomy post 
myocardial infarction. Studies have shown that in 50%-70% of cases there is a significant 
residual stenosis (> 50%) of the infarct related artery following thrombolysis (Sutton JM 
and Topol EJ, 1991). Therefore if this subtends an area of viable myocardium salvaged by 
thrombolysis, this may cause recurrent ischemic events(Schaer DH et al. 1987). Exercise 
testing therefore may induce reversible ischemia in these patients irrespective of additional 
vessel disease. Residual stenosis of the infarct related artery causing reversible ischemia is 
therefore an additional reason for left ventricular dysfunction during exercise. Exercise 
testing, post myocardial infarction has shown in the pre-thrombolytic era to be predictive of 
future cardiac events (Sullivan ID et al. 1979; Starling MR et al. 1980;; Davidson MD and 
DeBusk RF 1980, Jelinek VM et al. 1982; Fioretti P et al. 1986, Vermeulen A, 1988,
Beider M et al. 1988, Nielsen JR et al. 1990). Recent studies have reassessed the usefulness 
of the exercise test following thrombolysis and have shown reduced sensitivity, specificity 
and predictive accuracy for the exercise test in the prediction of future ischemic events or
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cardiac death (Ellis SG et al. 1989; Arnold AER et al. 1993; Stevenson R et al. 1993). 
However, no study has attempted to correlate the early angiographic assessment ( 90 min 
and 24 hrs) of coronary artery patency of the infarct related artery following thrombolysis 
and additional coronary artery disease, with the results of symptom limited pre-discharge 
exercise testing and long term clinical follow up. In the TIMIII (The TIMI Study Group,
1993) angiography was performed relatively late between 18 and 48 hrs. Exercise testing in 
this study was submaximal and used the less common mode of supine bicycle ergometry. 
More recent studies (The Gusto angiographic invesigators, 1993) have shown the clinical 
benefits of full patency TIMI score 3 at 90 min post thrombolysis. In addition the follow up 
period for all these studies has been relatively short and no study to date has identified the 
predictive value of the exercise following thrombolysis for myocardial infarction over a 
longer follow up period of 5 years.
9.2 Demographic Characteristics 
9.2.1 Age
In the United States 75% of all deaths from coronary artery disease occur in patients > 65 
years of age (US Dept of Health and Human Services et al. 1981). Elderly patients have 
been shown to have a three fold increase in late mortality following myocardial infarction 
(Norris RM et al. 1974; Henning H et al. 1997). In addition, elderly patients have been 
shown to have an increased incidence of multivessel disease (Tofler GH et al. 1988) which 
is obviously one reason for a worse prognosis. The mean age in this study was 55.9+ 9 yrs 
with an age range of 31-74 yrs. Patients in the study were obtained from four separate 
studies of thrombolytic regimes, all of which had an upper age limit of 75 yrs of age for 
recruitment. Therefore it is not possible to comment on the clinical outcome of patients > 
75 yrs of age in this study. Patients who failed to achieve the median workload measured 
in the metabolic equivalents (5.8 mets) were shown to be statistically significantly older, 
with a mean age of 57.8 yrs, compared to 52.3 yrs in those patients who an increased 
exercise capacity. However, there was no significant difference in the age of patients and 
other exercise variables. The median age in this study was 56 yrs. Patients were divided
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into two groups according to the median age. Those patients older than the median age of 
56 yrs had a significantly higher incidence of cardiac events as an outpatient (p=0.054) and 
a significantly greater mortality over the 5 yr period (p=0.023). There was a trend towards a 
greater incidence of cardiac events overall in the older patients. There was no significant 
difference in the age of patients with three vessel disease compared to those with one or two 
vessel disease, this however can be explained by the relatively young group of patients 
which were studied.
9.2.2 Sex
Of the 212 patients, 76 % were male and 34% were female. Given the age range of patients 
was 18-74 yrs this study could potentially include females who are pre-menopausal with a 
reduced incidence of myocardial infarction. In addition, elderly women above the age of 75 
were excluded from this study, where the incidence of myocardial infarction was similar 
between males and females. For these reasons it is not surprising that the distribution of 
patients was heavily weighted towards males. Recent multivariate analysis showed no 
evidence that sex type had any effect on prognosis (Arnold AER et al. 1993). In our study 
males were more likely to complain of symptoms during exercise testing compared to 
females (40% v 17%, p<0.05). In addition, there was a trend towards males reporting more 
symptoms of angina compared to females (14% v 3%). Given that the study was heavily 
weighted towards males, this may represent a type II error. Sex type did not affect other 
exercise variables or influence the incidence of clinical events during the 5 year follow up 
study.
9.2.3 Infarct Related Artery
It was possible to find the infarct related artery in 200 of the 212 patients who received 
thrombolysis for myocardial infarction in this study. In 12 patients the infarct related artery 
could not be defined. 8 of these patients deteriorated clinically after admission with acute 
myocardial infarction and the subsequently died. In 4 patients it was not possible to 
perform angiography due to technical reasons. The right coronary artery was affected in 94
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patients (47%), the LAD in 91 patients (45%) and the Circumflex in 15 patients (7%). The 
low incidence of circumflex artery as the infarct related vessel may be explained by the fact 
that occlusion of this artery commonly presents as a true posterior infarct. This is diagnosed 
by ST segment depression and sequential changes of r wave formation in the anteroseptal 
leads V I-3 of a standard 12 lead ECG. Such ECG changes did not fulfil the criteria for any 
of the four studies which required frank ST elevation in 2 contiguous leads. With the low 
number of circumflex occlusions in the study it was decided to compare left anterior 
descending and right coronary arteries directly and omit circumflex occlusion from the 
analysis to avoid a type II error. Some studies which identified infarct-related artery post 
thrombolysis have shown no difference between right coronary artery and left anterior 
descending artery in the results of exercise testing post myocardial infarction (Sutton JM 
and Topol EJ, 1991), development of left ventricular dysfunction (Zaret BL et al. 1995) or 
clinical outcome (Arnold AER et al. 1993). In this study, however, patients with anterior 
descending artery occlusion were less likely to achieve median workload of 5.8 mets 
(p<0.05). This suggests that LAD occlusion regardless of reperfusion with thrombolysis 
was associated with more extensive myocardial damage, resulting in reduced left 
ventricular function and reduced exercise capacity compared to RCA occlusion. Reversible 
ischemia during exercise teasing defined by ST segment depression was more common in 
patients who had right coronary artery thrombosis. This was also seen in TIMI II study (The 
TIMI Study Group, 1993).The explanation for this is not clear but perhaps patients with 
RCA occlusions having less overall myocardial damage and improved left ventricular 
function have a greater exercise capacity and are limited during exercise by the effects of 
reversible ischemia, if there is significant coronary stenosis of the infarct related artery or 
additional vessel disease, rather than LV dysfunction. There was no significant difference 
in the incidence of triple vessel disease in patients with LAD v RCA as infarct-related 
vessel. However, ST segment elevation occurred much more commonly in LAD compared 
to RCA as infarct-related artery (47% v 8%, p < 0.001). ST segment elevation in pre- 
thrombolytic era has been shown to occur mainly in the presence of anterior infarction and 
thought to an electrical phenomenon indicative of a wall motion abnormality rather than 
myocardial ischemia . It has been associated with a lower left ventricular ejection fraction
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and a poor prognosis (Sullivan ID et al. 1979). This data suggests that left anterior 
descending artery occlusion results in more extensive damage to the left ventricle with 
increased incidence of wall motion abnormality during exercise testing. The development 
of acute peri-infarct left ventricular failure (p=0.029) and chronic heart failure as an 
outpatient (p=0.0136) and overall development of heart failure (p=0.003) was strongly 
associated with LAD as the infarct-related vessel compared to RCA. Studies following 
thrombolysis have not specifically related heart failure associated with infarct related artery. 
This is evidence that LAD artery as the infarct-related artery, despite reperfusion therapy 
with thrombolysis, is associated with reduced left ventricular function and the development 
of acute left ventricular failure at the time of infarct and congestive cardiac failure over the 
5 year follow up period. Patients with LAD compared to RCA occlusions had a greater 
incidence of T wave normalisation during exercise testing which is likely to represent the 
same clinical situation as ST elevation.
9.2.4 Site o f Infarct
Acute anterior myocardial infarction was compared directly with inferior myocardial 
infarction. This did include the majority of patients with CX artery occlusions who had 
infarcts in an the inferior territory. Only 5 patients were defined as having sustained a true 
lateral infarct with isolated changes in lead I and AVL or V5 and V6 and to avoid a type II 
error these patients were omitted from the analysis. Patients with anterior myocardial 
infarction had a reduced exercise capacity measured in metabolic equivalents and increased 
incidence of an inadequate rise of systolic blood pressure. This implies there is a greater 
impairment of left ventricular function in anterior myocardial infarction. 96 % of anterior 
myocardial infarctions, occurred with occlusion of the left anterior descending artery and 
therefore ST-T changes during exercise were similar to those seen with LAD occlusions. 
There was a greater incidence of ST segment elevation and T wave normalisation in the 
infarct site during exercise testing. There was also an increased incidence of ST segment 
depression with inferior myocardial infarction (similar to right coronary artery occlusion) 
compared to anterior myocardial infarction. This agrees with the results of TIMI II study
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(The TIMI Study Group, 1993) but was contrary to a smaller study which showed an 
increased incidence of reversible ischemia in patients following anterior infarction 
following treatment with thrombolysis alone for myocardial infarction (Sutton JM and 
Topol EJ, 1991). Peri-infarct acute left ventricular failure was significantly more common 
in patients with anterior myocardial infarction, as was heart failure as an out-patient and 
overall heart failure Therefore, although this study showed patency rates of 62% (TIMI 
grade 2,3) at 90 mins, anterior infarct was still a predictor of all heart failure following 
myocardial infarction which implies more extensive damage to the left ventricle with this 
diagnosis. Overall mortality from sudden cardiac death was not influenced by site of 
infarct, however the total number of deaths was small with an overall mortality of 9% from 
sudden cardiac death in the peri-infarct period and subsequent 5 years of follow up.
9.2.5 Reciprocal depression
Reciprocal ST segment depression is defined as significant ST segment depression in leads 
relating to the non-infarct site in an ECG with ST segment elevation diagnostic of an acute 
myocardial infarction. There remains controversy over its significance; whether it 
represents remote myocardial ischemia due to additional vessel disease (Khaja F et al.
1983) or is merely an electrical phenomenon mirroring ST segment elevation in the infarct 
site (Akhras F et al. 1985; Jennings K et al. 1983). Reciprocal depression on the original 
ECG following admission for acute myocardial infarction predicted the development of ST 
segment depression during exercise testing. There was a reduced incidence of ST segment 
elevation during exercise in patients with reciprocal depression. This may reflect the fact 
that reciprocal depression was significantly more common with inferior myocardial 
infarction ,with associated ST segment depression occurring predominantly in leads I and 
AVL,which has a reduced incidence of ST elevation. Patients with reciprocal depression 
on their ECG and a greater incidence of post-infarct ischemic pain and peri-infarct acute 
left ventricular failure. Reciprocal depression tends to occur with marked ST elevation 
which represents a larger infarct. Reciprocal depression did not predict outpatient or overall 
cardiac events. Therefore reciprocal depression on the admission ECG reflects the amount
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of myocardium at jeopardy of infarction it does not necessarily equate to the amount of 
myocardial damage as thrombolysis will achieve patency of the infarct related artery and 
subsequent salvage. This results in preservation of left ventricular function: which is a 
major determinant of clinical outcome.
9.2.6 Time to therapy
All patients in this study were treated within 6 hrs of onset of symptoms of acute 
myocardial infarction.. 3 Groups were identified according to the time of administration of 
thrombolysis following onset of symptoms: 0-2 hrs, 2-4 hrs and 4-6 hrs. Angina during 
exercise testing was more common in patients treated within 2 hrs of thrombolysis. This 
suggests greater salvage of myocardium with early treatment. However, time to treatment 
did not predict any other variables during exercise testing confirming the results of other 
studies (Sutton JM and Topol EJ, 1991). Time to treatment does not equal time to 
reperfusion and combining this time with the results of patency at 90 min and 24 hrs may 
reflect time to reperfusion more closely. Post-infarct angina as an outpatient was similarly 
more common in patients treated within 2 hrs with thrombolysis. Multiple comparisons of 
the three treatment groups were performed and showed the major differences occurred in 
the development of angina between those treated between 0-2 hrs and 4-6 hrs, and 2-4 hrs 
and 4-6 hrs. This implies improved benefit to patients treated with thrombolysis within 4 
hrs of the onset of symptoms. All cardiac events as an outpatient showed a trend towards an 
increased incidence in patients treated within 2 hrs of thrombolysis. Multiple comparisons 
showed this effect was significantly different in those patients treated within 2 hrs 
compared 2-4 hrs and 4-6 hrs.
9.3 Exercise variables in the prediction of clinical outcome
9.3.1 Exercise Capacity
There was no relationship between exercise capacity measured as total exercise time or 
metabolic equivalent and cardiac events during the follow up period. Several studies in the 
pre-thrombolytic era (Davidson MD and DeBusk RE, 1980; Jennings K et al. 1984; Weld
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FM et al. 1997; Valesco JA et al. 1981) showed that reduced exercise capacity caused by 3 
vessel disease or impaired LV function, was predictive of an adverse outcome. A study in 
the post-thrombolytic era, showed that failure to achieve a median workload of 7 mets was 
predictive of recurrent cardiac events. However, it had a poor positive predictive accuracy 
of 21%. This reflects improved mortality with thrombolysis and the other potential reasons 
for reduced exercise capacity in the post thrombolytic era which do not necessarily have an 
adverse prognosis.
9.3.2 Systolic Blood Pressure
Prior to widespread use of thrombolysis, an abnormal systolic blood pressure response 
during exercise testing post myocardial was shown to be predictive of future cardiac events. 
An increased mortality was associated with failure of systolic blood pressure to rise by 30 
mmHg during exercise testing (Nielsen JR et al. 1990; Jennings K et al. 1984) or failure to 
reach a peak systolic blood pressure >140 mmHg (Fioretti P et al. 1984; Starling MR et al. 
1980). In a study in 1993 it was shown that failure of systolic blood pressure to increase by 
>30 mmHg was a weak predictor of mortality after thrombolysis for acute myocardial 
infarction within the 1st year, with a relative risk of 2.9 (Arnold AER et al. 1993). In this 
study accurate blood pressure data was recorded by manual measurement in only 48 of the 
156 patients who were exercised. Total number of events in each group were small and this 
may have caused a type II error in this analysis.
9.3.3 Rate Pressure Product
Rate pressure product in the pre-thrombolysis rate pressure product was shown in one study 
(Saunamaki KI and Anderson JD, 1982) to be a predictor of cardiac death over a mean 
follow up period of 5.7 yrs. Median rate pressure product in our study was 5800. Failure to 
achieve this median value was not predictive of outpatient clinical events but was subject to 
the same potential problems with type II error as systolic blood pressure data. In addition 
patients on B blockers would have a reduced rate pressure product and as no attempt was 
made to alter prescribed treatment prior to the exercise test patients these may have been
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classified in the group who failed to achieve the median rate pressure product without any 
added risk.
9.3.4 ST segment depression
In the pre thrombolytic era approximately 30% of patients recovering from a myocardial 
infarction had ST segment depression during predischarge exercise testing (Williams WL et 
al. 1984). In 1979 Theroux et al in an influential study of 210 patients with uncomplicated 
myocardial infarction showed that ST segment depression of > 1 mm in a low level 
exercise test performed at a mean of 11 days post-infarct was highly predictive of mortality 
in the 1st year. The strength of this study was on lack of intervention with medical therapy 
or revascularisation during the follow up year. Any intervention was performed on the basis 
of clinical symptoms and not the results of exercise testing. However, there were very 
small numbers of events in both groups. Other studies supported this result (Davidson MD 
and DeBusk RF, 1980; Beider M et al. 1988; Kentala E, 1976). However, Sanz G et al. In 
1982 showed that ST segment depression was not predictive of clinical outcome in 259 
males recovering from myocardial infarction. Further studies (Nielsen JR et al. 1990; 
Jennings K et al. 1984; ESC Working Group on Exercise Physiology Pathophysiology and 
Electrocardiography, 1993) also identified reversible ischemia as a predictor of adverse 
prognosis. In a meta-analysis of 12 studies published in (Arnold AER et al. 1993), there 
was a increase in sudden death or reinfarction with ST segment depression of > 1 mm 
during exercise testing post myocardial infarction with an overall odds ratio of 1.9. The 
positive predictive accuracy of ST segment depression in identifying all cardiac events was 
80% and mortality alone was 90% in the study by Theroux in 1979. Since the widespread 
use of thrombolysis the predictive value of exercise testing has been re-assessed (Stevenson 
R et al. 1993). In this study there was reduced sensitivity, specificity and positive 
predictive accuracy compared to the previous studies in the pre-thrombolytic era. However, 
there was retained negative predictive accuracy. Therefore a normal exercise test following 
myocardial infarction treated by thrombolysis indicates a good prognosis, and these patients 
can potentially be discharged from clinical follow up. However, an abnormal exercise test
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is no longer able to clearly stratify patients into those at high risk of further current 
ischemic events. Before the advent of thrombolysis, the Q wave myocardial infarction 
caused a fixed amount of myocardial damage which healed with scar tissue formation. 
Subsequent recurrent ischemic events including reversible ischemia during exercise testing 
therefore reflected the presence of additional vessel disease which carries an adverse 
clinical prognosis. Thrombolysis alters coronary artery anatomy post-infarct by achieving 
reperfusion of an infarct-related artery in at least 60% of patients and resulting in a residual 
stenosis in about 70% of patients (Sutton and Topol 1991) which supplies an area of 
myocardium with variable viability. This is, therefore, an additional reason for recurrent 
ischemic events and reversible ischemia during exercising testing post-myocardial 
infarction. Therefore, there are additional reasons why a patient might develop ST segment 
depression during exercise testing. They do not however carry the same adverse prognosis, 
especially in patients with single vessel disease. Thrombolysis reduces mortality in 
myocardial infarction and preserves left ventricular function. By Baye’s theorem the 
positive predictive accuracy of any test performed to identify adverse outcome will be 
reduced as a result improved mortality post-myocardial infarction with thrombolysis 
(Northridge DB and Hall RJC, 1997)
9.3.5 ST-Segment Elevation:
ST segment elevation during exercise testing following myocardial infarction is more 
common in patients with anterior-myocardial infarction. It usually occurs in the infarct site 
which often has residual ST elevation following myocardial infarction. Some studies have 
shown ST elevation during exercising testing to be predictive of outcome (Beider M et al. 
1988; Sullivan ID et al. 1979) but there remains controversy as to its the significance 
(Nielsen JR et al. 1990; Fioretti P et al. 1986). It is likely that ST segment elevation during 
exercise represents a wall motion abnormality of the infarct site rather than reversible 
ischemia. This has a complex relationship with exercise ejection fraction (Sanz G et al.
1982) and subsequent functional capacity. The TIMI II study showed that ST Elevation 
during post infarct exercise testing occurred predominantly in the infarct site and these
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patients had a lower resting ejection fraction and increased 1 yr mortality (The TIMI Study 
Group, 1993). .In this present study of 212 patients treated with thrombolysis ,ST segment 
elevation, during exercise testing occurred frequently in the infarct site as defined by the 
admission ECG, but failed to predict clinical outcome in keeping with recent studies in the 
post thrombolysis era (Stevenson R et al. 1993). Normalisation of inverted T-wave during 
exercise testing post-myocardial infarction has not been extensively investigated in 
previous studies. This occurred exclusively at the site of infarction. However, this is not 
surprising as T wave inversion occurs as part of sequential ECG changes in the site of 
myocardial infarction and is not normally present in a non-infarct site. T-wave 
normalisation did not predict clinical outcome and should be considered as a benign 
electrical phenomenon.
9.3.6 ST-Segment Depression with low workload
In an attempt to improve the predictive value of ST-segment depression this variable was to 
combined this variable with failure to achieve a median workload of 5.8 mets and the 
combination used to reassess predictive value of the exercise test. ST segment depression at 
a low workload has been shown to improve the predictive value of the predischarge 
exercise test (Stevenson R et al. 1993) following thrombolysis but this present study failed 
to confirm these results. Perhaps the median workload of 5.8 mets was not representative 
of a significant reduction in exercise capacity .In clinical management of patients with 
angina, age predicted exercise time, calculated from a nomogram, is used to assess a 
reduction in functional capacity. This criterion has not been applied to patients post 
myocardial infarction in the predischarge exercise test which commonly uses modified 
protocols.
9.3.7 Failure to Undergo Exercise Testing
Several studies have shown patients failing to undergo an exercise test following a 
myocardial infarction had a worse prognosis (Gissi Working group, 1993; The TIMI Study 
Group, 1993; Peart I et al. 1989).This implies that this group of patients had complicated
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myocardial infarctions, other physical disabilities or ongoing disease processes which 
rendered them unsuitable for exercise testing. Fourteen patients who died during the in­
patient period were ineligible to perform pre-discharge exercise testing and therefore not 
included in the results as this would lead to significant bias. Twenty-six per cent of patients 
eligible to have exercise testing did not do so. In this study, following acute admission to 
the Coronary Care Unit and subsequent angiography, the patients were then transferred to a 
general medical ward, usually but not always, under the care of one of the three Consultant 
Cardiologists. Occasionally, patients were transferred under the care of general physicians 
who happened to be on call for emergency referrals on the day of the patient’s admission to 
Coronary Care. As the analysis of clinical events was retrospective, it was not possible to 
define why 26% of patients did not undergo exercise testing as the reasons were not stated 
in the patients’ case records. Therefore, within this group of patients, although the majority 
were not physically fit to undergo exercise testing at the time of discharge there may also be 
a subgroup of patients who were fit to undergo exercise testing but did not do so because of 
the management strategy of the attending physician. Failure to undergo predischarge 
exercise testing did not predict any cardiac events during follow-up. Given that a proportion 
of these patients were suffering from additional chronic diseases, it was reasonable to 
include deaths from other causes. 18% of patients who did not undergo predischarge 
exercise testing died from all causes over the 5-years of out-patient follow-up. This was 
statistically significant compared to those who completed an exercise test and probably 
reflects an increased incidence of cardiac complications post myocardial infarct and 
comorbidity in the non exercise test group.
9.3.8 Symptoms during exercise testing
In this study, patients underwent a symptom limited exercise test and were only stopped by 
the attending physician if they reached maximum heart rate, developed a significant 
arrhythmia, ST-segment depression of >3mm or systolic blood pressure fell by > 20mmHg.. 
Patients reported a variety of symptoms but 70 patients,(45%) were asymptomatic during 
exercise testing and were stopped electively by attending physicians for the reasons
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outlined above. Combined symptoms during predischarge exercise testing did not predict 
clinical outcome. This is probably due to the non specific nature of the symptoms reported 
during exercise.
9.3.9 Angina:
Only 19 patients [12%] experienced angina during the predischarge exercise test. In the pre 
thrombolytic era approximately 20% of patients recovering from a myocardial infarction 
developed angina during predischarge exercise testing(Williams WL et al. 1984, Theroux et 
al. 1979 showed that angina occurring during the predischarge exercise test predicted 
development of post-infarct angina as an outpatient. Furthermore, the development of 
angina during exercise testing was not predictive of clinical cardiac events. In this present 
study patients with angina during post-infarct exercise testing were more likely to develop 
symptoms of angina during daily activity as an outpatient (63% v 37% p=0.007)..A 
reanalyses of this data from Theroux presented on page 33 of the introduction shows that 
angina was predictive of all coronary events if post-infarct angina itself was removed as an 
event but was not predictive of mortality. The predictive accuracy of the positive test, 
namely angina during exercise testing, was poor for both all cardiac events 31 % and 
mortality 16%. Other studies report angina pectoris as predictive of future coronary artery 
bypass surgery (ESC Working Group on Exercise Physiology Pathophysiology and 
Electrocardiography, 1993),recurrent myocardial infarction or sudden cardiac death (Peart I 
et al. 1989; Davidson MD and DeBusk RF, 1980). The number of patients undergoing 
coronary artery bypass surgery over a 5 year period was very small in the study by Theroux 
P et al. 1979 and was not considered as a cardiac event in isolation.
Patients with significant angina post infarct may be considered for CABG on clinical 
grounds. Of the 62 Patients with angina as an outpatient over the 5 year follow up period 18 
had CABG performed. This would depend on severity of symptoms , suitability of coronary 
anatomy and comorbidity. 8 patients without symptoms of angina had CABG performed 
on prognostic grounds following repeat angiography. In general patients were not referred
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for CABG on the basis of angiography at 90 min and 24 hrs post thrombolysis as the 
prognosis on the basis of coronary anatomy was unknown. Patients were usually 
reinvestigated by coronary angiography on clinical grounds after recovery from the infarct.
9.4 Coronary patency:
Coronary artery patency of the infarct-related vessel in this study was assessed by TIMI 
scoring of coronary angiogram performed at 90 minutes and 24-hours following 
thrombolysis for acute myocardial infarction.
9.4.1 TIMI score at 90 mins:
194 of the 212 patients underwent angiography. At 90 minutes, 8 patients were clinically 
too unwell to undergo coronary angiographic assessment. The TIMI score at 90 minutes did 
not predict any symptoms or complaints of angina during exercise testing. Similarly, there 
was no relationship between a TIMI score at 90 minutes and ST-T changes during exercise 
and measurements of functional capacity.
9.4.2 TIMI score at 24-hours:
187 out of 212 patients underwent angiography 24-hours following thrombolysis. Coronary 
angiography was contraindicated because of the significant deterioration in the clinical 
condition of 11 patients ,8 patients died during the first 24-hours. It was not possible to 
perform repeat angiography in 7 patients for technical reasons, involving the arterial sheath 
which had been left in situ in the right femoral artery. At 24-hours, 58% of patients had 
TIMI -grade 3 flow in infarct-related vessel, 12% of patients had no established flow [TIMI 
grade 0]. There was no relationship between TIMI score at 24-hours and symptoms during 
exercise testing, ST-segment changes or measurements of functional capacity. The 
coronary patency was further defined by combining TIMI score 0 and 1 as non-patent 
arteries and TIMI score of 2 and 3 as patent arteries at 90 minutes and 24-hours (62% of 
patients and 83% of patients had patent vessels at 90 minutes and 24-hours, respectively). 
Patency did not appear to affect the results of the exercise testing in terms of symptoms,
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ST-T change of measurements of functional capacity. Thrombolysis has been shown to 
lead to an increased incidence of recurrent ischemic events (Schaer DH et al. 1987) post­
infarct defined as
1. Spontaneous angina at rest or during ward ambulation,
2. Provokable angina during predischarge exercise test
3. Reinfarction
Patients who reperfused with thrombolysis were more likely to experience recurrent 
ischemic events as were those with sub-total occlusion of the infarct-related vessel 
identified with pre-treatment coronary angiography. This early study, however, did not use 
TIMI scoring system to quantify patency of the infarct-related vessel and, therefore, treated 
reperfusion qualitatively as and all or nothing phenomenon. Only symptoms of angina 
during exercise testing were recorded no other exercise variables were considered. Patients 
treated with thrombolysis were shown to have no increased incidence of positive exercise 
test defined as typical angina or ST-segment depression versus placebo (Hamouratidis N et 
al. 1991). Patients with recannalised arteries had increased incidence of normal exercise 
tests. However, in this study angiography was performed 22.9 days following thrombolysis 
when infarct artery remodelling and time-dependent reperfusion without myocardial 
salvage may have occurred. Van Der Wall EE et al 1997 performed an angiographic 
assessment of patency at 2-hours following streptokinase and showed no relationship 
between coronary patency defined as TIMI grade 2 and 3 and non patent vessels in a the 
number of persistent or reversible perfusion defects present on thallium scanning. The 
authors did not attempt to relate patency or other variables during exercise testing.
Coronary patency per se may not guarantee significant salvage of myocardium.
Reperfusion following thrombolysis may occur at various time points post therapy resulting 
in a variable amount of residual .viable myocardium in the region supplied by the infarct- 
related artery. Other factors, such as a collateral circulation, the site of coronary occlusion
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or duration of occlusion, may influence the quantity of myocardium salvaged. In this 
present study failure to achieve coronary patency with thrombolysis [TIMI score 0 and 1] at 
90 minutes was shown to predict post-infarct ischemic pain. This includes 6 patients with 
coronary reocclusion between 90 minutes and 24-hours, therefore, it is not surprising that 
post-infarct ischemic pain was more common in this group. Failure to achieve coronary 
patency at 24-hours gave a trend towards increased incidence of peri infarct acute left 
ventricular failure. Non-patency at 90 min was predictive of chronic heart failure as an out­
patient. There was an increased incidence of overall heart failure in those patients with non 
patent arteries at 90 minutes. This is supported by recent evidence from the GUSTO study 
in 1993 which showed overall patency: TIMI grades 2 and 3 combined and full patency 
TIMI grade 3 resulted in a reduced incidence of left ventricular dysfunction assessed by left 
ventricular angiography and improved mortality at 30-days..
9.4.3 Effect o f fu ll Patency:
The effect of full patency TIMI grade 3 on exercise variables following thrombolysis were 
further assessed by comparing TIMI score 3 against TIMI score 0, 1 and 2 at 90 minutes 
and 24-hours with thrombolysis. 36% and 58% of patients were assessed as TIMI grade 3 
at 90 minutes and 24-hours, respectively. There was no relationship between TIMI grade 3 
and development of symptoms, ST-T changes or measurements of functional capacity 
during exercise testing. However, TIMI grade 3 was shown to favourably improve patient 
prognosis. The development of peri-infarct acute left ventricular failure, chronic heart 
failure as an out-patient and heart failure overall, were all significantly reduced in patients 
with TIMI grade 3 patency post-thrombolysis. Sudden cardiac events were also 
significantly reduced with TIMI grade 3. This supports the data from GUSTO study 1993 
which compared TIMI grade 3 versus TIMI grade 0,1,2 and showed a significant reduction 
in the incidence of left ventricular dysfunction and improved mortality. Although factors 
other than patency will affect left ventricular function and the development of heart failure 
in the peri-infarct and post-infarct periods, achieving early patency is a definite benefit to
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prognosis.
9.4.4 Time to Patency:
By combining TIMI scores of the angiographic assessments at 90 minutes and 24-hours, it 
was possible to define four patency groups: early patency [EP], late patency[LP] non­
patency [NP] and Reocclusion[R].Only six patients [3%] had coronary reocclusions at 24- 
hours following thrombolysis, 60% of patients had early patency, 24% had late patency and 
13% were non-patent. To avoid a type II error reocclusion with such small numbers were 
not included in further analysis. Time to patency had no effect on symptoms during 
exercise testing, ST-T change or measurements of functional capacity. Post infarct ischemic 
pain occurred more frequently in patients with non-patent vessels, i.e. TIMI grade 0,1 at 90 
minutes and 24-hours. It is possible that reperfusion had occurred in these patients between 
90 minutes and 24-hours but at the time of the 24-hour angiogram, the vessel was again 
non-patent. Therefore reperfusion and reocclusion was associated with anginal pain. Acute 
left ventricular failure in the peri-infarct period, chronic heart failure as an out-patient and 
combination of both [overall heart failure ] were significantly more common in patients 
with non-patent arteries compared to early and late patency. No previous studies have used 
TIMI scoring in this way to predict results of exercise testing and clinical outcome over 5 
years.
9.5 Residual Stenosis of the Infarct-Related Artery:
In this study, residual stenosis of the infarct-related artery was considered both in single 
vessel disease and in the presence of additional vessel disease. The TIMI scoring system of 
coronary artery stenosis was used and which defines a significant stenosis as being > 50% 
narrowing of the luminal diameter of the coronary artery. Patients with no additional vessel 
disease were considered as having the single vessel disease and further analysed to 
determine the effect of significant residual stenosis. Coronary artery anatomy, following 
the 24-hour angiogram, was used to predict the results of exercise testing and clinical 
outcome because this was the closest angiographic assessment in time to the exercise test.
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72 % of patients had a significant stenosis of the infarct-related artery with or without 
multivessel disease and in 13% of patients the infarct-related artery was occluded. 147 of 
186 patients who had coronary artery anatomy defined at 24-hour angiogram were 
exercised prior to discharge. No relationship was noted between residual stenosis of the 
infarct-related artery and development symptoms or ST-segment changes or functional 
capacity during predischarge exercise testing .Therefore, although a residual stenosis of the 
infarct related artery was present in over 70% of patients it also requires viable myocardium 
to result in reversible ischemia during the exercise test. No assessment of myocardial 
function was made in this study.
Ischemic pain post-infarct occurred in 5 of the 24 patients with occluded vessels and was 
significantly more common when compared to those with no residual stenosis. Coronary 
occlusion occurring between 90 minutes and 24-hours may result from reocclusion of a 
previously patent vessel or persistent occlusion of arteries with TIMI grade 0 or 1 at 90 
minutes. Angiographic assessment has been made at two points in time and cannot, 
therefore, account for fluctuating patency between these two time-points which may have 
resulted in early post-infarct ischemic pain. Post-infarct acute left ventricular failure was 
more common in patients with occluded vessels. The number of events in the occlusion 
group compared to the no stenosis and stenosis group were relatively small which may have 
affected the results in multiple group comparisons. In an occluded vessel at 24-hours, 
unless there is a significant collateral circulation, there will be significant myocardial 
necrosis of the area supplied by that vessel which will result in a variable degree of left 
ventricular dysfunction, dependent on the site of occlusion. It is, therefore, not surprising 
that patients with persistent coronary occlusion, post-thrombolysis are more likely to 
develop peri infarct left ventricular failure. However no assessment of site of occlusion was 
made in this study. All cardiac ischemic events were similarly more common in patients 
with occluded vessels. There is no significant difference in the occurrence of outpatient 
cardiac events or overall cardiac events with residual stenosis. Patients with no residual 
stenosis in the infarct related artery or any additional vessel disease were still categorised as
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single vessel disease .. The concept of 0 vessel disease used by some authors was not 
applied to this data. Patients with a residual stenosis of < 50% still have an underlying 
atheroscleortic plaque and therefore the potential for recurrent ischemic events. 99 [54%] of 
patients had single vessel disease. Similarly, 70% of these patients had a significant 
stenosis and 10% had occluded vessels. The residual stenosis in the patients with single 
vessel disease did not predict the results of exercise testing in terms of symptoms and ST- 
segment changes or functional capacity. Patients with occluded vessels, however, had a 
significant increase in pain post-infarct but not left ventricular failure following infarction 
or all cardiac ischemic events. Out-patient and overall cardiac events were not predicted in 
the presence of residual stenosis of single vessel disease. Patients with single vessel disease 
carry an improved prognosis and are therefore less likely to suffer recurrent ischemic 
events. It is interesting that the presence of stenosis, following thrombolysis for acute 
myocardial infarction, does not result necessarily in an increased incidence of inducible 
ischemia or symptoms during exercise testing. Sutton JM and Topol EJ in 1991 showed 
that only increased creatinine kinase levels predicted the absence of reversible ischemia 
during exercise testing. In addition, the presence of residual stenosis in single or multiple 
vessel disease was not predictive of inducible ischemia during exercise testing. A further 
study by Ellis SG et al. 1989, of patients recruited to the TIMIIIB study showed no 
increase in the incidence of recurrent ischemic events during hospital in-patient period in 
patients with TIMI -grade 2 or 3 or a significant residual stenosis who had not undergone 
PTCA or thrombolysis. A smaller study, however,(Grines CL et al. 1988) found significant 
residual stenosis in > 50% was predictive of reocclusion. In this study, angiography was 
carried out at day-7 which may have influenced surprisingly high reocclusion rate of 23%. 
However, as there were only 50 patients in this study, the number of events recorded in 
each group was small, suggesting the possibility of a Type II error.
9.6 Number of Vessels Affected by Coronary Artery Disease:
The coronary angiogram at 24-hours with reference to the TIMI score of coronary artery 
stenosis of was used to define the number of affected vessels for each patient. If only the
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infarct-related artery was affected, patients were defined as having single vessel disease 
regardless of the presence of a residual stenosis. It was not felt that the concept of no vessel 
disease was valid, given that an acute myocardial infarction had occurred in each patient, 
implying underlying atherosclerosis in the infarct-related artery at least. 19% of patients 
were shown to have triple vessel disease and 47% single vessel disease. Symptoms during 
exercise were unaffected by the number of diseased vessels. However, patients with three- 
vessel disease were more likely to have an ST-segment depression of ^  1 mm during 
exercise testing. Functional capacity was unrelated to the number of diseased vessels. 
Clinical outcome with three-vessel disease showed an increased incidence of all cardiac 
ischemic events as an out-patient, with 50% of patients experiencing at least one clinical 
event in this group. There was an increased mortality in patients with 3 vessel disease 
compared to with 1 and 2 vessel disease combined (22% v 6%) In the pre-thrombolytic era 
ST-segment depression at exercise testing post-myocardial infarction was shown to identify 
90% of patients with triple vessel disease (Griffith LSC et al. 1997; Mannering D et al. 
1987) Inadequate systolic blood pressure response was also associated with 3 vessel 
disease. In a study in younger patients [males < 55yrs of age] only-32% of patients with 
multiple vessel disease could be identified by ST-segment depression during post-infarct 
exercise testing. This is possibly due to the low incidence of multi-vessel disease in this 
younger population. Prior to thrombolysis, myocardial necrosis and subsequent scar tissue 
formation following myocardial infarction, commonly resulting in area of non-viable 
myocardium. Therefore, reversible ischemia requiring viable myocardium implies 
additional vessel disease. Following thrombolysis, a residual stenosis subtending an area of 
viable myocardium is an additional reason for reversible ischemia during exercise testing.
In TIMI II study following thrombolysis with or without PTCA patients with multi vessel 
disease were more likely to have ST segment depression during exercise testing (The TIMI 
Study Group, 1993) supporting the results of this present study. It still seems that despite 
thrombolysis patients with three-vessel disease and are more likely to have ST-segment 
depression during exercise testing However ST-segment depression during does not reliably 
detect the presence of three vessel disease with a low predictive accuracy of the positive test 
at 27%. The value of predischarge exercise testing is now in identifying patients with a
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normal exercise response post infarct. The negative predictive accuracy remains high in the 
thrombolytic era at 89% identifying patients at low risk of recurrent cardiac events and a 
good prognosis who can be safely discharged from cardiological follow up.
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9.7 Summary and Clinical Relevance
In the pre thrombolytic era the results of exercise testing post myocardial infarction were 
predictive of clinical outcome, risk stratification and extent of coronary artery disease. In 
this study 212 patients received thrombolysis within 6 hrs of the onset of symptoms of 
acute myocardial infection and underwent coronary angiography at 90 min and 24 hrs 
following therapy to determine patency of the infarct related artery and additional vessel 
disease. 156 of these patients were exercised before hospital discharge on a motorised 
treadmill using a symptom limited modified Bruce protocol. The results of the early 
invasive assessment and exercise testing were related and also used to predict clinical 
outcome. Patency of the infarct related artery: TIMI score 2,3, TIMI score 3 and early 
patency were not associated with exercise test variables but were predictive of a favourable 
clinical outcome in keeping with recent data from the Gusto study 1993. Residual stenosis 
of the infarct related artery failed to predict the exercise response or clinical outcome. 
Patients with 3 vessel disease had an increased incidence of ST segment depression during 
exercise testing. However the positive predictive value of ST segment depression was low 
in prediction of clinical outcome or identification of 3 vessel disease. The exercise test post 
myocardial infarction in the thrombolytic era retains its high negative predictive accuracy.
Thrombolysis results in reperfusion of an occluded infarct related artery at some point in 
time following therapy and salvage of myocardium at jeopardy of cell necrosis. Residual 
left ventricular function therefore depends on a number of factors: site of occlusion, time to 
reperfusion, degree of coronary patency, reocclusion and presence of a residual stenosis of 
infarct related artery. In the prethrombolytic era, left ventricular function was a major 
determinant of clinical outcome. Reversible ischemia on the exercise test was due to the 
presence of additional vessel disease. In the absence of reperfusion of infarct related artery 
a coronary occlusion will cause infarction of the myocardial muscle it supplies, healing 
with scar tissue formation. However, following thrombolysis a residual stenosis of the
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infarct related artery offers an alternative reason for inducible ischemia if there is 
myocardial salvage and viable muscle.
The prognosis in patients with a residual stenosis subtending an area of viable myocardium, 
particularly with single vessel disease is likely to carry an improved prognosis compared to 
those patients with 3 vessel disease. It is therefore not surprising that reversible ischemia 
during the predischarge exercise testing now representing a variety of anatomical 
conditions, no longer has the same predictive accuracy. Thrombolysis improves mortality 
from myocardial infarction and in accordance with Bayes thoerum any test designed to 
identify an adverse outcome will result in a reduced positive predictive accuracy. A normal 
exercise test post myocardial infarction in the post thrombolytic era still identifies low risk 
patients with a good clinical outcome.
Therefore thrombolysis should be given for treatment of myocardial infarction with a view 
to achieving early and complete reperfusion to minimise left ventricular damage The 
exercise test should be performed post infarct, preferably prior to hospital discharge.
A normal exercise response identifies patients at low risk who can be discharged from 
cardiological follow up without further investigation. Patients with an very poor exercise 
capacity, significant early reversible ischemia or severe angina post infarct should be 
considered for further investigation to define coronary anatomy with a view to 
intervention. There remains an intermediate group of patients with moderate abnormalities 
on their exercise test who require a period of follow up under the cardiologist. This is 
needed to monitor the clinical progress of the patient before deciding to embark on further 
investigations or discharge the patient back to the general practitioner.
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1. APPENDIX I
1.1 COMPARISON OF ANISTREPLASE/STREPTOKINASE PROTOCOL
1. STUDY OBJECTIVES
1.1 To measure and compare angiographically documented coronary artery patency 
at 90 minutes following intravenous APS AC 30 Units or intravenous 
streptokinase 1.5 million units.
1.2 To compare reocclusion rates at 24 hours after dosing.
2. STUDY MEDICATION
2.1 Intravenous APSAC
APSAC is the active site p-anisoylated derivative of the primary (human) lys- 
plasminogen-streptokinase complex prepared by immediate acylation of the 
serine residue in the active centre of that complex as it is formed. The molecular 
weight is close to 131,000 Daltons.
APSAC is formulated in a mixture of clinical grade human albumin, D-mannitol 
and ly-lysine. It is presented in vials, each containing 30 Units APSAC as a 
sterile, white lyophilized powder.
2.2 Storage
APSAC 300 vials have a shelf-life of 2 years when stored at or below 5°C.
2.3 Streptokinase
Streptokinase is presented as a freeze-dried powder in vials containing 600,000 
units of streptokinase. Streptokinase is stable for at least 3 years when stored at 
room temperature (<25°C). Solutions prepared for infusion but left over or not 
used should be discarded.
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3. STUDY DESIGN
A double blind, double dummy, randomised, angiographically controlled study 
of intravenous APSAC or intravenous streptokinase in acute myocardial 
infarction with stratification according to infarct site.
3.1 Number of patients
A minimum of 809 patients will complete the study. One hundred and twenty- 
eight patients were recruited.
3.2 Patient Entry
Patients with clinical evidence of acute myocardial infarction who satisfy the 
inclusion/exclusion criteria will be eligible for randomisation.
3.3 Stratification and Randomisation
Patients will be stratified according to the site of infarction. Each stratum has 
been separately pre-randomised to receive APSAC 30 Units intravenous or 
streptokinase 1.5 million Units intravenous.
3.4 Coronary Angiography
Angiography will be performed at 90 minutes and at 24 hours after dosing.
3.5 Blood pressure and heart rate monitoring
Blood pressure and heart rate will be monitored immediately before drug and 
continuously throughout the 90 minutes post-treatment period. Blood pressure 
and heart rate will be recorded on the case report forms every 2 minutes until the 
end of the 90 minute angiogram.
3.6 Primary Data end Points
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3.6.1. Angiographically documented patency (occlusion/perfusion grade 2,3) or 
occlusion (occlusion/perfusion grade 0.1) of the presumed infarct related vessel 
at 90 minutes after dosing.
3.6.2. Angiographically documented reocclusion (occlusion/perfusion grade 0,1) or 
sustained patency (occlusion/perfusion grade 2,3) at 24 hours after dosing in 
those who had patent infarct related vessels at 90 minutes.
4. PATIENTS AND METHODS
All patients with suspected acute myocardial infarction who satisfy the 
inclusion/exclusion criteria will be admitted.
5. INCLUSION CRITERIA
Patients admitted to hospital;
5.1 Aged 70 years or under.
5.2 With chest pain or other symptoms of acute myocardial infarction of at least 30 
minutes duration who can be treated within 6 hours of symptom onset.
5.3 With ECG evidence of ST segment elevation of at least 0.1 mV in two or more
standard leads and/or 0.2 mV in two or more praecordial leads.
5.4 In whom appropriate consent is obtained for participation in the study.
6. EXCLUSION CRITERIA
6.1 Patients with systolic blood pressure below 95 mmHg.
6.2 Patients on anticoagulant therapy.
6.3 Patients with a known history of haemorrhagic diatheses or significant recent
bleeding from another site.
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6.4 Patients with documented or suspected active peptic ulceration within 1 year.
6.5 Patients with a history of cerebrovascular accident.
6.6 Patients who have had surgery, major trauma or head injury within the previous 
months.
6.7 Patients who have received streptokinase or APSAC therapy within the previous 
6 months.
6.8 Patients with severe hypertension, blood pressure above 200/120 mmHg.
6.9 Patients who have received prolonged chest compression prior to randomisation.
6.10 Pregnant females or those in whom pregnancy cannot be ruled out. Females 
who are menstruating or who are of child bearing potential.
6.11 Patients with diabetic proliferative retinopathy.
6.12 Patients in whom coronary angiography is contraindicated.
6.13 Patients who have had coronary angioplasty within 1 month of presentation or 
those with a history of CABG or prosthetic valve insertion.
6.14 Any condition requiring immediate surgical intervention.
6.15 any clinical suspicion of dissecting aneurysm.
6.16 transmural myocardial infarction within 3 months.
6.17 Patients with serious or life-threatening disease unrelated to the circulatory 
system.
7. CORONARY ANGIOGRAPHY
7.1 Coronary angiography will be via a brachial or femoral artery approach. At least
three views (LCA) or two views (RCA) of the infarct related vessel will be taken 
during procedure. One of these will be the optimal view for maximising the 
percent residual stenosis.
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7.2 An angiogram will be performed at 90 minutes from the start of dosing. The
catheter will then be withdrawn, but the sheath will be left in place for up to 48
hours.
7.3 Patency will be defined by TIMI scoring at 90 mins and 24 hrs post 
thrombolysis. Grade 0, 1 is defined as non patent. Grade 2,3 as patent.
8. BLOOD PRESSURE MONITORING
Arterial pressure and heart rate will be recorded immediately before and 
continuously for 90 mins after dosing. Copies of all tracings will be reported in 
the relevant section of the case record from prior to their being placed in the 
inside cover.
9. HEPARIN ADMINISTRATION
All patients should receive heparin in a dose of 1000-1500 units per hour from 
between 4 and 6 hours after thrombolytic therapy or when the thrombin time has 
decreased to less than twice the control value.
Heparin treatment will be continued for 24 hours and further anticoagulation is 
at the physicians discretion.
10. ECG RECORDINGS
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All patients will have single lead continuous ECG rhythm recordings for the first 
24 hours of the study. Rhythm disturbances will be reported in the appropriate 
section of the case report form.
Five 12 lead ECG’s are required, these include one on admission, at 2, 4, 16, 18 
and 24 hours. If the patients clinical condition changes substantially within the 
first 24 hours, further ECG’s may be required.
11. CLINICAL ASSESSMENTS
11.1 Any symptoms thought to be associated with the procedure, the treatment or the 
disease will be noted.
11.2 Heart rate and blood pressure will be measured before dosing and continually for 
the first 90 mins after dosing. There will be further non-invasive measurements 
at 6,12 and 24 hours after dosing or more frequently if indicated by a change in 
the patient’s condition.
11.3 Temperature will be monitored at 6, 12 and 24 hours after dosing.
Measurements will be taken more frequently if indicated by changes in the 
patient’s condition.
12. LABORATORY OBSERVATIONS
Blood samples will be drawn to determine hepatitis B status, cardiac enzyme 
concentrations, clinical chemistry, haematology.
12.1 Hepatitis B status.
A blood sample will be taken before dosing and tested for HBsAg.
12.2 Cardiac Enzymes Concentrations
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Blood samples must be taken before dosing, at 90 mins and 24 hours after 
dosing for the estimation of CPK and routine cardiac enzymes.
12.3 Clinical Chemistry and Haematology
Blood samples will be taken before dosing, at 90 mins and 24 hours after dosing 
for a routine screen.
12.4 Urinalysis
A urine sample will be collected at 24 hrs after dosing for the estimation of pH, 
blood, ketones, protein and bilirubin by means of “Dipstix”.
13. PRECAUTIONS
13.1 Ancillary medications
No anti-platelet medication for 24 hrs after thrombolytic therapy.
Additional drugs, such as analgesics, antiarrhythmics etc., should be 
administered in accordance with normal hospital practice. All patients will 
receive a continuous infusion of intravenous nitrates.
13.2 Dealing with excessive production of plasmin
For the treatment of severe uncontrolled bleeding, it is suggested that the 
following steps be taken:
a) discontinue thrombolytic agent
b) application of local pressure where possible
c) reversal of the lytic state; Administer TRANEXAMIC ACID in a
standard dose of 500 mg intravenously over 2 mins (other agents may be 
used). A further 500 mg tranexamic acid may be administered if the 
bleeding is not controlled after the replacement of clotting factors.
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d) replace clotting factors with cryoprecipitate, fresh frozen plasma, or
whole blood.
e) replace blood loss.
14. DRUG ACCOUNTABILITY
14.1 On-site Storage and Distribution
All investigational drug supplies will be stored in a refrigerator, maintained at 
5°C at the study site. Shelf life for APSAC is 2 years. Access to the study 
medication must be limited to the principal investigator and other authorised 
members of his staff.
During periodic monitoring by Beecham staff, the drug supplies and case records 
will be reviewed for accuracy and completeness.
15. INFORMED CONSENT AND PATIENT PRIVACY
It is the investigator’s responsibility that each subject or subject’s legal 
representative signs an informed consent statement prior to participation in this 
study. Copies of the consent form with the patient’s initials will be retained by 
the investigator.
The patients will be informed of their rights to privacy but will be made aware 
that study data will be submitted to Beecham and to drug regulatory authorities 
for review and evaluation. They will also be informed that both Beecham and
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the regulatory authorities have the right to inspect the patient’s medical records 
to verify the accuracy and completeness of the study records and results.
16. REPORTING OF ADVERSE EVENTS
The date, time of onset, duration and severity of any adverse reaction will be 
recorded. In the event of a persistent severe adverse event, e.g. hemiplegia 
resulting from CVA, the outcome should be determined at intervals up to 1 year.
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1. APPENDIX 11
1.1 A PILOT STUDY OF BOLUS TP A 35mg x 2 IN PATIENTS WITH ACUTE 
MYOCARDIAL INFARCTION INTRODUCTION
OBJECTIVES
To assess the effect of two boluses of rt-PA on the patency of coronary vessels at 30,
60 and 90 minutes in patients with acute myocardial infarction by invasive and non 
invasive methods.
STUDY DESIGN
This study has an open dose-ranging design to evaluate bolus rt-PA. Initially 20 
patients will be treated with two boluses, the initial bolus being 35 mg rt-PA. This 
would be repeated at 30 minutes, giving a total dose of 70 mg. Following the first 20 
patient's treatment, the results will be analysed, and a further 20 patients will be treated 
at a further dosing level of 50 mg, repeated after 30 minutes. This dose increment will 
be dependent on the results obtained. The maximum total dose of rt-PA used in this 
study will be 100 mg, as is the recommended dose schedule at present used in clinical 
practice.
STUDY POPULATION 
Inclusion Criteria
(1) Patients with acute myocardial infarction defined as:
a) Cardiac pain at rest lasting from thirty minutes up to six hours.
b) ECG changes at presentation consistent with a diagnosis of acute 
myocardial infarction.
Normally this will include ST segment elevation of at least 2 mm in two 
praecordial leads or ST segment elevation of 1 mm in two inferior leads.
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However, patients with ECG diagnosis of posterior myocardial
infarction and right ventricular myocardial infarction will also be
included.
(ii) Males and females.
(iii) Age 18 to 75 inclusive.
(iv) Patients who have no contra-indications to angiography.
(v) Patients able to give informed consent to participate.
(Vi) Patients with no history or ECG changes of previous myocardial infarction in
same distribution.
(vii) Patients weighing over 67 kg.
Exclusion Criteria
(i) Patients with ECG abnormalities that make it impossible to diagnose acute
myocardial infarction. This will include patients with left bundle branch block 
and other severe conduction defect abnormalities.
(ii) Patients with any contra-indications to thrombolytic therapy:
Any bleeding diathesis
Major trauma or surgery within three months 
Puncture of a non-compressible vessel within 10 days 
Any major haemorrhage
Any patient on Warfarin or Coumarin anticoagulants 
Any previous cerebrovascular accident including TIA 
Any previous history of peptic ulceration
Any proliferative retinopathy
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Women who are pregnant, lactating or menstruating 
History of severe poorly controlled hypertension
Any additional contraindication that is felt by the clinician to be relevant at 
that
time to bolus rt-PA therapy.
METHODS
The patients will be assessed pre-study within the Coronary Care Unit of Stobhill 
General Hospital. Thrombolytic therapy has been administered as standard 
therapy since 1982, and this study will be conducted within the Unit using 
standard monitoring facilities and general nursing medical care as appropriate. 
Written informed consent will be obtained from patients, both for administration 
of thrombolytic therapy, and also permission for performance of coronary 
arteriography. Where appropriate, and when available, the protocol and procedure 
will be discussed with any accompanying relatives.
The first bolus dose of rt-PA will be given as soon as possible following diagnosis. 
In addition, all patients will receive 150 mg of aspirin orally on admission. 
Analgesia will be given as per standard practice, and at no stage will any routine 
antiarrhythmic, inotropic nor vasodilator therapy be witheld. A second bolus dose 
of rt-PA will be given 30 minutes after the first bolus. At 3 hours following 
dosing, a bolus of heparin 5,000 units and an infusion of 1,000 units per hour will 
then be commenced with the rate of infusion being controlled using standard 
coagulation screens. The second bolus of therapy will not be administered if there 
are any new contra-indications such as the occurrence of bleeding, cerebrovascular 
accident or if any surgical intervention is required.
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Coronary arteriography will be performed 30 minutes after the infusion of rt-PA. 
An angiogram of the culprit vessel, as judged by the admission ECG, will be 
performed, and a second bolus dose will be administered thereafter. An arterial 
sheath will be left in situ, and the coronary arteriogram continued with further 
angiograms performed at 45, 60 and 90 minutes. The arterial sheath will be left in 
situ, and coronary angiography will be repeated at 24 hours.
At all times the performance of coronary angiography will be undertaken if the 
patient's clinical condition is stable, and the investigation appropriate. Any form 
of medical or intervention therapy can be performed at any time at the discretion 
of the Consultant Cardiologist managing the patient's overall condition.
Standard twelve lead ECGs will be performed at 0 time, time 2 hours, 4 hours, 8 
hours, 12 hours and 24 hours following dosing. Serial cardiac enzymes will be 
performed, including CPK, AST, ALT and LDH at 4, 12 and 24 hours following 
admission to confirm diagnosis of acute myocardial infarction. Routine 
haematology and biochemistry will be performed as required for patient 
management, and a coagulation status will be performed to allow anticoagulation.
Standard electrocardiographic monitoring with Holter monitor will be performed 
for 24 hours, and this data will be analysed by Reynolds Pathfinder to correlate ST 
segment changes with the reperfusion data obtained from coronary angiography.
All clinical events will be monitored and the patient's follow up therapy will be 
undertaken as deemed appropriate by the Cardiologist.
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The coronary arteriograms will be analysed blindly to assess the achievement of 
reperfusion, and to assess the relative degree. In addition, the morphological 
appearance of the coronary artery following reperfusion will also be assessed using 
standard techniques, as previously performed in the European Collaborative Study 
for Tissue Plasminogen Activator.
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APPENDIX III
1.1 PATIENT INFORMATION SHEET: THROMBOLYTIC THERAPY
A heart attack or a coronary thrombosis is the term used for a condition in which 
the flow of blood to the heart muscle is reduced to a degree that damage occurs. 
The reduction in blood flow is usually due to a blood clot or thrombus obstructing 
the arteries leading to the heart muscle. After a period of time, damage is 
irreversible and the course of the illness will follow the normal healing process. If 
a patient is admitted to hospital early enough, then treatment may be introduced 
which can dissolve the blood clot and can restore flow of blood to the area of 
muscle under threat of permanent damage.
The standard treatment for heart attack within the Coronary Care Unit of Stobhill 
Hospital is to give this therapy to dissolve the blood clot - that is thrombolytic 
treatment, to those patients admitted in the early stage of coronary thrombosis to 
obtain coronary artery flow, and to reduce the degree of damage. This form of 
treatment cannot be given to patients who have a predisposition to bleeding, such 
as those with stomach or duodenal ulcers, or to patients who have had strokes or 
operations in the recent past.
Two standard drugs are available at present for thrombolytic therapy called 
Streptokinase and Tissue Plasminogen Activator. This latter drug has been shown 
to be very successful in dissolving blood clots, and has been used in a widespread 
manner in both United States and mainland Europe, as well as in the U.K. We use 
thrombolytic treatment only in those cases who should benefit, and who have no 
contra- indication. This treatment is in addition to all normal forms of treatment. 
Although we are studying Tissue Plasminogen Activator, its use will not prevent 
the introduction of any other treatment which is necessary for the underlying 
condition. To maximise the dose of Tissue Plasminogen Activator to be given to 
any patient, we are studying its effects on blood clotting, and therefore frequent 
blood sampling is taken from a small plastic tube inserted in the arm.
As a follow up to thrombolytic therapy to assess its success and to determine if 
any other procedures or treatment should be given, an x-ray test, called a coronary 
arteriogram, is often helpful and we are performing this as part of the present 
study. This requires the insertion of a little plastic tube into an artery, and 
therefore signed consent is required before the performance of this test. The actual 
method of the test will be explained separately by the Doctor who will perform the 
procedure at the time.
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CONSENT FORM
I .............................. o f .................................
hereby consent to receive the thrombolytic agent to undergo the procedure of 
coronary arteriography, the nature and effect of which have been explained to me
by Dr................  I consent to the administration of a local anaesthetic for these
purposes. I also consent to such further or alternative procedures which may be 
found to be necessary during the course of the arteriogram.
D ate................... Signed...............................................
I confirm that I have explained to the patient the proposed nature and effect of this 
therapy and the procedure of coronary arteriography.
D ate..................... (Doctor's Signature)........................
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1. APPENDIX IV
1.1 DEFINITION OF TIMI SCORES
(Williams et al., 1986)
GRADE 0 NO REPERFUSION: There is no antegrade flow beyond the point of
occlusion.
GRADE 1 PENETRATION WITH MINIMAL PERFUSION: The contrast
material passes beyond the area of obstruction, but "hangs up" and fails 
to opacify the entire coronary bed distal to the obstruction for duration 
of the cine run.
GRADE 2 PARTIAL PERFUSION: The contrast material passes across the
obstruction and opacifies the coronary bed distal to the obstruction. 
However, the rate of entry into the vessel distal to the obstruction or its 
rate of clearance from the distal bed (or both) are perceptibly slower 
than its entry or clearance from comparable areas not perfused by the 
previously occluded vessel, e.g. the opposite coronary artery or the 
coronary bed proximal to the obstruction.
GRADE 3 COMPLETE PERFUSION: Antegrade flow into the bed distal to the
obstruction occurs as promptly as antegrade flow into the bed proximal 
to the obstruction, and clearance of contrast material from the involved 
bed is as rapid as clearance from an uninvolved bed as the same vessel 
or the opposite artery.
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APPENDIX V
Timi Scoring for Coronary Artery Stenosis
Scor
e
Coronary Artery Stenosis
0 Normal
1 <50%
2 50-90%
3 91-99% (complete filling)
4 91-99% (incomplete filling)
5 100%
6 absent
7 unknown
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APPENDIX VI
EXERCISE TEST PROTOCOLS 
BRUCE PROTOCOL
STAGE SPEED (mph) G R A D E(%)
DURATION
(minutes)
1 1.7 10 3
2 2.5 12 3
3 3.4 14 3
4 4.2 16 3
5 5.0 18 3
6 5.5 20 3
7 6.0 22 3
MODIFIED BRUCE PROTOCOL
STAGE SPEED (mph) GRADE (%)
DURATION
(minutes)
1 1.7 0 3
2 1.7 5 3
3 1.7 10 3
4 2.5 12 3
5 3.4 14 3
6 4.2 16 3
7 5.0 18 3
8 5.5 20 3
9 6.6 22 3
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APPENDIX VII
RAW DATA
Demographic Data
Patency Scores
Exercise Variables
Residual Stenosis and Vessel Disease
Cardiac Event Dates
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Demographic Data 
Median age
1 indicates > median age
0 indicates < median age 
Sex
1 male
2 female
Reciprocal depression
1 present
0 absent
Time to therapy
1 indicates <2hrs or <4hrs
2 indicates >2hrs or >4hrs 
Infarct related artery
1 LAD
2 RCA
3 CX
Infarct site
1 anterior
2 inferior
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lit
1
1
1
2
1
1
1
2
2
1
1
1
1
2
1
1
2
2
2
2
1
1
1
1
1
1
1
2
2
1
1
2
2
1 1 1 2 1 2
1 1 1 2 2 2
0 1 1 2 1 2
0 1 0 2 2 1
1 1 2 1 2
0 1 1 1 1 2
0 1 1 2 2 2
0 1 1 1 1
1 1 0 2 1 1
1 1 0 2 1 2
1 1 1 2 1 2
0 1 1 2 1 2
1 1 1 1 1 1
1 1 2 1 1
1 1 1 2 2 1
0 1 1 2 2 2
1 1 1 2 1 2
0 1 0 2 1 1
0 0 2 2
0 1 0 2 1 1
0 1 0 2 2 1
0 1 1 2 1 2
0 1 1 2 2 2
0 1 1 1 1 2
0 1 1 2 2 3
0 1 1 2 1 2
0 1 2 2 2
0 1 1 2 2 2
1 1 1 2 2 1
0 2 1 2 1 1
1 2 1 2 1 2
1 2 1 2 1 2
1 1 1 2 1
0 1 2 1 1
0 1 1 2 1 1
1 1 1 2 1 2
1 1 1 2 2
0 1 1 2 1 1
0 1 1 2 1 2
1 0 2 1 2
1 1 1 2 2 1
0 1 0 2 2 2
0 2 0 2 2 2
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lit
1
2
2
2
1
1
1
1
1
1
1
2
2
2
1
1
2
1
1
1
2
2
2
2
2
1
2
1
2
2
2
2
1
2
1
1
1
2
1
1
1
Age
>Median
Sex Reciprocal
Depression
Time to Therapy Time to Therapy
1 2 1
0 1 0
1 1 1
0 1 1
1 1 1
1 1
1 1
1 1 1
0 1 1
1 1 1
1 1
0 1 0
0 1 0
1 1 0
0 1 0
0 1 1
1 1
1 0
0 1 1
1 1
1 1 1
1 1 0
1 1 0
0 1 1
0 1 0
0 1 0
1 1 0
1 1 0
1 1 1
0 1 1
1 1 1
1 0
1 1 0
1 1
0 1 0
0 1 0
0 1 1
1 1 0
0 1 1
1 1 1
1 1 1
1 2 1
0 1 1
<2hrs
1
2
2
2
1
2
2
2
2
2
2
2
2
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
2
2
2
2
2
2
2
2
2
2
2
1
1
<4hrs
1
1
2
1
1
2
1
1
1
2
1
1
1
1
2
1
2
2
1
1
2
2
1
1
1
2
2
1
1
1
2
1
2
1
1
2
2
1
1
2
1
1
1
Infarct Related 
artery
2
1
1
1
2
3
2
2
2
1
2
1
1
1
2
3
1
2
3
2
1
1
1
1
3
1
2
1
1
1
1
2
1
2
2
3
2
1
3
2
2
212
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
iit
2
2
2
2
1
2
1
1
2
2
2
2
2
2
2
2
1
1
1
2
1
1
1
2
1
1
1
2
1
1
2
2
1
1
2
1
2
2
2
2
1 1 0 2 2 1
1 1 0 2 2 1
0 1 1 2 1 1
1 1 0 2 1 1
0 1 1 2 1 3
1 1 0 2 1
1 1 1 2 1 2
0 1 1 1 1 2
0 1 1 2 1 1
1 0 2 1 1
1 0 2 1 1
0 1 0 2 1 1
0 1 1 2 1 1
0 1 0 1 1 1
1 1 2 1 1
1 1 0 2 1
0 1 1 2 1 2
1 1 0 1 1 3
1 1 1 2 1 2
0 1 2 1 2
0 1 1 2 1 1
0 1 0 2 1 2
0 2 1 2 2
0 2 1 2 1 2
0 2 1 2 1 1
0 1 0 2 1 2
0 1 1 2 1 2
1 1 1 1 1 2
1 1 2
1 1 0 2 1
0 1 1 2 1 3
1 1 1 2 1 3
0 1 0 2 1 1
0 1 0 2 1
1 1 1 2 2
0 1 2 1 2
1 1 0 2 1
1 1 2 1 2
1 1 0 2 1 1
1 1 1 1 1 1
1 1 0 2 1 1
1 1 1 2 1 1
0 1 0 2 2 1
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130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
>it
2
2
1
2
2
2
2
1
1
2
2
1
1
2
2
2
2
2
1
1
2
1
1
1
1
1
1
1
1
2
1
1
2
2
2
1
1
2
Age Sex Reciprocal
>Median Depression
1 2 0
1 2 0
1 2 1
0 1 0
0 2 0
1 2 0
0 1 0
1 1 1
1 1 0
1 1 1
1 1 1
0 1 0
1 1 1
1 1 0
1 1 0
1 1 1
0 1 1
0 1 0
0 1 1
0 1 0
1 1 1
0 1 1
1 1 0
0 1 1
1 1 0
1
0 1
0
0
1 1 1
0 1 1
0 2 1
1 2 1
0 2 1
1 1 0
1 2 0
1 2 1
1 2 1
1 1 1
1 2 0
0 1 1
0 1 0
0 2 1
1 2 0
0 1 1
Time to Therapy Time to Therapy
<2hrs <4hrs
2 2
2 1
2 2
2 1
2 2
2 1
2 1
2 1
1 1
1 1
2 1
1 1
2 2
2 2
2 2
2 1
2 1
2 1
2 1
1 1
2 1
2 1
2 2
2 1
2 2
2 2
2 1
2 1
2 2
2 2
2 1
2 1
2 1
2 1
2 2
1 1
2 1
2 1
1 1
1 1
2 1
2 2
2 1
Infarct Related 
artery
1
3
2
3
1
1
1
2
2
1
2
2
2
1
1
1
1
2
1
2
2
1
2
2
2
3
2
2
2
2
1
2
2
2
1
1
1
2
2
214
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
tit
2
1
2
2
1
2
1
1
1
1
1
1
2
1
2
2
2
2
1
1
2
2
1
1
1
2
2
1
1
2
1
1
2
Age
>Median
0
1
1
0
0
0
1
1
1
1
1
0
1
1
0
0
0
0
0
0
0
0
0
1
0
1
0
1
0
1
0
1
1
Sex Reciprocal 
Depression <2hrs <4hrs artery
1 1 1
1 1 2
2 2 1
1 1 1
2 2 2
2 1 1
2 1 2
2 1 3
2 2 2
2 1 2
2 1 2
2 2 2
1 1 1
2 2 2
2 1 1
2 2 2
2 1 1
2 1 1
2 1 1
2 1 1
2 1 2
2 1 2
2 2 1
2 1 1
2 1 1
2 2 1
2 1 2
2 2 2
2 1 1
2 2 1
2 2 2
2 1 1
2 2 1
2 2 2
2 1 2
2 1 1
2 1
2 1 2
2 2 2
2 1 1
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Patencey Data 
TIMI Score
As defined by appendix IV 
Patency Status
1 indicates a patent artery (timi score 2 or 3)
0 indicates a non patent artery (timi score 0 or 1) 
TIMI Score 3 
3 indicates TIMI Score 3 
0 indicates timi score 0 ,1,2
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itie
NO
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
TIMI Score TIMI Score Patency
90 min 24 hrs Status
0 1 0
3 3 1
3
3 3 1
0 3 2
3 3 1
0 3 2
0 0 0
2 0 3
0 3 2
3 3 1
0
0 0 0
2 3 1
3 3 1
0 3 2
3 3 1
0 2 2
2 3 1
0 3 2
3 3 1
3 3 1
3 3 1
3 3 1
0 0 0
2 3 1
0 2 2
3 3 1
0
3 3 1
3 3 1
3 3 1
0 1 0
0
3 3 1
0
0 3 2
0
0 2 2
3 3 1
0 0 0
Patency Patency TIMI Score 3
90 min 24 hrs 90 min
0 0 0
1 1 3
1 3
1 1 3
0 1 0
1 1 3
0 1 0
0 0 0
1 0 0
0 1 0
1 1 3
0 0
0 0 0
1 1 0
1 1 3
0 1 0
1 1 3
0 1 0
1 1 0
0 1 0
1 1 3
1 1 3
1 1 3
1 1 3
0 0 0
1 1 0
0 1 0
1 1 3
0 0
1 1 3
1 1 3
1 1 3
0 0 0
0 0
1 1 3
0 0
0 1 0
0 0
0 1 0
1 1 3
0 0 0
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NO
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
TIMI Score TIMI Score Patency
90 min 24 hrs Status
3 3 1
2 3 1
2 2 1
0 3 2
3 3 1
3
2
0 1 0
3 3 1
0
0 3 2
1 3 2
1 3 2
3 3 1
1 3 2
0 3 2
1 2 2
0
3 3 1
0 2 2
3 3 1
3 2 1
1 2 2
1 3 2
3 3 1
0 2 2
3 3 1
3 3 1
3 3 1
3 3 1
3 3 1
3 3 1
3 3 1
0 3 2
2 3 1
0 3 2
3 3 1
0 2 2
0 3 2
0 3 2
3 0 3
Patency Patency TIMI Score 3 
90 min 24 hrs 90 min
1 1 3
1 1 0
1 1 0
0 1 0
1 1 3
1 
1
0 0 0
1 1 3
0 0 
0 1 0
0 1 0
0 1 0
1 1 3
0 1 0
0 1 0
0 1 0
1 1 3
0 1 0
1 1 3
1 1 3
0 1 0
0 1 0
1 1 3
0 1 0
1 1 3
1 1 3
1 1 3
1 1 3
1 1 3
1 1 3
1 1 3
0 1 0
1 1 0
0 1 0
1 1 3
0 1 0
0 1 0
0 1 0
1 0 3
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NO
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
TIMI Score TIMI Score Patency
90 min 24 hrs Status
0 2 2
0 0 0
2 2 1
2 3 1
3 3 1
3 3 1
0 0 0
2 2 1
1 2 2
2 3 1
0 1 0
3
3 3 1
3 3 1
0 3 2
3 3 1
3 3 1
1 0 0
0
2 2 1
2 2 1
0 3 2
3 3 • 1
0 3 2
2 3 1
3 3 1
3 3 1
0 0 0
0 0 0
1 3 2
0 0 0
2 3 1
0 3 2
2 3 1
2 2 1
3 3 1
3 3 1
1 2 2
3 3 1
3 3 1
Patency Patency TIMI Score 3
90 min 24 hrs 90 min
0 1 0
0 0 0
1 1 0
1 1 0
1 1 3
1 1 3
0 0 0
1 1 0
0 1 0
1 1 0
0 0 0
1
1 1 3
1 1 3
0 1 0
1 1 3
1 1 3
0 0 0
1 1 0
1 1 0
0 1 0
1 1 3
0 1 0
1 1 0
1 1 3
1 1 3
0 0 0
0 0 0
0 1 0
0 0 0
1 1 0
0 1 0
1 1 0
1 1 0
1 1 3
1 1 3
0 1 0
1 1 3
1 1 3
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NO
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
TIMI Score TIMI Score Patency
90 min 24 hrs Status
3 3 1
0 0 0
2 2 1
3
2 3 1
3 3 1
2 3 1
2 2 1
2
3 2 1
0 0 0
2 2 1
3 3 1
2 2 1
2 2 1
2 2 1
3 3 1
2 2 1
2 2 1
2 3 1
2 3 1
2 1 3
2 1 3
3 3 1
2 1 3
0 2 2
3 3 1
1 2 2
3 3 1
2 2 1
2 2 1
0 0 0
0 0 0
2 2 1
0 2 2
0 3 2
0 3 2
2 2 1
2 3 2
3 3 1
Patency Patency TIMI Score 3 
90 min 24 hrs 90 min
1 1 3
0 0 0
1 1 0
1 3
1 1 0
1 1 3
1 1 0
1 1 0
1
1 1 3
0 0 0
1 1 0
1 1 3
1 1 0
1 1 0
1 1 0
1 1 3
1 1 0
1 1 0
1 1 0
1 1 0
1 0 0
1 0 0
1 1 3
1 0 0
0 1 0
1 1 3
0 1 0
1 1 3
1 1 0
1 1 0
0 0 0
0 0 0
1 1 0
0 1 0
0 1 0
0 1 0
1 1 0
1 1 0
1 1 3
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Patiei
NO
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
TIMI Score TIMI Score Patency
90 min 24 hrs Status
2 3 1
3 3 1
1
1 0 0
1 2 2
2 0 3
0 3 2
3
2 3 1
2 3 1
2 3 1
3
2 3 1
0 1 0
3 2 1
3
0 2 2
0 0 0
0 0 0
2 3 1
3 2 1
2 2 1
2 2 1
0 0 0
0 3 2
2 2 1
3 3 1
2 3 1
3 3 1
2 2 1
2 2 1
2 2 1
3 3 1
3 3 1
0 2 2
0
3 3 1
3 3 1
Patency Patency TIMI Score 3 
90 min 24 hrs 90 min
1 1 0
1 1 3
0 0 
0 0 0
0 1 0
1 0 0
0 1 0
3
1 0
1 0
1 0
3
1 0
0 0
1 3
3
0 1 0
0 0 0
0 0 0
1 1 0
1 1 3
1 1 0
1 1 0
0 0 0
0 1 0
1 1 0
1 1 3
1 1 0
1 1 3
1 1 0
1 1 0
1 1 0
1 1 3
1 1 3
0 1 0
0 0 
1 1 3
1 1 3
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No of diseased arteries and residual stenosis 
No o f diseased arteries
1 single vessel disease
2 double vessel disease
3 triple vessel disease 
blank represents missing data 
residual stenosis in single vessel disease
0 no stenosis or stenosis < 50% of luminal diameter 
11 residual stenosis > 50%
4 occluded vessel
residual stenosis with additional vessel disease
0 no stenosis or stenosis < 50% of luminal diameter
1 residual stenosis > 50%
2 occluded vessel
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itiei
NO
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
15
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
NO of Diseased
Arteries
1
2
Residual Stenosis 
of IRA in Single 
Vessel disease
11
0
11
11
11
0
11
11
11
4
11
11
0
11
0
3
Residual Stenosis
of IRA +1- additional
Vessel disease
2
2
0
0
2
1
1
1
0
1
1
1
0
1
1
1
2
1
1
0
1
0
1
1
0
1
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NO
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
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Exercise Variables 
CODES for all exercise variables 
1 indicates the variables is present 
0 indicates the variable is absent 
Blank indicates missing data
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